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Abstract 
Alzheimer’s disease (AD) and Parkinson’s disease (PD) are the most common forms of 
dementia and a leading cause of death amongst the older population worldwide. Pathologically, 
both AD and PD are characterized as progressive neurodegenerative disorders, in which there 
is a progressive loss of neuronal structure and function leading to loss of neurons in parts of 
the brain associated with cognition, memory and movement. Amyloidogenic protein 
misfolding and aggregation is at the centre of the neurodegenerative processes associated with 
AD and PD. In the case of AD, the amyloidogenic protein is amyloid β (Aβ) and in PD, it is 
the α Synuclein (αS) protein, or its mutant forms such as αSA53T found in familial PD which 
aggregates and exerts toxicity. In both AD and PD, we lack truly disease-modifying drug 
treatments, with current medications largely providing only modest and transient symptomatic 
improvement.  
Therefore, the aim of this project was to identify a diverse set of new molecules from both 
natural and synthetic origin, that can alter Aβ and αSA53T aggregation and fibril formation. 
Mostly small molecule binding has been studied by molecular docking and effects on Aβ and 
αSA53T aggregation investigated using a ligand-binding fluorescence kinetic assay 
(Thioflavin T) and transmission electron microscopy (TEM). For neuroprotection studies, a 
mitochondrial viability (MTT) assay of neuronal cells (PC-12) was used. Finally, using 
molecular docking and density functional theory (DFT) approaches, a set of novel amyloid-
binding ligands was designed in silico through ligand-based drug design. In the first study, four 
polyphenolic bioactives including a neolignan, ellagitannin and two flavonoid class of 
compounds have been comparatively studied for their binding interactions with Aβ, effects on 
fibril and aggregate formation and neuroprotection. In the second study, a structure-based 
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virtual screening method based on molecular docking has been implemented to identify new 
small molecule inhibitors of Aβ aggregation and neurotoxicity. Five heterocyclic compounds 
were selected and tested using the anti-aggregation and neuroprotection methods. Of these, the 
two best ‘hits’ bearing a novel molecular scaffold have been used in further studies. In the third 
study, the two virtual screening hits, polyphenolic bioactives from first study and two 
structurally related flavonoids were tested for inhibition of amyloidogenic aggregation and 
neuroprotection of the pathological αS mutant, αSA53T. Seven molecules have been compared 
as per the first and second study. Additionally, the impact on native αSA53T protein 
conformation was investigated by ion mobility mass spectrometry (IM-MS). In the fourth 
study, a diverse set of natural bioactives including a neolignan, flavonoid, chalcone, diterpene 
and alkaloid class of compound were tested for antiaggregative effects on both αSA53T and 
Aβ proteins. Additionally, their direct interactions with these amyloidogenic protein targets 
were studied by molecular docking.  
The final study employed molecular docking and small molecular structure optimization using 
DFT method for rational design of a set of novel amyloid ligands. The favourable molecular 
attributes gleaned from both the bioactive neolignan in the first study and a favourable 
molecular scaffold in the second study were used to optimise binding for potential anti-
aggregation. These ligands were predicted to have improved binding to Aβ and αSA53T in 
silico. Since there is an urgent need of disease-modifying therapies in both AD and PD, 
identification of anti-amyloidogenic and neuroprotective molecules would facilitate future 
drug discovery efforts. Design of a novel amyloid binder would be valuable for research and 
development of a therapeutic candidate or may assist in further design of an amyloid tracer 
molecule for diagnostic imaging.  
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Chapter 1: Introduction 
1.1  Dementia and neurodegenerative diseases 
1.1.1 Overview 
Dementia commonly refers to the state of significant cognitive decline that interferes with the 
normal social functioning of older individuals as a result of neurodegeneration.  
Neurodegeneration or neurodegenerative disorder is a term collectively used for a variety of 
ailments that primarily affect the structure and function of neurons in the brain in a progressive 
manner. As the term ‘degeneration’ implies, in a neurodegenerative disorder there is 
progressive damage and eventual loss of neurons in specific regions of the brain. This 
pathology is exemplified by some of the most common forms of neurodegenerative diseases, 
such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). Primarily, these diseases are 
associated with protein misfolding that leads to protein aggregation (Bucciantini, Giannoni et 
al. 2002). Since the majority of cases (50% – 70%) of dementia are AD, it can be divided into 
two broad classes: Alzheimer-type dementia and non-Alzheimer type dementia. Alzheimer-
type dementia is predominantly characterised by memory loss along with other cognitive 
impairments in skilled motor function (apraxia), language (aphasia) or perception and visual 
or other (agnosias). The non-Alzheimer type dementia can be divided into three categories: 
Lewy body dementia, frontotemporal dementia and vascular dementia. PD is common form of 
Lewy body dementia, where cognitive decline is accompanied by movement disorders.    
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1.1.2 Dementia and AD prevalence 
AD is one of the leading causes of death among older individuals aged over 65 years, globally 
(Figure 1) (Alzheimer's Association 2015). Figure 1 provides the global distribution of 
dementia and estimation for future with a higher total number of dementia patients in low- and 
middle-income countries. This is due to the greater overall population in those countries.  
According to the crude estimated prevalence in the World Alzheimer’s report 2015, 4.7% and 
4.6% of the total population of Asia and Africa have been suffering with dementia, 
respectively. Whereas, 6.4% and 5.9% of the total population of North America and Europe 
have been suffering from dementia, respectively. According to the World Alzheimer Report 
2016, it is estimated that there were 46.8 million people suffering from AD in 2015 worldwide. 
This number is estimated to rise to 131.5 million by 2050 and 68% of this total number of 
dementia patients would be in the low- and middle-income countries (Ferri, Prince et al. 2006, 
Prince, Bryce et al. 2013). 
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Figure 1. Global distribution of dementia and estimation for future, in both developing and 
developed world. Source: World Alzheimer Report, 2015. 
The 2015 worldwide consensus study on the prevalence of dementia estimated that a new case 
of dementia is reported  every 7 seconds (Ferri, Prince et al. 2006). Even though dementia is 
prevalent among older individuals, a 2017 report based on the American population estimated 
about 700,000  Americans (aged below 65 years) will have AD when they die and many of 
them will die because of the complications of AD (Alzheimer's Association 2017). In Australia, 
recent dementia statistics have reported that dementia is the second leading cause of death 
contributing to 5.4% of all deaths in males and 10.6% in all deaths in females each year 
(Australian Bureau of Statistics, 2017). In 2018, there is an estimated 425,416 patients are 
living with dementia which is estimated to increase to 1,100,890 by 2056 (Economic Cost of 
Dementia in Australia 2016-2056). 
1.1.3 Prevalence of PD 
PD is another complex neurodegenerative disease that affects 1 - 3% of the population aged 
over 60 years (Poewe, Seppi et al. 2017, Tysnes and Storstein 2017). In addition to cognitive 
decline,  PD is also regarded as a movement disorder due to motor neuron degeneration with 
three cardinal signs; tremor, rigidity and bradykinesia (Tysnes and Storstein 2017). Recent 
studies have highlighted the non-motor symptoms of PD as an early indication (Schrag, 
Horsfall et al. 2015). Epidemiological studies have found a higher prevalence of PD in 
developed countries such as the US, Europe and Australia than in Asia among people aged 
over 70 years (Pringsheim, Jette et al. 2014). Out of the total PD cases, single gene mutations 
related to PD account for  5–10% (Lill 2016). Predominantly, autosomal dominant mutations 
in the SNCA, LRRK2 and VPS35 genes and autosomal recessive mutations in PINK1, DJ1 and 
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Parkin genes are linked to PD with high penetrance (Lill 2016). Consequently, the socio-
economic burden of dementia is also on the rise. The World Alzheimer Report 2016 mentioned 
the total estimated worldwide cost of dementia is US$818 billion. By 2018, this cost will 
increase to a trillion $USD. Given the scenario where majority of dementia patients live in 
developing countries, disease management will become challenging due to both complex 
socio-economic factors and health costs associated with disease management globally.   
 
1.1.4 Neuropathology of AD 
The defining neuropathology of AD involves two primary lesions in the hippocampal region 
of the brain; development of senile or neuritic plaques and neurofibrillary tangles (NFT) (Perl 
2010). Studies of senile plaques, a hallmark of AD, consistently revealed the presence of a 
central core of amyloid β (Aβ) protein, termed as amyloid plaque core (APC) (Figure 2a). Aβ 
is a 4 kD protein arranged in a radial fashion within the plaques and is surrounded by a corona 
of abnormally configured neuronal processes or neurites (Figure 2a). The aggregation of Aβ 
displays a beta-pleated sheet conformation. In addition to Aβ, microglial cells and reactive 
astrocytes are found at the periphery (Perl 2010) (Figure 2a). Another form of Aβ aggregates 
are the diffuse plaques, where focal diffuse deposits of Aβ protein may occur in the cerebral 
cortex in the absence of accompanying dystrophic neurites (Yamaguchi, Hirai et al. 1989) 
(Figure 2b). The other lesion, NFTs consist of hyperphosphorylated tau protein, a microtubule 
associated protein (Figure 2b). Abnormal accumulation of tau in the perikaryal cytoplasm of 
diseased neurons creates NFTs inside the neuron (Figure 2b).  
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Figure 2. (a) Schematic diagram of the Aβ plaque and neurofibrillary tangles. These deposited 
proteins form the amyloid fibrils which may crystallize within the center of a plaque to form 
an Aβ plaque core (APC). Adapted from Masters et. al. (Masters, Multhaup et al. 1985). (b) A 
section of the cerebral cortex from an AD patient showing Aβ plaques (arrowheads), NFT 
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(arrow) and neutrophil threads (broken arrow) by Bielschowsky’s stain. Adapted from Yanker 
et. al. (Yankner  and Mesulam 1991).  
 
1.1.5 Neuropathology of PD 
In PD there is a loss of dopaminergic neurons in the substantia nigra pars compacta (SNCA) 
(Baba, Nakajo et al. 1998). Autopsy evidence of PD patient’s brains show accumulation of 
Lewy bodies (LB) or Lewy pathology (LP) in both degenerating neurons as well as in 
extracellular spaces of the SNCA region. The aggregation of cytosolic protein α Synuclein (αS) 
is found to be associated with LB formation, as αS aggregates are the primary component of 
LB found in PD and dementia with Lewy bodies (DLB) (Baba, Nakajo et al. 1998) (Figure 3a 
and b). Moreover, pathological αS can transmit from cell to cell contributing towards 
progressive neurodegeneration in PD (Luk, Kehm et al. 2012). Although αS performs normal 
physiological and cellular functions such as vesicle trafficking, maintenance of the synaptic 
SNARE complex and vesicle pools and regulation of dopamine (DA) metabolism, under 
pathological conditions it becomes susceptible to amyloidogenic aggregation. Apart from the 
wild type αS, missense point mutations in the SNCA gene can lead to more aggregation-prone 
αSAla53Thr (αS53T) protein (Li, Uversky et al. 2001). This αSA53T mutation not only causes 
familial PD, but these mutant protein carriers have also been shown to be associated with 
frontotemporal dementia in some patients (Bougea, Koros et al. 2017). Interestingly, LB-
containing αS was found in the majority of sporadic AD patient’s brains in the amygdala region 
(Lippa, Fujiwara et al. 1998, Hamilton 2000). This highlights the common overlap of 
amyloidogenic protein aggregation between AD and PD (Bucciantini, Giannoni et al. 2002). 
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Figure 3: Sections of Substantia nigra in Parkinson’s disease. (a) Substantia nigra pars 
compacta neuron with a Lewy body, extracellular neuromelanin and pigment-laden 
macrophages by haematoxylin/eosin stain, 500x. (b) α Synuclein positive Lewy neurite, 400x. 
Adapted from Werner et. al. (Werner, Heyny-von Haussen et al. 2008). 
1.2  Current treatments for AD and PD 
Despite the huge disease burden of both AD and PD, there is no cure for these diseases. Present 
medications are symptomatic and provide transient relief; however, they do not alter the course 
of disease progression. For AD, most of the approved drugs are classified as cholinesterase 
inhibitors that are used in various stages of AD. Since neurodegeneration of cholinergic 
neurons is profound, inhibition of cholinesterase has been shown to temporarily maintain 
acetylcholine levels for memory functioning (Nordberg and Svensson 1998, Trinh, Hoblyn et 
al. 2003). Another drug, memantine, works as a NMDA receptor antagonist and protects 
neuronal loss from excess glutamate toxicity (Tariot, Farlow et al. 2004). However, memantine 
does not protect neurons from the progression of the disease. Since 2003, no new drug has been 
approved for the treatment of AD.   
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The treatment of PD includes medications and surgical therapy. The medications are primarily 
dopamine replacement therapy in the form of levodopa, which has adverse side effects 
(DeMaagd and Philip 2015, Ferrazzoli, Carter et al. 2016). Dopamine receptor agonists have 
also been used (DeMaagd and Philip 2015). The efficacy of dopamine replacement therapy or 
levodopa depends on its enzymatic degradation by catechol-o-methyltransferase (COMT) and 
monoamine oxidase B (MAO-B) in the brain. In order to have a prolonged efficacy of levodopa 
treatment, a combination of levodopa and COMT inhibitor treatment is used (Ruottinen, H. 
and Rinne, U. K., 1998). Similarly, MAO-B is a major metabolising enzyme of dopamine. 
Therefore, COMT and MAO-B enzymes are attractive drug target for PD treatment to slow 
down dopamine degradation in the brain (Riederer, P. and Laux, G., 2011, Rabey, Sagi et al. 
2000, Gonçalves, Alves et al. 2017). A cholinesterase inhibitor like donepezil, which is a 
prescribed drug for AD, has also been used in PD to manage dementia (Aarsland, Laake et al. 
2002). Like AD, these medications are used for managing symptoms and do not address the 
underlying neurodegenerative pathology.  
1.3  The amyloidogenic proteins Aβ and αS 
1.3.1  Amyloidogenesis 
Both Aβ and αS belong to the class of amyloidogenic proteins due to their high propensity for 
aggregation and transition to potentially cytotoxic β-sheet rich conformations. Aβ is generated 
due to the abnormal proteolysis of the large membrane protein, amyloid precursor protein 
(APP). APP is a complex protein and normally plays an important role in neural growth and 
repair in its full length configuration (Turner, O'Connor et al. 2003). Its fragmentation by 
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dedicated proteases such as beta-secretase (beta-site amyloid precursor protein cleaving 
enzyme 1, or BACE 1) followed by γ-secretase leads to the generation of neurotoxic 39-43 
residue Aβ proteins (Mori, Takio et al. 1992, Iwatsubo, Saido et al. 1996). Out of these variable 
sequences, Aβ1-40 and Aβ1-42 are more predominant and frequently connected to AD pathology 
(Lemere, Lopera et al. 1996). Elevated plasma concentrations of Aβ1-42 were observed in 
familial AD related mutations (Scheuner, Eckman et al. 1996) and also in AD affected brain 
tissue (Kuo, Emmerling et al. 1996). Aβ1-42 is considered the most toxic species (Lambert, 
Barlow et al. 1998) related to neuronal cell death due to its high propensity for self-assembly 
(Chromy, Nowak et al. 2003).  
αS, on the other hand, is a widely expressed cytosolic protein that is involved with important 
biological functions as mentioned earlier. Despite being primarily associated with PD, it is also 
known for multipathogenicity in other synucleinopathy diseases like DLB and multiple system 
atrophy (MSA), amongst others  (Gai, Power et al. , Spillantini and Goedert 2000). It is a 140 
amino-acid sequence protein belonging to the class of intrinsically disordered proteins (IDP), 
as it lacks a defined three-dimensional structure but comprises an ensemble of various 
conformations (Uversky 2011). 
1.3.2  The amyloid hypothesis 
The amyloid hypothesis or the amyloid cascade hypothesis dates back to 1906, when Alois 
Alzheimer first described the plaques and tangles in the brain as the pathognomonic signs of 
AD (Alzheimer 1911). Subsequent studies have characterised these plaques as made up of 
mostly Aβ protein aggregates. Further discovery of the autosomal dominant mutations for 
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familial AD (FAD) has been a cornerstone of the understanding of AD pathobiology and led 
to the development of the amyloid hypothesis (Goate, Chartier-Harlin et al. 1991, Hardy and 
Higgins 1992). It proposes that AD is essentially a disease of imbalance between the production 
and clearance of various pathogenic species of Aβ, occurring very early and often as an 
initiating factor of the disease (Hardy and Selkoe 2002) (Figure 4). According to the amyloid 
hypothesis, other neuropathologic lesions such as tau accumulation or NFT formation are 
subsequent events to Aβ aggregation (Hardy and Selkoe 2002) (Figure 4).  
Figure 4. The amyloid hypothesis describing the sequential pathogenic events that occur in the 
development of AD. Adapted from Hardy. J and Selkoe. D. (Hardy and Selkoe 2002). 
Since Aβ plaque formation often occurs decades earlier than the clinical diagnosis of the 
disease, the amyloid hypothesis is believed to be a route for disease-modifying therapeutics. 
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Autopsy samples from AD patient’s brains showed formation of Aβ plaques and purification 
of amyloid plaque core protein revealed the presence of Aβ fibrillar structures (Masters, Simms 
et al. 1985, Lu, Qiang et al. 2013). Therefore, neurotoxicity of Aβ fibrils was previously 
believed to be the basis for the amyloid cascade hypothesis in AD (Hardy and Higgins 1992) . 
Subsequent research demonstrated that small oligomeric, soluble Aβ aggregates were more 
related to neurotoxicity and neurodegeneration rather than the fibrils (Lambert, Barlow et al. 
1998, Hartley, Walsh et al. 1999, Walsh, Hartley et al. 1999).  
1.3.3. Structures of Aβ and αS 
At the molecular level, most amyloidogenic proteins including Aβ and αS display structural 
polymorphisms. This implies that these proteins are capable of misfolding into different 
structural conformations that are associated with toxicity (Tycko 2015). For Aβ, a number of 
structural conformations ranging from monomers, oligomers and polymers have been reported 
to be associated with its toxicity (Luhrs, Ritter et al. 2005, Xiao, Ma et al. 2015, Gremer, 
Scholzel et al. 2017). NMR and cryo-EM analysis suggest the presence of parallel-β-sheet 
segments in these Aβ conformations have been associated with aggregation and fibril growth. 
The oligomeric conformation (PDB ID: 2BEG) and the monomeric conformation (PDB ID: 
1IYT) available from the Protein Data Bank have been used in this study for understanding 
ligand binding to Aβ (Figure 5a and b). The α-helical conformation of Aβ monomer in solution 
has a similarity with a viral protein that has also been implicated with toxicity (Crescenzi, 
Tomaselli et al. 2002) (Figure 5a). Additionally, the structure of the Aβ monomer comes from 
a 1H NMR study undertaken in a mixture of trifluoroethanol (TFE) and water. TFE is an apolar 
solvent that encourages intramolecular hydrogen bonds, in contrast to water which readily 
hydrogen bonds with peptides and surface-exposed amino acids in proteins. As a result, since 
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Aβ is a relatively short peptide (40-42 amino acids in length), it adopts an unstructured 
conformation in water (Figure 5a). The mostly α-helical Aβ structure of Crescenzi et al. (Figure 
5a) is most likely the conformation that the peptide adopts in a hydrophobic environment, for 
example when it binds to a membrane (Figure 5a). The structures of Aβ oligomer and A53T α-
synuclein in Figures 5b, c are for the protein when incorporated into the amyloid fibrillar form, 
as determined by solid state NMR studies. 
αS is a 140-residue protein whose structure is divided into three distinct regions; the N-terminal 
lipid binding region from residue 1-60, the non-amyloid β component or NAC region from 
residue 60-90 and the acidic C-terminal region from residue 90–140 (Culvenor, McLean et al. 
1999). The various structural conformations of αS covering the complete sequence of the 
protein is not very well understood, due to its intrinsically disordered nature. Nevertheless, a 
recent NMR study revealed the full sequence structure of a pathologic αS conformation (Tuttle, 
Comellas et al. 2016). This structure presents characteristic amyloid features such as β-sheet 
segments and hydrophobic-core residues. Since there is not a complete sequence structure of 
the αSA53T mutant available in the Protein Data Bank (PDB), the above-mentioned structure 
has been mutated and used in this study (Figure 5c).   
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Figure 5. NMR structures of amyloidogenic proteins that are used in this study in the molecular 
modelling (a) Aβ monomer (PDB ID: 1IYT), (b) Aβ oligomer (PDB ID: 2BEG) and (c) 
αSA53T monomer (PDB ID: 2N0A).  
1.3.4  Amyloidogenic protein aggregation 
Various mechanisms have been proposed in the literature regarding the conversion of Aβ 
monomers to oligomers of different size and shape. Since Aβ1-40 and Aβ1-42 are primarily 
associated with neurotoxicity, they have been studied extensively for their 
structural/conformational changes that lead to further Aβ fibril development. Overall, there are 
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four suggested stages of amyloid fibril assembly from the native monomeric structure (Harper, 
Wong et al. 1999). Firstly, the monomer misfolds and aggregates into small oligomeric species 
that leads to protofibril initiation, which is a nucleation-dependent event. This may require 
fewer than 20 Aβ molecules (Walsh, Lomakin et al. 1997). The initiation process is followed 
by protofibril elongation, where coalescence of smaller protofibrils occur. This process has 
been explained experimentally and computationally (Kowalewski and Holtzman 1999, Cheon, 
Chang et al. 2007). The protofibril association stage includes winding and a conformational 
change into a β-sheet rich segment, as elucidated computationally (Cheon, Chang et al. 2007). 
The final step is the fibril elongation that can be initiated by the addition of preformed fibrillar 
seeds to Aβ protofibrils for growth of fibrils in vitro (Harper, Lieber et al. 1997).  
1. 4 Mechanisms of toxicity by Aβ and αS amyloidogenic proteins
1.4.1  Toxicity related to Aβ and αS aggregation 
The aggregation of amyloidogenic proteins into small soluble oligomers and mature fibrils 
leads to toxic actions toward neuronal cells (Harte, Klyubin et al. 2015). Aβ displays structural 
polymorphisms during its aggregation and forms a heterogeneous population of small 
oligomers and protofibrils in addition to fibrillar conformations. Recent studies on amyloid 
toxicity revealed that the small oligomeric conformations are more toxic than the mature fibrils, 
as they can form annular protofibrils or ‘amyloid pores’ that may interrupt membrane 
permeabilization (Lashuel, Hartley et al. 2002, Bieschke, Herbst et al. 2011). Aβ oligomers 
trigger toxicity by enhancing oxidative stress, disrupting membranes and initiating cellular 
organelle dysfunction. Consistent with the toxicity of amyloidogenic proteins such as Aβ, 
conformational changes and folding of αS into oligomers and prefibrillar species are the most 
toxic and pathogenic forms (Ingelsson 2016). The mutant forms of αS such as A53T form a 
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different conformational ensemble than the wild type αS during self-assembly (Tosatto, 
Horrocks et al. 2015). Release of αS by unconventional exocytosis into extracellular space 
elicits neurodegeneration, progressive spreading of αS pathology and neuroinflammation (Lee, 
Bae et al. 2014).  
1.4.2  Oxidative stress and lipid peroxidation from Aβ and αS aggregation 
One of the mechanisms of Aβ-induced neurotoxicity is where Aβ produces reactive oxygen 
species (ROS) which then activates apoptosis signal-regulating kinase 1 (ASK1) (Kadowaki, 
Nishitoh et al. 2004). The other mechanism involves generation of hydroxyl-2-nonenal (HNE) 
as a result of oxidative lipid damage as found in both AD and PD (Lovell, Ehmann et al. 1997, 
Castellani, Perry et al. 2002). Misfolded Aβ produces oxidative damage to lipid membranes by 
acting as a prooxidant. This oxidative lipid damage produces HNE, which in turn promotes 
more Aβ misfolding (Murray, Liu et al. 2007). Aβ promotes copper-mediated HNE generation 
that covalently modifies the histidine residue of Aβ, rendering it more aggregation-prone 
(Murray, Liu et al. 2007). Another study also reported that a pathologically thin lipid bilayer 
occurs as a result of oxidative damage in AD pathology, which in turn promotes Aβ toxic 
aggregation (Korshavn, Satriano et al. 2017). Likewise, HNE generation due to oxidative 
damage of lipids is also implicated in protein misfolding and neurotoxicity to nigral neurons in 
PD (Yoritaka, Hattori et al. 1996). Additionally, protein carbonyl generation due to free radical 
attack on amino acids has been observed in the substantia nigra (SN) of PD patients (Floor and 
Wetzel 1998).  
1.4.3  Inflammatory responses associated with Aβ and αS aggregation 
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In addition to oxidative stress, aggregation of Aβ can activate inflammatory responses via 
pattern recognition receptors (PRR) such as Toll-like, NOD-like (nucleotide-binding 
oligomerization domain) receptors or NLR, formyl peptide, receptor for advanced glycation 
end product (RAGE) and scavenger receptors on glial cells and neurons that contribute to AD 
pathology (Salminen, Ojala et al. 2009). Not surprisingly, amyloidogenic folding of αS also 
triggers inflammatory responses by activating similar types of receptors such as Toll like 
receptor 2 (TLR2) and NOD-like receptors pyrin domain containing 3 (NRLP3) inflammasome 
(Gustot, Gallea et al. 2015).     
In PD, the activation of microglial and astroglial cells brings about major inflammatory 
responses. Based on the staining for microglial activation and post-mortem analysis of PD 
affected brains, it is postulated that the dopaminergic neurodegeneration occurring early in the 
disease process is accompanied by the widespread activation of microglial cells (McGeer, 
Itagaki et al. 1988, Gerhard, Pavese et al. 2006). Alvarez-Erviti et. al. have also reported that 
release of αS or its pathological mutant A53T by neuronal cells activates proinflammatory 
cytokines from glial cells in vitro (Alvarez-Erviti, Couch et al. 2011). The αS aggregates 
released from the neuronal cells are taken up by astrocytes resulting in induction of 
proinflammatory cytokines and chemokines. This inflammatory response is due to the 
transmission of αS aggregates from neurons to glial cells, correlated with the extent of glial 
accumulation of αS aggregates and changes in glial gene expression profiles to an 
inflammatory response (Lee, Suk et al. 2010).    
1.4.4  Other mechanisms of toxicity by Aβ and αS aggregates 
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It is worth mentioning that the impaired mitochondrial electron transport chain is a primary 
source of oxidative stress. In PD, a defect in the mitochondrial NADH-ubiquinone reductase 
(complex 1) in the substantia nigra (SN) region has been observed (Mizuno, Ohta et al. 1989, 
Schapira, Cooper et al. 1990). Similarly, a significant decrease in cytochrome oxidase 
(complex IV) activity has been reported in AD (Parker, Filley et al. 1990, Mutisya, Bowling et 
al. 1994). Furthermore, Aβ interaction with the cell membrane leads to increased intraneuronal 
Ca2+ ions and disrupted calcium homoeostasis (Hardy and Higgins 1992). Studies connecting 
oxidative stress with inflammatory responses from Aβ aggregation have demonstrated that in 
AD, Aβ deposition increases ROS production resulting in lipid and protein peroxidation. This 
occurs through an extracellular signal-regulated phospholipase A2 cascade for formation of 
arachidonic acid (AA) from membrane phospholipids (Adibhatla and Hatcher 2008, Hsieh and 
Yang 2013), which triggers COX-mediated inflammatory responses such as release of IL-1 
(Mrak and Griffin 2005, Adibhatla and Hatcher 2008).   
1.4.5  Synaptic dysfunction by αS amyloidogenic aggregation 
Deposition of αS oligomers and aggregates in the presynaptic region can interact with the N-
terminal domain of VAMP-2 and block presynaptic SNARE-mediated vesicle docking, which 
leads to inhibition of dopamine release (Choi, Choi et al. 2013). Abnormal interaction of αS 
with the Rab GTPase family like Rab3A and rabphilin is implicated with exocytosis of 
neurotransmitters associated with Lewy body diseases (Dalfo, Barrachina et al. 2004). The 
misfolded oligomeric and other amyloid forms of αS trigger misregulation of synaptic proteins 
leading to functional impairment of the presynaptic terminal (Volpicelli-Daley, Luk et al. 
2011). This impairment is shown to be progressive and selective to dopaminergic neurons 
(Janezic, Threlfell et al. 2013). Since degeneration of dopaminergic neurons is a primary 
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phenotype of PD, synaptic dysfunction by αS oligomers and aggregates implies that inhibition 
of αS aggregation is a potential disease modifying strategy.  
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Figure 6. Amyloidogenic protein, Aβ and αS aggregation process that leads to neurotoxicity 
in AD and PD. The self-assembly of native unfolded monomer or misfolded monomer of Aβ 
and αS can drive the formation of toxic oligomeric conformations that trigger a chain of toxic 
injuries to neuronal cells and eventual neurodegeneration. Adapted from the review study of 
Eisele et. al. (Eisele, Monteiro et al. 2015). 
1. 5. Different approaches to reduce Aβ and αS accumulation
1.5.1 Reducing Aβ and αS production 
Studies aiming at a reduction of Aβ have largely been focused on β-site amyloid-precursor-
protein-cleaving enzyme 1 (BACE 1); that is, the aspartic protease that cleaves APP at the β-
secretase site and generates Aβ. Earlier studies have identified many naturally occurring 
compounds such as green tea catechins, punicalagin and ellagic acid as non-competitive 
BACE1 inhibitors (Jeon, Bae et al. 2003, Kwak, Jeon et al. 2005). Small molecule drug 
discovery endeavours in AD have been intensely focused towards BACE1 inhibitor design as 
seen by a plethora of clinical candidates from major pharmaceutical companies (Yan and 
Vassar 2014). Despite the challenges, BACE 1 inhibitors are the first class of disease-
modifying small molecule drugs for Aβ that have entered into clinical trials (Kennedy, 
Stamford et al. 2016, Ufer, Rouzade-Dominguez et al. 2016, Yan 2016). However, the results 
from the small molecule inhibitor of BACE1 (verubecestat 1) have not been promising and 
others are still at a trial stage (Mullard 2017).  
Unlike Aβ, which has been generated by sequential cleavage of proteolytic enzymes, αS is a 
cytosolic protein and therefore its reduction might require intervention at the RNA translation 
level. RNA interference (RNAi) approaches including short hairpin (sh) αS RNA delivery via 
a lentiviral vector and small interfering (siRNA) directed against αS, have been reported to 
reduce brain αS level in rats (Zharikov, Cannon et al. 2015). In respect of the important 
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physiological functions performed by αS in the CNS however, reductions in αS level might be 
approached with caution. The other approach has been to modify the transcription of the αS 
gene, where a recent study has identified beta-2-adrenoreceptor agonism as a mechanism to 
reduce αS gene expression (Mittal, Bjørnevik et al. 2017).  
1.5.2  Inhibiting Aβ and αS aggregation 
Studies on inhibition of Aβ aggregation are mostly in preclinical development and have 
employed either small molecular inhibitors or peptidic anti-aggregators  (Nakagami, Nishimura 
et al. 2002, Lecanu, Yao et al. 2004, Jillian, Xiaoyan et al. 2009, Doig and Derreumaux 2015). 
There have been various natural small molecule inhibitors of Aβ and αS investigated. Out of 
the various natural products, EGCG, curcumin and resveratrol have been studied extensively 
for inhibition of different amyloidogenic protein aggregates (Marambaud, Zhao et al. 2005, 
Yang, Lim et al. 2005, Ehrnhoefer, Bieschke et al. 2008, Ahmad and Lapidus 2012). Other 
natural products such as baicalein have demonstrated inhibition of αS aggregation by 
stabilizing its toxic oligomers and inhibiting oligomer formation in living cells (Hong, Fink et 
al. 2008, Lu, Ardah et al. 2011).  In addition, baicalein inhibited Aβ oligomerization, 
disaggregated preformed Aβ aggregates and prevented Aβ fibril-induced toxicity in PC-12 
cells (Lu, Ardah et al. 2011). A detailed introduction about the antiaggregative and anti-
amyloid properties of natural small molecules, has been provided in Publication 1: Book 
Chapter (section 1.6.4). 
Among other inhibitors, small heat shock proteins (HSP) have been documented to act as 
molecular chaperones that prevent amyloidogenic aggregation (Hatters et al. 2001, Rekas et al. 
2004, Gorenberg and Chandra 2017). Another protein therapeutic is a combination of human 
immunoglobulin and  a general amyloid interaction motif (GAIM), which binds to αS as a 
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generic amyloid inhibitor and is in a clinical trial (Krishnan, Tsubery et al. 2014). Another 
recent approach features the use of small antibody fragments called intrabodies to inhibit αS 
aggregation (Bhatt, Messer et al. 2013). Intrabodies are typically composed of 140–250 amino 
acids and target antigens intracellularly with high specificity and affinity for target epitopes.   
1.5.3  Clearance of Aβ and αS aggregates 
Antibody-based immunotherapy has predominantly accounted for clearance of Aβ aggregates 
and plaques from AD-affected patient’s brains. Monoclonal antibodies have recently gained 
attention, with the promising results of aducanumab in clinical trials (Sevigny, Chiao et al. 
2016). Strategies for clearance of αS employ an enhancement of the autophagic process. 
Rapamycin and its analogues, acting through the mammalian target of rapamycin (mTOR) to 
increase macroautophagic functions, have been shown to reduce αS aggregation (Moors, 
Hoozemans et al. 2017). Another autophagy-enhancing approach involves the lysosomal 
enzyme β-glucocerebrosidase (GCase), as mutations in the GCase encoding gene GBA1 have 
been reported as a common risk factor for αS aggregation-related disorders, primarily due to 
reduced GCase activity (Sardi, Cheng et al. 2015). For degrading and clearing extracellular αS 
aggregation, active and passive immunotherapies in the form of monoclonal antibodies have 
been trialled recently (Schenk, Koller et al. 2017, Brys, Ellenbogen et al. 2018).  
 
In view of the recent multimodal approach to overcome the amyloidogenic proteinopathy 
caused by Aβ and αS, it is essential to identify new molecular inhibitors that can generically 
target amyloidogenic aggregation.  
 
1. 6  Natural products as inhibitors of amyloidogenic protein aggregation 
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1.6.1 Advantages of natural products in drug discovery 
Presently there is neither any disease-modifying approach in both AD and PD nor any 
therapeutic agent that targets amyloidogenic protein aggregation. Provided the multiferous 
health benefits and a rich diversity of molecular structures, natural products offer an attractive 
collection to search for amyloid inhibitors that can be further developed as therapeutics 
(Ganesan 2008). Historically, small molecules found in natural products or inspired by a natural 
product have served as the key active ingredient in many drugs and candidates in clinical trials 
(Chin, Balunas et al. 2006, Newman and Cragg 2007, Harvey 2008). Recent drug discovery 
efforts extensively relied on natural product structures for design of new molecular entities 
(NMEs) (Patridge, Gareiss et al. 2016, Rodrigues, Reker et al. 2016). In addition, target 
oriented synthetic tractability and structural flexibility of small molecules help building 
focused libraries for classical drug discovery (Schreiber 2000).  
1.6.2  Health benefits of natural polyphenols 
Polyphenols are by definition organic molecules with multiple phenol rings that are widely 
distributed in various dietary sources as micronutrients and in other plant sources as a stress 
protective mechanism (Manach, Scalbert et al. 2004). Polyphenols cover an extensive group of 
compounds such as flavonoids, curcuminoids, stilbenes, lignans, tannins, phenolic acids, 
anthocyanidins, chalcones and other compounds. The anti-oxidant properties of various 
polyphenols are often highlighted in their health benefits against several diseases associated 
with oxidative stress (Manach, Scalbert et al. 2004). Based on the present understanding, 
polyphenols exert their powerful antioxidant effects by three mechanisms; H atom transfer, 
single electron transfer and metal chelation (Leopoldini, Russo et al. 2011). A comprehensive 
study of polyphenol metal chelation activity demonstrated that ‘gallol’ or ‘catechol’ group in 
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polyphenols, mostly found in flavonoids, exhibited higher antioxidant property due to chelation 
of iron and copper ions (Perron and Brumaghim 2009). Additionally, flavonoids can scavenge 
reactive oxygen molecules by supressing xanthine oxidase activity (Hanasaki, Ogawa et al. 
1994). The powerful antioxidant property and reduction of reactive oxygen species (ROS) of 
polyphenols contribute toward protection from cardio-vascular disease, various cancers, 
diabetes and age related disorders including neurodegenerative disease (Pandey and Rizvi 
2009).  
In addition to antioxidant effects, polyphenols also possess anti-inflammatory properties. 
Flavonoids and their glycoside derivatives reduce inflammation by various pathways such as 
inhibiting cyclooxygenase (COX) and lipoxygenase (LOX) responsible for generating 
leukotrienes (LTs) (Moroney, Alcaraz et al. 1988). Also, some flavonoids such as quercetin 
inhibit the phospholipase A2 enzyme as part of their anti-inflammatory response (Lee, 
Matteliano et al. 1982). Since oxidative stress and inflammatory responses are some of the 
primary mechanisms of amyloidogenic protein toxicity, antioxidant and anti-inflammatory 
compounds might provide benefit towards protecting neurons from these toxic injuries.  
1.6.3  Polyphenols that inhibit amyloidogenic protein aggregation and toxicity 
Various polyphenol bioactive compounds have demonstrated interactions with amyloidogenic 
proteins which inhibit their aggregation. Among these, flavonoids are the most effective group 
of compounds in altering amyloidogenic protein aggregation (Shimmyo, Kihara et al. 2008, 
Bieschke, Russ et al. 2010, Meng, Munishkina et al. 2010, Lu, Ardah et al. 2011). Flavonoids 
collectively represent molecules with a benzopyran ring connected with a phenyl ring, termed 
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a B-ring. They are further subdivided into flavone, flavanol, flavanone, flavanonol, flavan, 
flavan-3-ol, isoflavone and anthocyanidin classes. The flavan-3-ol, epigallocatechin-3-gallate 
(commonly known as EGCG) and flavone myricetin have been demonstrated to cause 
inhibition of amyloidogenic protein aggregation including Aβ and αS (Shimmyo, Kihara et al. 
2008, Bieschke, Russ et al. 2010). Moreover, EGCG remodelled amyloidogenic fibrils into off-
target non-toxic pathways and disrupted preformed amyloid aggregates (Ehrnhoefer, Bieschke 
et al. 2008). Other catechol-type (two or more adjacent hydroxyl groups) flavonoids such as 
taxifolin, epicatechin, quercetin and fisetin have also elicited significant inhibition of amyloid 
aggregation (Bastianetto, Yao et al. 2006, Porat, Abramowitz et al. 2006, Ansari, Abdul et al. 
2009, Sato, Murakami et al. 2013, Ahmad, Ali et al. 2017). The non-catechol type flavonoids 
such as morin, datiscetin, kaempferol have also shown antiaggregative activities towards Aβ 
(Hanaki, Murakami et al. 2016). Baicalein, another catechol-type flavonoid caused extensive 
inhibition of αS aggregation by stabilizing its oligomeric conformations into an off-target 
pathway (Hong, Fink et al. 2008). In addition to inhibiting protein aggregation, flavonoids also 
protected neuronal cells in vitro and in vivo from amyloid pathology (Hong, Fink et al. 2008, 
Rezai-Zadeh, Arendash et al. 2008, Bieschke, Russ et al. 2010, Lu, Ardah et al. 2011, Lorenzen, 
Nielsen et al. 2014).  
Aside from flavonoids, curcumin is the most widely researched bioactive polyphenol for 
inhibition of amyloidogenic aggregation and toxicity. Curcumin reduces Aβ levels by several 
mechanisms, of which binding to Aβ deposits and inhibiting oligomer and fibril formation in 
vivo is noteworthy (Yang, Lim et al. 2005). Moreover, curcumin decreased Aβ levels by 
attenuating the maturation of its precursor protein, APP (Zhang, Browne et al. 2010). Curcumin 
also reduced αS aggregation by binding to monomers, increasing its reconfiguration rate which 
makes the protein more diffusive (Ahmad and Lapidus 2012). The stilbene resveratrol has also 
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been studied extensively for its potential to mitigate amyloid toxicity through degradation of 
Aβ by a proteasome-dependent mechanism (Marambaud, Zhao et al. 2005). The antioxidant 
property of resveratrol can activate the neuroprotective sirtuin protein, SIRT1 (silent mating 
type information regulation-2 homolog) to protect neuroblastoma cells from oxidative stress 
caused by αS aggregation (Albani, Polito et al. 2009). Figure 7 shows the chemical structures 
of EGCG, curcumin and resveratrol, three commonly known natural product amyloidogenic 
aggregation inhibitors as discussed above.  
The search for natural products to develop therapeutics for neurodegeneration has identified 
other classes of bioactive compounds such as terpenoids, alkaloids and carotenoids as effective 
agents against dementia (Papandreou, Kanakis et al. 2006, Yoo and Park 2012). Terpenoid-
rich Gingko biloba extracts and ginkgolides have been studied thoroughly for protection 
against Aβ and αS-induced toxicity (Wu, Wu et al. 2006, Shi, Zhao et al. 2009, Yu, Chen et al. 
2017). 
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Figure 7: Chemical structures of the commonly known polyphenols as inhibitors of 
amyloidogenic protein aggregation. 
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Alzheimer’s disease (AD) is a progressive 
neurodegenerative disorder for which current drug 
treatments are not considered disease modifying. 
Therefore, new therapeutic approaches targeting the 
cause of the disease are desirable. Aggregation of 
β-amyloid (Aβ), the hallmark protein associated with
brain plaques in AD, involves a process of oligomeriza-
tion of Aβ protein monomers (typically 1–40 and 1–42
fragments) to form fibrils and/or protofibrils (Ferreira 
and Klein, 2011; Newman et al., 2007). Aβ aggregates
through intermolecular β sheet formation and elicits
neurotoxicity via multiple mechanisms in the brain.
Aβ is produced by unconventional proteolysis of
membrane-bound amyloid precursor protein (APP) by 
β and γ secretase via a process termed the amyloido-
genic pathway. Misfolded Aβ monomers have the pro-
pensity to self-aggregate and form neurotoxic oligomers 
and fibrils that are associated with neuronal inflam-
mation, excitotoxicity, and oxidative stress (Canevari 
et al., 2004). Inflammatory responses can be evoked in Bioactive Nutraceuticals and Dietary Supplements in Neurological and Brain Disease
http://dx.doi.org/10.1016/B978-0-12-411462-3.00008-4 
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(Fioravanzo et al., 2010; Jana et al., 2008), resulting in the 
generation of inflammatory mediators such as cytokines 
and reactive oxygen species (ROS; Behl et al., 1994), and 
oxidative stress is believed to be one of the major contrib-
uting factors to neurodegenerative disease progression 
(Milton et al., 2008).
Understanding the primary neurotoxic mechanisms 
of Aβ has fuelled research interest towards an array of
naturally occurring polyphenolic compounds able to 
elicit neuroprotection via multiple mechanisms (Smid 
et al., 2012). Among such compounds, flavonoids are 
the largest group of polyphenolics that have gained 
recognition for various health benefits, including neu-
roprotection (Ramassamy, 2006). Flavonoids have 
demonstrated activity in reducing oxidative stress and 
inflammatory responses to Aβ. In our discussion, we
focus on selected flavonoids with a widely recognized 
potential as antiamyloid treatments (Rossi et al., 2008), 
and further focus on the direct interaction of such com-
pounds with the formation or stability of aggregated, 
toxic Aβ species.© 2015 Elsevier Inc. All rights reserved.
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(-) EPIGALLOCATECHIN-3-GALLATE
The green tea polyphenol (-) epigallocatechin-3-gallate 
(EGCG) has a demonstrable capacity to protect neuronal 
cells from Aβ-mediated toxicity in vitro. Its direct antiam-
yloid interaction occurs via inhibition of the formation 
of β-amyloid fibrils and disruption of mature fibrils
(Ehrnhoefer et al., 2008; Harvey et al., 2011). It can 
remodel and inactivate preformed fibrils to nontoxic, 
unstructured, or ‘off-target’ forms (Bieschke et al., 2010). 
The remarkable β sheet disruptive capacity of EGCG
extends not only to actions at Aβ but also includes
α-synuclein and other amyloidogenic proteins such as
plasmodium merozoite surface protein (Chandrashek-
aran et al., 2010, 2011), prion scrapie protein (Rambold 
et al., 2008), semen-derived enhancer of virus infection 
(SEVI) amyloid (Hauber et al., 2009), and transthyretin 
(Miyata et al., 2010).
Experimentally, EGCG has been found to protect 
neuronal cells against Aβ and pro-oxidant evoked neu-
rotoxicity. In neuronal cells, EGCG pretreatment sig-
nificantly reduced Aβ mediated neurotoxicity in vitro
(Harvey et al., 2011). Hippocampal neurons pretreated 
with EGCG when exposed to Aβ for 48 hours had ele-
vated cell survival and decreased caspase activity (Choi 
et al., 2001). EGCG also has a protective effect against 
Aβ-induced neuronal apoptosis through scavenging
ROS (Jung et al., 2007).
Importantly, EGCG promotes remodeling of pre-
formed oligomers of Aβ that may allow elimination of
accumulated toxic Aβ species during amyloidogenesis.
Blocking seeded polymerization is of importance from a 
therapeutic standpoint, because patients diagnosed with 
AD are already likely to have accumulated preformed 
Aβ fibrils and aggregates. The remodeling of mature
fibrils or misfolded proteins such as Aβ1-40 in vitro is also
dependent on the auto-oxidation of EGCG, and bind-
ing with hydrophobic regions of Aβ plays an important
role in EGCG-mediated remodeling. Oxidized EGCG 
molecules may react with free amines within the amy-
loid fibril through formation of Schiff base, cross-linking 
the fibrils that may prevent dissociation and toxicity 
(Palhano et al., 2013).
In terms of direct antiamyloid interactions, EGCG 
can halt fibrillogenesis by hydrogen-bonding with Aβ,
modifying its pathway to allow formation of nontoxic 
oligomers (Ehrnhoefer et al., 2008). EGCG traps Aβ and
α-synuclein in monomeric and oligomeric forms with
a diminished ability to participate in amyloidogenesis. 
This probably prevents the conformational rearrange-
ments within oligomers required to nucleate aggrega-
tion. The unstructured oligomers induced by EGCG 
are unable to seed further aggregation; instead they 
are believed to follow an alternative, nontoxic pathway I. ROLE OF COMPLEMENTARY AN
Sukanya Das, PhD Thesis, 2018(Kayed et al., 2003). These oligomers are more suscepti-
ble to disaggregate by molecular chaperones or protein-
remodeling factors than toxic oligomers.
Studies using molecular dynamics (MD) and molec-
ular mechanics Poisson-Boltzman surface area (MM-
PBSA) free energy calculations have shown that nonpolar 
interactions, mainly van der Waals forces, contributed 
the major interactions in EGCG/Aβ1-42 binding, whereas
polar interactions such as hydrogen bonding were sec-
ondary (Liu et al., 2011). NMR investigation of EGCG-
induced, nontoxic Aβ oligomer formation corroborated
that EGCG interferes with the aromatic hydrophobic 
core of Aβ (Lopez del Amo et al., 2012). Twelve impor-
tant residues of Aβ1-42 strongly interact with EGCG; all
contribute significantly to the EGCG and Aβ1-42 interac-
tion (Liu et al., 2011). Direct binding of EGCG to Aβ1-42
expels water from its surface as a process to elicit con-
formational changes to Aβ, and inhibition of the Aβ1-42
conformational transition by EGCG is dose dependent. 
Similarly, EGCG has a site-specific interaction with SEVI 
amyloid precursor peptide PAP248-286 monomers. It inter-
acts with two side chain regions of primarily charged 
residues, particularly lysine, by the pH-dependent Schiff-
base, allowing formation of a tightly bound complex 
(Popovych et al., 2012).
An atomistic replica exchange molecular dynamics 
(REMD) study of Aβ1-42 secondary structure and its con-
formational changes due to EGCG found that binding 
with small molecule EGCG causes remarkable changes 
in the Aβ1-42 dimer in an aqueous solution (Zhang et al.,
2013). In the presence of EGCG, Aβ secondary structures
demonstrated a reduction in β sheet content, increased
coil and α-helix content, and reduced interchain and
intrachain content. Thermodynamic analysis of the 
molecular interactions between Aβ and EGCG revealed
that hydrogen bonding occurred mainly in regions 
1–16 and hydrophobic bonding in regions 17–42 of Aβ
(Shi-Hui Wang, 2010, 2012).
However, EGCG binds to unfolded proteins in a non-
selective fashion as well, which may have unanticipated 
consequences in therapeutic settings. For example, 
EGCG interfered with proteins involved in mitigating 
cell damage, such as the normal cellular prion protein 
PrP(C), rendering cells susceptible to oxidative stress 
(Rambold et al., 2008).
CURCUMIN
The natural polyphenol curcumin, (bis-4-hydroxy-
3-methoxyphenyl)-1,6-diene-3,5-dione, is present in
the yellow curry spice turmeric derived from Curcuma
longa. Over the last decade, several studies have demon-
strated that it possesses antiamyloid and antiaggregativeD ALTERNATIVE SUPPLEMENTS
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properties relevant to AD pathogenesis and progression. 
Clinical trials with curcumin are ongoing, but so far they 
have demonstrated limitations in curcumin bioavailabil-
ity and efficacy in regards to improvements in cognitive 
function (Ringman et al., 2012). Nonetheless, animal 
studies have shown that both curcumin and turmeric 
extract are effective at lowering Aβ burden in AD trans-
genic mice models. Curcumin is able to label plaques, 
block toxicity of oligomers, and significantly reduce 
amyloid levels following oral dosing (Begum et al., 2008; 
Shytle et al., 2012). High level ab initio molecular mod-
eling of curcumin reveals that the molecule possesses 
unique charge and bonding characteristics to enable 
penetration through the blood–brain barrier and bind-
ing to Aβ protein (Balasubramanian, 2006).
Overall, curcumin’s direct antiaggregative capacity 
can be attributed to both inhibition of Aβ aggregation
and disaggregation of preformed amyloid fibrils. Cur-
cumin can bind and inhibit fibril formation, including 
full-length Aβ sequence and Aβ1-28, Aβ12-28, and Aβ25-35
fragments. However, curcumin’s effects did not depend 
on Aβ sequence but were instead dependent on fibril-
related conformation. Despite the common overlapping 
sequence of these fibrillogenic peptides, amino acids 
25–28, curcumin cannot bind nonaggregating peptides 
that span this Aβ17-28 region (Yang et al., 2005). Multi-
scale computational methods have demonstrated that, 
when compared, both EGCG and curcumin preferen-
tially interact with the central hydrophobic core (CHC) 
region of the Aβ17-42 trimer (Chebaro et al., 2012).
RESVERATROL
The phytoalexin stilbenoid resveratrol (3,5,4’-trihy-
droxy-trans-stilbene) is commonly found in grapes and 
red wines and has neuroprotective properties against 
Aβ-evoked toxicity (Richard et al., 2011). Resveratrol
dose-dependently inhibits Aβ1-42 fibril formation and
neurotoxicity, with part of its activity attributed to directly 
interfering with Aβ aggregation and oligomer conforma-
tion (Feng et al., 2009), including remodeling to off-target 
conformations (Ladiwala et al., 2010). Structural ana-
logues of resveratrol can more potently inhibit Aβ accu-
mulation in cells compared to resveratrol (Vingtdeux 
et al., 2011). Modelling of resveratrol binding to the Aβ17-42
model trimer revealed varying binding sites compared to 
EGCG and curcumin; however, a similar affinity for the 
CHC region was evidenced (Chebaro et al., 2012). Exten-
sive replica exchange molecular dynamics simulations 
also revealed that resveratrol blocks the lateral growth of 
single-layered β sheet oligomer in human IAPP segments
22–27, which contributes to a reduction in aggregation 
levels (Jiang et al., 2011).I. ROLE OF COMPLEMENTARY AN
Sukanya Das, PhD Thesis, 2018CONCLUSION
Among the numerous primary antioxidants stud-
ied for their potential neuroprotective abilities, EGCG, 
curcumin, and resveratrol have been among the most 
widely studied natural product compounds for further 
consideration as nutraceutical-based therapeutic treat-
ments for AD or other amyloidoses. Among these three 
examples of dietary polyphenols, EGCG has demon-
strated diverse properties in relation to binding with 
Aβ oligomers, disrupting mature Aβ fibril formation,
or otherwise modulating the amyloidogenic process-
ing pathway from APP. Of the three, EGCG possesses 
significant development potential for consideration as 
a neuroprotective therapeutic option in clinical trials in 
AD. Notwithstanding the core clinical challenges of AD-
modifying therapies generally, EGCG still has significant 
limitations to overcome (e.g., bioavailability) before it 
can be considered a viable therapeutic option (Mereles 
and Hunstein, 2011).
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1.6.5  Clinical application of natural products as amyloidogenic protein aggregation 
inhibitors 
The demonstrated preclinical efficacy of the noted amyloidogenic aggregation inhibitor natural 
molecules such as EGCG has not translated into efficacy in clinical studies due to poor 
bioavailability (Cascella, Bimonte et al. 2017). Other polyphenols such as curcumin and 
resveratrol,  have been used in AD clinical trials where they too have lacked efficacy (Mecocci 
and Polidori 2012). Additionally, AD clinical trials investigating the effect of standardised 
Gingko biloba extract known as EGb761 have not been promising (Sandrine, Pierre-Jean et al. 
2008). EGCG has also been studied for inhibition of αS aggregation that may result in delayed 
progression of disability in patients with multiple system atrophy (MSA), another αS 
aggregation-related disease (ClinicalTrials.gov Identifier: NCT02008721 (Levin, Maaß et al. 
2016). Clinical trials involving amyloidogenic protein aggregation inhibitors have consistently 
fallen short of benchmarks for efficacy. Rational design of new small molecules inspired from 
natural products and their further design for desirable drug-like properties may improve clinical 
translation of small molecular amyloidogenic aggregation inhibitors.   
1.7  Search for new inhibitors of amyloidogenic aggregation from synthetic origin 
The search for amyloidogenic protein aggregation inhibitors outside natural origin involves 
identification of novel synthetic compounds based on standard drug discovery methods. 
Fragment-based drug discovery (FBDD) is an established and alternative approach to 
traditional high throughput screening (HTS) for identifying novel small molecular structures 
for a drug target (Shuker, Hajduk et al. 1996, Erlanson 2012, Murray, Verdonk et al. 2012). 
This structure-based method has made a significant contribution in successful development of 
anti-Aβ drug classes such as BACE1 inhibitors (Stamford and Strickland 2013). This method 
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requires a fragment library and employs screening methods to detect binders for further 
development. Computer-aided screening methods such as ‘virtual screening’ is also widely 
used for screening a compound library. Nonetheless, screening studies for compounds bearing 
a fragment of interest, such as heterocyclic rings targeted to Aβ are limited. In this thesis 
(Chapter 3), a virtual screening study has been employed to identify compounds bearing 
fragments of interest that can directly interact with Aβ.  
1.8 Biochemical and cell-based assays coupled with molecular modelling for identifying 
new amyloid binders 
1.8.1  Monitoring amyloidogenic protein aggregation by thioflavin T assay 
Thioflavin T (ThT) is a dye that specifically binds to amyloid structures of protein and gives 
fluorescence output at an approximate wavelength of 482 nm when excited at 450 nm (Naiki, 
Higuchi et al. 1989). Chemically, it is a benzothiazole salt where the benzothiazole group is 
connected to a dimethylamionobenzene group by a non-planar conformation at ground state. 
Upon excitation, ThT undergoes twisted internal charge transfer as a molecular rotor that 
accounts for its fluorescence output (Stsiapura, Maskevich et al. 2007). When ThT binds to the 
amyloid structures of a protein, this intramolecular rotation cannot take place due to steric 
hinderance and produces high fluorescence output which is proportional to the amount of 
amyloid protein present in solution (Ban, Hamada et al. 2003, Stsiapura, Maskevich et al. 
2007). The ThT assay has been considered a standard method for determining amyloid 
aggregation and fibrillisation kinetics in vitro. Furthermore, the ThT assay can also shed light 
on how the presence of a compound impacts the aggregation of an amyloid protein, whereby 
decreased fluorescence may be indicative of inhibition of amyloid aggregation. The result of 
this assay is analysed by ‘Area under the curve’ (AUC) analysis. Following analysis, the AUC 
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graph is expressed as X-axis (time) value multiplied by Y-axis (relative fluorescence unit or 
RFU in arbitrary unit or AU) value. This statistical analysis provides information about the 
significance of an aggregation inhibitor. Hence, the ThT assay can be useful in comparing the 
anti-aggregatory effects of various compounds towards Aβ and αS.  In the present study, a 
kinetic ThT assay for both Aβ and αSA53T aggregation and the effect of a diverse group of 
molecules have been performed to understand their potential anti-aggregative effects.  
1.8.2  Visualisation of amyloidogenic aggregation by electron microscopy 
Despite the advantage of monitoring amyloidogenic aggregation by the ThT assay, there are 
some inherent limitations of this method. The assay can be susceptible to fluorescence 
quenching by the presence of some flavonoids owing to the reactivity of the oxidised-flavonoid 
quinone formed (Coelho-Cerqueira, Pinheiro et al. 2014). This quenching can present false 
positive results for inhibition. Additionally, some compounds can interact with ThT or compete 
with the binding site on the amyloid protein which can lead to erroneous results (Hudson, 
Ecroyd et al. 2009). Therefore, visualisation of amyloid aggregates and fibrils by electron 
microscopy, along with the ThT assay, is advantageous for a more rigorous determination of 
an anti-aggregative effect of a compound. In this regard, transmission electron microscopy 
(TEM) can uncover valuable information about the actual effect of each compound on amyloid 
aggregation, fibril formation and morphology (Petkova, Leapman et al. 2005). In the present 
study, visualisation of Aβ and αSA53T aggregates and fibrils has been carried out by TEM in 
addition to the ThT assay.  
1.8.3  Probing the structural conversion of αSA53T protein by Ion mobility-mass spectrometry 
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Ion mobility-mass spectrometry (IM-MS) is a powerful tool to investigate the early structural 
conversion of amyloidogenic proteins. Since amyloidogenic proteins such as αS exhibit 
structural polymorphism during the early aggregation process and form a heterogeneous 
population, sensitive biochemical techniques capable of monitoring all the transient species 
would be beneficial. IM-MS methods combining ion mobility with mass spectrometry are 
particularly informative, as it can study the conformation of each charge state of a protein and 
measure their cross sections (Jurneczko and Barran 2011). Additionally, it can retain the weak 
non-covalent interactions in gas phase between a protein and its ligand, which makes it suitable 
for studying the effect of various compounds on αSA53T (Sarni‐Manchado and Cheynier 
2002).  
It is well known that αS belongs to the class of intrinsically disordered proteins (IDP) that lack 
a detectable secondary structure (Eliezer, Kutluay et al. 2001). Given the advantages of mass 
spectrometry and IMMS in particular in being able to study the structural changes of IDP, it 
would be suitable to study the change of the structural conformation of αS from interaction 
with a ligand that might inhibit amyloidogenic aggregation, and is employed in Chapter 4 of 
this thesis (Leavell, Gaucher et al. 2002, Touboul, Maillard et al. 2009, Frimpong, Abzalimov 
et al. 2010, Jurneczko, Cruickshank et al. 2012).  
1.8.4  Study of neuronal cell viability using the MTT assay for neuroprotection 
As mentioned earlier, both Aβ and αS or its pathological mutant αSA53T can evoke damage 
to neuronal cells by oxidative stress, inflammatory responses and other perturbations. 
Mitochondrial dysfunction is a major driver of the neurodegeneration observed in the 
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neurotoxicity of Aβ and αS aggregates. As a result, measuring mitochondrial activity as an 
indicator of viable cells is an established method to study amyloid toxicity in vitro. Living cells 
with active mitochondrial function can reduce the MTT dye, which is a yellow tetrazole salt 
reduced by cellular oxidoreductase enzymes to give a purple colour. The intensity of the 
produced purple colour is correlated with the number of viable cells under experimental 
conditions. The MTT assay is thus a standard colorimetric assay that is used to study the 
neurotoxicity exerted by Aβ and αS towards cultured neuronal cells and the subsequent 
neuroprotection by a compound. In this study, rat phaeochromocytoma (PC-12) cells have been 
used to study the neuroprotective effect of various compounds as well as to study the oxidative 
stress and lipid peroxidation arising from prooxidant tert-butyl hydrogen peroxide (t-bhp) 
exposure.  
1.8.5  Studying the interaction of molecules with Aβ and αSA53T by molecular docking 
Computational simulation methods such as molecular docking provide valuable information 
regarding small molecule or ligand prospective interactions with a target macromolecule or 
protein. It is a key tool that enables the interaction study and comparison of a large number of 
ligands towards a target in a very short time and relatively inexpensively. The goal of docking 
is to predict the optimal binding solutions of a protein-ligand complex in a three-dimensional 
representation that can be comparable to other structural biological findings such as X-ray 
crystallography. All docking methods employ a scoring function in order to rank its predicted 
binding solutions. The scoring function considers the available knowledge about the ligand and 
the target. In this study, molecular docking methods have been used extensively to study the 
interaction of each compound with different Aβ and αSA53T structures. Moreover, docking 
has been used here for a ligand-based drug design approach for designing novel amyloid 
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binding ligands. The scoring function used in the docking mode presented in this study is 
termed as piecewise linear potential or PLANTSPLP scoring function (Korb, Stützle et al. 2009).  
Due to its efficiency, molecular docking approaches have been employed for virtual screening 
databases to find novel fragments or ligands (Meng, Zhang et al. 2011, Grinter and Zou 2014). 
Nevertheless, the predictability of the scoring function and benchmarking in docking 
methodology play an important role in the success of docking, as well as in virtual screening. 
Hence, combining docking with an experimental ligand binding assay allows a platform of 
testable predictions. In this present study, a structure-based virtual screening study using both 
molecular docking and experimental testing has been undertaken to validate the docking 
predictions. Subsequently, the docking insights have been used to design novel ligands 
following ligand-based drug design methods.    
1.9  Research hypothesis: 
The main hypothesis of this thesis is to test whether the in silico molecular modelling 
predictions about favourable binding profile of a small molecule would lead to inhibition or 
alteration of aggregation in vitro. The molecular docking performed here in this thesis provide 
an inexpensive, fast and computationally guided ligand selection or screening tool as opposed 
to experimental throughput screening. Therefore, it is of great value to validate the reliability 
of molecular docking simulations for identifying new small molecular binder of amyloidogenic 
proteins. Chapter 3 in particular, has tested this hypothesis where the small molecules for in 
vitro experiments have been selected based on their docking profiles. Chapter 2, 4 and 5 have 
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partially tested the hypothesis as the molecular docking prediction has been in agreement with 
the in vitro results.  
1.10  Research Aims: Identification, characterization and design of molecules for dual 
inhibition of Aβ and αS aggregation and toxicity 
Studies investigating inhibition of amyloidogenic protein aggregation such as Aβ and αS by 
various molecules provide insight into the chemical structures that might be useful in drug 
design targeting amyloid proteins. However, compounds that are well-known for inhibition of 
Aβ and αS aggregation in vitro have generally not been effective in clinical trials (Mereles and 
Hunstein 2011). Despite serious research endeavours, there seems to be inherent limitations in 
using some previously identified natural molecules for rational drug-design (Baell 2016, 
Nelson, Dahlin et al. 2017). Therefore, identification of new natural molecules that are 
structurally distinct from EGCG or curcumin and can suppress pathogenic amyloid aggregation 
would be important for designing therapeutics targeting both AD and PD. Additionally, 
identification of new synthetic molecules that can work as effectively as the natural molecules 
towards mitigating Aβ and αS aggregation and toxicity would be valuable for drug-discovery, 
since synthetic molecules possess certain advantages in the early drug candidate selection. 
Finally, the design of novel ligands predicted to have superior binding towards amyloidogenic 
proteins would be valuable for both novel therapeutics or diagnostic imaging after further 
structure optimization for selective binding to an amyloid target.  
Research aims addressed in Publication 2 (Chapter 2) 
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1. To identify new bioactive polyphenols outside the flavonoid group that can be a
potent inhibitor of Aβ1-42 aggregation, alter fibril morphology and protect neuronal cells 
from Aβ1-42 mediated neurotoxicity.   
2. To investigate the effect of the neolignan honokiol on Aβ1-42 aggregation and fibril
morphology in comparison with the characterised flavonoids myricetin and luteolin. 
3. To determine whether punicalagin, the antioxidant ellagitannin in pomegranate, can
potently inhibit Aβ1-42 aggregation and alter fibril morphology in comparison with 
myricetin, luteolin and honokiol.   
4. To investigate if the anti-aggregative action of honokiol and punicalagin is correlated
with neuroprotection from Aβ1-42 toxicity in neuronal (PC-12) cells in comparison with 
the neuroprotection conferred by myricetin and luteolin.  
5. To study the binding interaction of honokiol and punicalagin to different Aβ1-42
conformations in comparison with select flavonoids. 
Research aims addressed in Publication 3 (Chapter 3) 
1. To identify new binders of Aβ1-42 through virtual screening of an open source
chemical database, filtered for a five-membered heterocycle (FMH) ring with only 
nitrogen or nitrogen and oxygen as the heteroatom and with no exocyclic C=O/S/N 
group.  
2. Test in vitro virtual screening ‘hit’ compounds for translating whether their low
docking score with Aβ1-42 correlates to inhibition of Aβ1-42 aggregation and alteration 
of fibril morphology.  
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3. To study the concentration-dependent toxicity profile of each selected ‘hit’
compound in cultured PC-12 cells. 
4. Based on the toxicity profile, to further test the non-toxic compounds for
neuroprotection of PC-12 cells from Aβ1-42 mediated toxicity. 
5. To undertake a comparative analysis of the proposed binding interactions according
to docking of selected ‘hit’ compounds to identify a novel molecular scaffold that can 
bind to Aβ1-42 to inhibit toxic amyloidogenic aggregation.  
Research aims addressed in Publication 4 (Chapter 4) 
1. To explore the effects of various molecular structures identified previously on
αSA53T early conformational change leading to amyloidogenic aggregation, aggregate 
or fibril morphology and exogenous toxicity to PC-12 cells.   
2. To examine the effect of different structures for inhibition of αSA53T amyloidogenic
aggregation: 
a. Whether only B-ring trihydroxylation as occurs in the semi-synthetic flavone
2-D08 can inhibit αSA53T toxic amyloidogenic aggregation in comparison to
myricetin. 
b. Comparison of effectiveness of dihydroxylation in both the A and B-ring
with myricetin or 2-D08 
3. To investigate whether the small neolignan honokiol can inhibit αSA53T
amyloidogenic aggregation and neurotoxicity in comparison with flavones. 
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4. To examine the effect of the bulky and extensively hydroxylated ellagitannin
molecule punicalagin on αSA53T amyloidogenic aggregation and neurotoxicity in 
comparison with select flavones and honokiol.  
5. Exploring the effect of two synthetic compounds bearing a novel molecular scaffold
on αSA53T amyloidogenic aggregation and neurotoxicity in comparison with natural 
flavones, neolignan and ellagitannin.  
Research aims addressed in Chapter 5 
1. To test the effect of magnolol, another neolignan that is structurally similar to
honokiol, on both Aβ and αSA53T amyloidogenic protein aggregation, fibril 
morphology and neuroprotection.  
2. To characterize the anti-aggregative properties of a structurally diverse set of
bioactives including two diterpenes, cryptotanshinone and tanshinone I, the alkaloid 
neferine, chalcone phloretin and flavone galangin on Aβ and αSA53T.  
Research aims addressed in Chapter 6 
1. To utilise the neolignan pharmacophore for an in-silico ligand-based drug design
approach to design improved novel amyloid binders, specifically for Aβ and αS. 
2. To incorporate the novel molecular scaffold identified from virtual screening into the
novel ligand design. 
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a. To design a novel ‘core’ molecular structure/fragment and study how other
commonly used five membered heterocycle (FMH) rings affect the binding to 
Aβ and αSA53T.   
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Chapter 2: Bioactive polyphenol interactions with β amyloid: a comparison 
of binding modelling, effects on fibril and aggregate formation and 
neuroprotective capacity 
Sukanya Das, Lina Stark, Ian F. Musgrave, Tara Pukala and Scott D. Smid (2016), ‘Bioactive 
polyphenol interactions with β amyloid: a comparison of binding modelling, effects on fibril 
and aggregate formation and neuroprotective capacity’, Food & Function, 7, 1138 – 1146.  
Reprinted as per Royal Society of Chemistry authors deposition and sharing rights as per the 
licence to publish, 2018. 
This study was focused on identifying new naturally occurring bioactive polyphenols that can 
potently inhibit Aβ1-42 amyloidogenic aggregation and alter Aβ1-42 fibril or aggregate 
morphology. The other aim of this study was to determine whether the inhibition of Aβ1-42 
aggregation results in neuroprotection from Aβ1-42 mediated toxicity in vitro. Additionally, this 
study was focused on comparing the effects of different structural features present in natural 
polyphenolic compounds on Aβ1-42 amyloidogenic aggregation and neurotoxicity. A neolignan 
polyphenol, honokiol and a bulky ellagitannin polyphenol, punicalagin were studied and 
compared with the flavones myricetin and luteolin. Both flavones contain the catechol (vicinal 
hydroxyl) group in their B-ring that is considered as a favourable structural feature in 
flavonoids for binding Aβ to mitigate toxicity (Sato, Murakami et al. 2013). Myricetin contains 
a trihydroxyl and luteolin contains a dihydroxyl group in their flavone B-ring. Myricetin was 
previously shown to alter the Aβ conformation that reduces toxicity (Shimmyo, Kihara et al. 
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2008), while luteolin was known to inhibit Aβ aggregation and act as a neuroprotectant against 
Aβ toxicity (Cheng, Hsieh et al. 2010, Churches, Caine et al. 2014). The comparative analysis 
of honokiol and punicalagin with these two flavones addressed the similarity or differences in 
the effect of neolignan biphenyl and ellagitannin structures on Aβ1-42 aggregation, as compared 
to catechol-type flavones.  
In addition, the other aim addressed in this study was the comparison of these four polyphenols 
and their proposed binding interaction with model Aβ1-42 monomeric and oligomeric structures. 
As discussed earlier, the Aβ monomeric structures shown in this figure are very unlikely to be 
the conformation of the peptide in water (which is unstructured) but rather what it adopts in a 
membrane-like environment. Aβ interacts readily with cell membranes and it may elicit its 
toxic effects by forming pores in the membrane leading to cell death, so the structures of the 
α-helical peptide with the bioactives bound has relevance. This direct binding comparison 
facilitated our understanding of different structural features participating in proposed binding 
interactions according to docking models. The results indicated that honokiol has a higher 
probability of sterically interacting with the model Aβ1-42 targets and therefore was used in 
subsequent studies (Chapter 6) as a template for the design of an effective amyloid binding 
small molecule.     
Overall, this study identified the potent antiaggregatory property of honokiol along with its 
ability to mitigate Aβ1-42-induced toxicity in neuronal PC-12 cells. Additionally, this study 
identified punicalagin as a potent inhibitor of Aβ1-42 aggregation that can also protect PC-12 
cells from Aβ1-42 toxicity. The anti-amyloid activity of honokiol and punicalagin is comparable 
to the noted flavone anti-amyloid bioactives, myricetin and luteolin.   
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Bioactive polyphenol interactions with
β amyloid: a comparison of binding
modelling, effects on fibril and aggregate
formation and neuroprotective capacity
Sukanya Das,a Lina Stark,b Ian F. Musgrave,a Tara Pukalac and Scott D. Smid*a
In this study we compared the effects of a diverse set of natural polyphenolics ligands on in silico inter-
active modelling, in vitro anti-aggregative properties and neuronal toxicity of β amyloid. The β amyloid-
binding characteristics of optimised structural conformations of polyphenols with ascribed neuroprotec-
tive actions including punicalagin, myricetin, luteolin and honokiol were determined in silico. Thioflavin T
and transmission electron microscopy were used to assess in vitro inhibitory effects of these polyphenols
on Aβ1–42 fibril and aggregation formation. Phaeochromocytoma (PC12) cells were exposed to Aβ1–42,
alone and in combination with test concentrations of each polyphenol (100 μM) and viability measured
using MTT assay. Aβ1–42 evoked a concentration-dependent loss of cell viability in PC12 cells, in which all
four polyphenols demonstrated significant inhibition of neurotoxicity. While all compounds variably
altered the morphology of Aβ aggregation, the flavonoids luteolin and myricetin and the lignan honokiol
all bound in a similar hydrophobic region of the amyloid pentamer and exerted the most pronounced
inhibition of Aβ1–42 aggregation. Each of the polyphenols demonstrated neuroprotective effects in PC12
cells exposed to Aβ1–42, including punicalagin. These findings highlight some structure–activity insights
that can be gleaned into the anti-aggregatory properties of bioactive polyphenols based on modelling of
their binding to β-amyloid, but also serve to highlight the more general cellular neuroprotective nature of
such compounds.
Introduction
A diverse array of natural polyphenols have been ascribed
neuroprotective properties in a number of models of neuronal
damage and neurodegeneration, and are considered potential
avenues for the development of neuroprotective drug thera-
pies.1,2 Bioactive polyphenols such as flavonoids been shown
to mediate neuroprotection against exposure to the toxic brain
protein β-amyloid found in Alzheimer’s disease via multiple
actions.3,4
Many naturally occurring compounds have demonstrated
interactions with amyloid proteins resulting in inhibition of
fibril or oligomer formation. Polyphenolic compounds,
individually or within extracts of their natural product
sources, have been shown to directly disrupt and remodel
amyloid fibrils into non-toxic conformations as part of their
with neuroprotective action, exemplified by the green tea
component epigallocatechin gallate (EGCG).5,6 Pomegranate
juice or extract has been shown to reduce amyloid burden
and microglial activation in transgenic mouse AD models,7,8
but the contribution from a constituent complex polypheno-
lic component ellagitannin, punicalagin, has not been ascer-
tained. Additionally, the Magnolia-derived lignan honokiol
has also demonstrated neuroprotective and anti-amyloid pro-
perties in vitro,9,10 yet an interaction directly affecting
β-amyloid conformational states is unknown. As examples,
these compounds all have a markedly divergent structure to
other plant-derived flavonoids such as luteolin and myrice-
tin, which have been identified as potent inhibitors of
β amyloid induced memory impairment and β amyloid
aggregation.11–14 It is not known if such structurally varying
polyphenolics such as punicalagin and honokiol can interact
directly in a common motif within β-amyloid to explain
potential neuroprotective actions.
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In this study we determined the capacity for such a set of
structurally diverse and naturally occurring polyphenols to
directly alter β-amyloid fibril formation and compared this
with their neuroprotective effects in vitro. Additionally, we
investigated the predictive capacity of selected polyphenolic
binding to β amyloid through in silico approaches and com-
pared this with their fibrillar inhibitory and neuroprotective
capacity. In this way we aimed to better understand the struc-
tural basis of β amyloid interactions with naturally occurring




Human amyloid-β 1–42 protein (Aβ1–42) was obtained from
Abcam (Cambridge, MA, USA). Select polyphenols used in this
study were the flavonoids luteolin and myricetin, the lignan
honokiol and the ellagitannin punicalagin, the latter a com-
ponent of pomegranate.15 All were sourced from Sigma-Aldrich
(St Louis, MO, USA). Thiazolyl blue tetrazolium bromide
(MTT), trypan blue, thioflavin T, DMSO, 10% neutral-buffered
formalin, Roswell Park Memorial Institute 1640 (RPMI)
medium, uranyl acetate, Dulbecco’s Modified Eagles Medium
(DMEM), poly-L-lysine solution, Triton ×100 and foetal calf
serum (FCS) were also obtained from Sigma-Aldrich. Non-
essential amino acids (NEAA), penicillin/streptomycin, 10×
trypsin EDTA and phosphate buffered saline (PBS) at pH 7.4
were obtained from Thermo Fisher Scientific (Scoresby, VIC,
Australia). Bovine serum albumin (BSA) was obtained from
Bovogen Biologicals (East Keilor, VIC, Australia).
PC12 cell culture
Rat phaeochromocytoma cells (Ordway PC12) cells displaying a
semi-differentiated phenotype with neuronal projections16
were kindly donated by Professor Jacqueline Phillips (Mac-
quarie University, NSW, Australia) and maintained in
RPMI-1640 media with 5% foetal calf serum (FCS), 1% L-gluta-
mine, 1% non-essential amino acids and 1% penicillin/
streptomycin. Cells were seeded at 2 × 104 cells per well in
RPMI-1640 and 10% FCS. PC12 cells were equilibrated for
24 hours before treatment with bioactives and/or Aβ1–42.
Aβ preparation and treatment in PC12 cells
Native, non-fibrillar Aβ1–42 was prepared by dissolving in 1%
DMSO to yield a protein concentration of 3.8 mM. Sterile PBS
was added to prepare a final concentration of 100 µM. Amyloid
was then dispensed into aliquots and immediately frozen at
−70 °C until required.
Punicalagin, luteolin, honokiol and myricetin were diluted
in PBS to their final stock concentrations prior to addition to
cells. Undifferentiated PC12 cells were treated with each of
these bioactives at 100 μM, 15 minutes prior to incubation
with Aβ1–42 (0–2 μM). Cells were then incubated for 48 hours at
37 °C, 5% CO2 prior to measurement of cell viability.
Cell viability measurements
Viability was determined in PC12 cells using the thiazolyl blue
tetrazolium bromide (MTT) assay. After incubation, 96-well
plates had all media removed and replaced with serum-free
media containing 0.25 mg ml−1 of MTT. The plate was further
incubated for 2 hours at 37 °C with 5% CO2, then MTT solu-
tion removed and cells lysed with DMSO. Absorbance was
measured at 570 nm using a PolarStar Galaxy microplate
reader (BMG Labtech, Durham, NC, USA).
Thioflavin T assay and microscopy of Aβ fibril and
aggregate formation
Thioflavin T (ThT) binds to β-amyloid fibrils with fluorescence
increasing proportionally to the amount of fibrils present in
solution. The ThT assay was used to confirm fibril formation
over time with β-amyloid in cell-free solution, in addition to
determining if fibril formation was directly affected by the
polyphenolic compounds. ThT (10 µM in PBS) was added to
wells on a microplate together with non-fibrillar Aβ1–42 (10 µM)
and the test polyphenol compound (each at 100 μM). In
addition, a range of concentration of each bioactive (0, 1, 10,
50 and 100 µM) was tested against Aβ1–42 (10 µM) to determine
the concentration–response relationship for inhibition of
fibrillisation. Fluorescence was then measured at 37 °C every
20 minutes for 48 hours using a Synergy MX microplate reader
(Bio-Tek, Bedfordshire, UK) with excitation and emission wave-
lengths at 446 nm and 490 nm respectively. ThT output from
all treatment groups was normalised to blank values (ThT
alone in PBS).
Transmission electron microscopy (TEM) was used to visua-
lise Aβ aggregates and fibrils and to investigate the effects of
selected polyphenols on Aβ morphology. Samples were pre-
pared by incubating native Aβ1–42 (10 µM) in PBS, either alone
or with flavonoids (100 μM each) for 48 hours at 37 °C. A 5 μl
sample was then placed onto a 400 mesh formvar carbon-
coated nickel electron microscopy grid (Proscitech, Kirwan,
QLD, Australia). After 1 minute this sample was blotted off
using filter paper and 10 µl of contrast dye containing 2%
uranyl acetate was then placed onto the grid, left for one
minute and blotted off with filter paper. Grids were then
loaded onto a specimen holder and then into a FEI Tecnai G2
Spirit Transmission Electron Microscope (FEI, Milton, QLD,
Australia). Sample grids were then viewed using a magnifi-
cation of 34 000–92 000×. Grids were extensively scanned
manually in search of fibrils and representative images taken.
Computational modelling of polyphenol optimized
conformation and binding to Aβ1–42
For three polyphenols (luteolin, myricetin and honokiol), equi-
librium geometries were optimized using density functional
theory (DFT) approach17 that utilizes Becke’s three-parameter
hybrid functional known as B3LYP.18 A large basis set, aug-cc-
pVDZ was used for approximation of molecular orbitals in
optimized geometry for all three molecules. All the compu-
tations were carried out using Gaussian 09 package of codes
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(http://www.gaussian.com/) at the Tizard supercomputer server
of eResearch SA (https://www.ersa.edu.au/tizard). Calculations
were carried out in no symmetry to facilitate full rearrange-
ment and relaxation of the structures to their most stable
form. For punicalagin, the optimized structure was extracted
from Human Metabolome Database (HMDB ID: HMDB05795),
as geometry optimization through computation such as
DFT-B3LYP or Hartree-Fock method was difficult to accom-
plish due to the large size and complexity of its molecular
structure.
Fully optimized ligand structures were studied for their
binding interactions with Aβ1–42 monomer (PDB ID: 1IYT) and










Honokiol 266.33 −47.18 −47.54 −2.00 16.53
Luteolin 287.24 −41.36 −36.20 −5.75 9.07
Myricetin 319.24 −38.86 −36.06 −5.08 19.19
Punicalagin 1070.61 −47.14 −56.14 0.00 15.70












Honokiol 266.33 −71.23 −71.93 −3.58 17.67
Luteolin 287.24 −65.07 −52.53 −12.67 21.06
Myricetin 319.24 −60.75 −46.74 −15.81 21.08
Punicalagin 1070.61 −52.40 −57.64 −4.00 16.43
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oligomeric pre-fibrillar pentamer β-sheet structure (PDB ID:
2BEG) were modelled using the CLC Drug Discovery Work-
bench, version 1.5.1 (http://www.clcbio.com/products/clc-drug-
discovery-workbench). This software uses a MolDock scoring
function to identify the optimal solution from its docking
algorithm based on a hybrid search algorithm denoted as
guided differential evolution.19 The MolDock scoring function
is based on a piecewise linear potential (PLP). Since Aβ1–42
monomers and oligomers do not have any singular pharmaco-
phore, a large search space was created covering the whole
protein. All ligand structures were kept flexible to allow
rotation of any bonds in order to bind Aβ1–42. There were 100
iterations performed for each docking simulation for all four
polyphenolic ligands. Results are summarized as a docking
score in Tables 1 and 2.
Statistical analysis
Data obtained from the MTT assay was analysed via a two-way
analysis of variance (ANOVA) to assess neuronal cell viability
arising from incubation in Aβ1–42, alone or in the presence of
polyphenol ligands, with a Bonferroni’s post hoc test used to
determine the significance level for each polyphenol treatment
interaction at each Aβ1–42 concentration tested. Area under the
curve analysis for Thioflavin T (ThT) fluorescence data was
analysed using one way ANOVA with a Dunnett’s multiple com-
parisons test used for determining the significance of bioactive
effects versus Aβ1–42. A significance value of p < 0.05 was used
for all experiments. Data analysis and production of graphs
was performed in GraphPad Prism 6 for Windows (GraphPad
Software, San Diego, USA).
Results
Thioflavin T fluorescence of Aβ1–42 fibrillisation kinetics
Thioflavin T (ThT)-based fibrillisation kinetics of Aβ1–42
demonstrated a gradual increase in fluorescence output reach-
ing a plateau by 900 min (15 h), indicative of maximum fibril
and aggregate formation (Fig. 1a). Thereafter, ThT levels were
stable over the duration of the assay up to 2880 min (48 h). All
of the four polyphenols tested: myricetin, honokiol, luteolin
and punicalagin (each at 100 µM) markedly inhibited the
development of ThT fluorescence, abolishing output both at
the initial period of fibrillisation and continuing over the full
48 h time course of incubation. Area under the curve analysis
showed extensive and significant overall inhibition of fibril for-
mation in the presence of each of the bioactive polyphenols at
100 μM over this time course (Fig. 1b). Inhibition of Aβ1–42
fibrillisation was also demonstrated to be concentration-
dependent for both luteolin and punicalagin within the range
of 1–100 µM as measured at the peak of the active fibril growth
phase at 10 h (Fig. 2a and b). For myricetin, the lowest concen-
tration tested (1 µM) still demonstrated marked inhibition of
ThT fluorescence (Fig. 2c), while honokiol also substantially
attenuated ThT output at 1 µM (Fig. 2d). The calculated relative
inhibitory concentration (IC50) of each polyphenol at 10 hours
was myricetin (0.25 µM) > honokiol (0.55 µM) = punicalagin
(0.56 µM) > luteolin (1.6 µM). Inhibition at all polyphenol con-
centrations continued over 48 h of incubation (not shown).
Transmission electron microscopy of Aβ1–42 fibrils and
aggregates
On microscopic evidence, the morphology of the amyloid
fibrils and aggregates was affected by incubation with each of
the polyphenols, but to varying effect on both the extent and
morphology of aggregation. For example, overall Aβ1–42 aggre-
gation was reduced and aggregates more amorphous in
appearance in the presence of myricetin (Fig. 3b). Luteolin
altered Aβ1–42 aggregate morphology in a similar way to myrice-
tin in appearance, although the extent of aggregation was
more than that observed in myricetin-treated samples (Fig. 3e).
Fibril and aggregate morphology in punicalagin (Fig. 3c) and
honokiol-treated (Fig. 3d) Aβ1–42 samples was similar, but in
both cases overall fibril appearance was less dense than in
control samples.
Effects of polyphenols on Aβ1–42 mediated neuronal toxicity
MTT assay of cell viability demonstrated that Aβ1–42 (0.1–2 μM)
evoked a concentration-dependent decrease in cell viability to
a maximum of 60% over 48 h (Fig. 4). Notably, each of the
polyphenols myricetin, honokiol, luteolin and punicalagin
(each at 100 μM) provided a significant degree of neuroprotec-
tion against β amyloid exposure over the full concentration
range of Aβ1–42.
Fig. 1 (a) Thioflavin T (ThT) fluorescence indicative of amyloid Aβ1–42
fibrillisation kinetics, alone and in the presence of each of four poly-
phenolic bioactives (100 μM each) over 48 h in cell-free PBS solution.
(b) Area under the curve analysis of ThT kinetics demonstrate significant
overall inhibition of amyloid fibrillisation from incubation with poly-
phenolics (****P < 0.0001; mean ± SEM of n = 4 experiments).
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Molecular modelling of optimised polyphenol binding to Aβ
monomer and pentamer
The optimised structures of each of the four polyphenols were
docked to the model Aβ1–42 monomer and pentamer. In the
monomer, honokiol and myricetin bound to the same region
(Fig. 5c and d) and interacted with key amino acid residues
Glu3, His6, Asp7, Gly9 and Try10 (residues not shown). Luteo-
lin bound to the rear side of the monomer (Fig. 5b) interacting
with residues Gln15, Lys16 and Phe19, while punicalagin
bound to the Aβ1–42 monomer in the broader region of residue
Leu17 to Val39 due to the larger size of the molecule (Fig. 5a).
The Aβ1–42 pentamer was made up of a chain of Aβ monomers
(chain A, B, C, D, E) aligned side by side to form a β-sheet like
structure (Fig. 6). Honokiol, luteolin and myricetin interacted
with the hydrophobic binding pocket formed by Lys16, Leu17,
Fig. 2 Thioflavin T (ThT) fluorescence demonstrating amyloid Aβ1–42 fibrillisation kinetics over 10 h in cell-free PBS solution, alone and in the pres-
ence of increasing concentrations of polyphenolic bioactives (1–100 μM each): (a) punicalagin (b) luteolin (c) myricetin and (d) honokiol.
Fig. 3 Representative transmission electron micrographs of Aβ1–42 fibril
and aggregate formation, alone and following 48 h incubation with
selected polyphenols (each at 100 μM): (a) Aβ1–42 (b) Aβ1–42 and myrice-
tin (c) Aβ1–42 and punicalagin (d) Aβ1–42 and honokiol (e) Aβ1–42 and
luteolin. Scale bar: 1 μm.
Fig. 5 Modelled bioactive ligand binding of each of the four optimised
polyphenolic conformations to Aβ1–42 monomer: (a) punicalagin, (b)
luteolin, (c) myricetin and (d) honokiol. Binding properties of each poly-
phenol are provided in Table 1.
Fig. 4 MTT assay representing cell viability of PC12 cells following 48 h
of Aβ1–42 incubation, alone or with either punicalagin, luteolin, myricetin
or honokiol (each at 100 μM). Each of the bioactive polyphenols exerted
significant protection over the full concentration range of Aβ1–42. ****p
< 0.0001 for each bioactive vs. Aβ1–42 (1–2 μM); ***p < 0.001 for each
bioactive vs. Aβ1–42 (0.1–0.5 μM); mean ± SEM of n = 4 experiments.
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Val18 and Phe19 residues of all chains of the Aβ oligomer
(amino acid residues not shown). Honokiol bound inside this
binding pocket by forming hydrogen bonds with Leu17 and
Gly38 of chains C and E. Myricetin and luteolin both formed
hydrogen bonds with residue Leu17, Val18 and Phe19 of chain
C, D and E. Punicalagin, unlike the other smaller ligands,
bound to the exterior surface, possibly due to steric hindrance
interacting with residue Leu17 to Ser26 and forming hydrogen
bonding with residue Gly25.
Among the four bioactive molecules, punicalagin showed
the lowest docking score of −52.40 and steric interaction score
of −57.64, hydrogen bonding score of −4.0 with the β-sheet
conformation of Aβ1–42 pentamer (Table 2). Honokiol, on the
other hand, showed the highest docking score of −71.23, steric
interaction score of −71.93 and hydrogen bonding score of
−3.58. Luteolin and myricetin demonstrated similar docking
scores of −65.07 and −60.75 respectively. Luteolin provided a
higher steric interaction score than myricetin, whereas myrice-
tin demonstrated the highest hydrogen bonding score overall.
Optimal docking poses showed that the terminal hydroxyl
groups of the flavonoids luteolin and myricetin were crucial
for hydrogen bonding to Aβ1–42 (Fig. 6).
Discussion
These studies have compared the neuroprotective properties of
selected natural polyphenols with their capacity to structurally
modify the aggregation of the major neurotoxic β amyloid frag-
ment 1–42 in vitro. In silico modelling has also been used to
compare the likely binding sites of such polyphenols to the
β amyloid pentamer, as a further tool in which to investigate
the most effective binding parameters that may predict the
structural modification of β amyloid protein to potentially
non-toxic conformations.
Of those polyphenols tested, there was a pattern related to
the favourable molecular binding of the representative poly-
phenol to β amyloid protein and its effect on fibril and aggre-
gate morphology. This was inferred by both the extensive
inhibition of ThT fluorescence and clear morphological evi-
dence of fibril and aggregate modification via transmission
electron microscopic imaging. The appearance of β amyloid in
the presence of myricetin and luteolin resembled amorphous
aggregates observed from the interaction of various other com-
pounds with β amyloid, including the anti-fibrillar flavonoid
epigallocatechin gallate.20 Myricetin and luteolin have been
previously documented to have an anti-aggregatory effect on
β amyloid production21,22 and myricetin has also been shown to
be effective against other ordered amyloid fibrils.23 Such amor-
phous aggregates are likely to undergo loss of an extensive
surface area present in the ‘meshwork’ of Aβ fibrils in which
ThT binds24 to account for these marked reductions in output.
It was not possible to predict if such resultant forms of
polyphenol-modified Aβ were benign or toxic to neuronal cells
solely from either inhibition of ThT fluorescence or from struc-
tural imaging alone. However, previous studies using various
polyphenolic compounds, including flavonoids, have revealed
not just inhibition of Aβ fibril formation but also stabilisation
of oligomers into off-target pathways that abrogate neurotoxi-
city,25 so this is likely to have also occurred to mitigate Aβ neu-
rotoxicity in the present study. The most common disposition
of Aβ following incubation with flavonoids is as low molecular
weight oligomers with some protofibrillar aggregates.25
However, even within the large class of flavonoid compounds,
small differences in chemical structure can result in marked
differences in both the type of interaction with Aβ and its
resultant morphology.26–28 In addition, while we saw a varying
composition of Aβ species following incubation with all the
polyphenols used in this study, the ability to modify β amyloid
fibril formation is not a generalised property of all such natu-
rally-occurring polyphenolics. A diverse range of phytochemi-
cals that do not alter Aβ1–42 fibril morphology include such
compounds as cyanidin glucoside and gallic acid,29 dihydro-
kaempferol, galangin and pinobanksin,27 naringenin25 and
cannabidiol.20
From the docking studies, it was found that all four poly-
phenolic molecules bind to Aβ1–42 oligomer mainly through
steric and hydrogen bonding interactions. Key amino acid resi-
dues involved in the interactions of honokiol, luteolin and
myricetin are Lys16, Leu17, Val18 and Phe19 of chain C, D and
E of the Aβ1–42 oligomer. Interaction with Lys16 residue may
be particularly relevant for these molecules to exert neuro-
protection, as Lys16 residue appears to be an important factor
in promoting Aβ1–42 toxicity.30 Interestingly, evidence suggests
flavonoids may exert anti-aggregatory effects against Aβ1–42 by
the quinone-driven covalent modification of such a key lysine
residue in Aβ1–42, noting myricetin as one such example of a
potent inhibitor.27 Computational modelling of other small
molecule inhibitors of Aβ1–42, such as the flavonoid derivative
2-(4-benzyloxyphenyl)-3-hydroxy-chromen-4-one,31 demon-
strated that it binds to the same hydrophobic groove of the
Aβ1–42 pentamer/oligomer (2BEG) interacting with similar
amino acid residues as observed in our molecular docking
studies.
Fig. 6 Modelled bioactive ligand binding of each of the four optimised
polyphenolic conformations to Aβ1–42 pentamer: (a) punicalagin, (b)
luteolin, (c) myricetin and (d) honokiol. Binding properties of each poly-
phenol are provided in Table 2.
Food & Function Paper
This journal is © The Royal Society of Chemistry 2016 Food Funct., 2016, 7, 1138–1146 | 1143
View Article Online
Sukanya Das, PhD Thesis, 2018   52
Binding of both of these compounds to β amyloid was most
favourable on the hydrophobic part of the pentamer sur-
rounded by key residue Lys16, Leu17, Val18, Phe19, Gly38 and
Val39. This occurs in a groove running parallel with the long
axis of fibrils which is also associated with ThT binding.32
This may also explain why some polyphenolic compounds
exert a strong degree of inhibition of ThT fluorescence without
necessarily inhibiting fibril formation, via effective displace-
ment of ThT from its binding site but lacking the structural
interactions to alter fibrillisation itself.20 This may also form
one mechanism underlying the propensity for some poly-
phenolics to interfere with ThT fluorescence, leading to false
positives for fibril inhibition and limiting the inferences that
can be made from such experiments in isolation.33
The amyloid anti-aggregatory and neuroprotective capacity
of luteolin and myricetin are shared amongst other very
similar flavonols and isoflavones, including such compounds
as fisetin and transilitin.11,21 In such studies, modelling for
flavonoid binding to β amyloid oligomers indicates extensive
and stabilising hydrogen bonding between the flavonoid and
amino acid side chains critical for β sheet formation and
further fibrillisation.11 Myricetin also destabilises the β-sheet
conformation of Aβ25–35 peptide chains by forming hydrogen
bonds with key residues responsible for β-sheet formation.34
Coupled with the aforementioned potential of flavonoids for
covalent modification of key Aβ amino acid side chains,27 the
findings of such exploratory studies generally reinforce the
development potential of drugs derived from the core structure
of selected flavonoids for further consideration as potential
treatments for Alzheimer’s disease.35,36 However, other natu-
rally occurring non-flavonoid small molecules bind to a
similar region in the exterior groove of β amyloid oligomers,
eliciting remodelling via a combination of planar ring hydro-
phobic and hydrogen bonding interactions.37
Punicalagin and honokiol both demonstrated a substantive
and concentration-dependent degree of inhibition of fibril for-
mation as judged by attenuation of ThT fluorescence. When
viewed under the electron microscope, dense aggregates were
absent, but some smaller and less developed fibrillar aggre-
gates were still present and this may be sufficient to account
for the residual ThT fluorescence following incubation with
these compounds. In modelling the interaction of honokiol
with the Aβ pentamer, it was seen to bind to the inner pore as
distinct from the other flavonoids and punicalagin, and bound
with the most favourable energy state of all the polyphenols
tested. The molecular docking results indicate that steric inter-
action plays a major role for a bioactive molecule to bind
Aβ1–42 along with hydrogen bonding. Honokiol, due to its
small size and favourable intramolecular position of aliphatic/
side chains is able to fit efficiently within the binding pocket
resulting in a comparatively higher docking interaction score.
Interestingly, honokiol was recently described to inhibit calci-
tonin aggregation,38 suggestive of further potential as a small
molecule template for anti-amyloid drug development.
In the aforementioned discussion of complexity of ligand
binding and implications for fibril formation and morphology,
it may be a moot point how any polyphenol may bind or other-
wise alter Aβ fibrillisation if the end result is cellular neuro-
protection. Indeed, our observations of neuroprotection arising
from incubation with each of the bioactives highlights the plei-
tropic action of such polyphenols against β-amyloid evoked
neurotoxicity. We have previously shown bioactive-evoked
neuroprotection against β-amyloid toxicity to be concentration-
dependent using EGCG.39 This evidence, together with the
concentration-dependent inhibition of ThT fluorescence by a
number of compounds in the present study, is suggestive that
the degree of neuroprotection is likely to be linked cumulat-
ively to the extent of formation of ultimately benign forms of
β-amyloid by such polyphenols.
Both luteolin and myricetin have been shown to provide
neuroprotection against Aβ-mediated neurotoxicity through
multiple actions.12,14,40–43 Punicalagin not only demonstrated
significant neuroprotection against Aβ-mediated neurotoxicity,
but also resulted in higher levels of cell viability than control;
possibly indicative of a proliferative effect of the elligatannin.
As a major polyphenolic component of pomegranate extract,
its presence may be responsible for the beneficial effects of
pomegranate extract or juice in experimental animal AD
models,7 which include attenuated amyloid burden, reduced
microglial activation and lessened inflammation in a trans-
genic AD mouse model.8 Our results highlight for the first
time an action on amyloid β aggregation as another potential
neuroprotective mechanism of punicalagin. Additional
amyloid-mitigating actions are implicated in the activities of
this molecule, including BACE1 inhibition.15 Honokiol as a
lignan is structurally dissimilar to the flavonoids luteolin and
myricetin; however it also afforded neuroprotection to PC12
cells against β-amyloid exposure. This is supportive of a pre-
vious study that also demonstrated honokiol-mediated protec-
tion to PC12 cells following Aβ exposure.9 A degree of
neuroprotection has been ascribed to honokiol via anti-
oxidant, anti-inflammatory and neurotrophic actions,44 and
the closely related compound 4-O-methylhonokiol has also
been demonstrated to have substantive neuroprotective and
anti-inflammatory properties.45,46 Our results indicate an
additional anti-aggregative action at β-amyloid to this mole-
cule, the first reported to our knowledge.
Conclusions
In conclusion, diverse naturally occurring polyphenols show
varying affinity and binding sites for β-amyloid and can differ-
entially affect amyloid fibrillisation kinetics and morphology.
Modelling of bioactive polyphenol binding to discrete sites in
β-amyloid oligomers may be broadly predictive of altered fibril
and aggregate morphology, but this alone is not predictive of
neuroprotective effects of such compounds. In particular,
diverse polyphenol structures such as punicalagin and hono-
kiol are also able to disrupt the aggregative propensity of
β amyloid and this may be implicated in their neuroprotective
activity.
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Chapter 3: Identification of dibenzyl imidazolidine and triazole acetamide 
derivatives through virtual screening targeting amyloid beta aggregation 
and neurotoxicity in PC12 cells 
Sukanya Das, Scott D. Smid (2017) ‘Identification of dibenzyl imidazolidine and triazole 
acetamide derivatives through virtual screening targeting amyloid beta aggregation and 
neurotoxicity in PC12 cells’, European Journal of Medicinal Chemistry, 130: (354 - 364).  
Reprinted with permission from Elsevier, Crown Copyright 2017. 
This study was aimed at identifying new small molecule inhibitors of Aβ amyloidogenic 
aggregation and toxicity that contain a five membered heterocyclic (FMH) ring with nitrogen 
and/or oxygen as the heteroatom. Five membered heterocyclic (FMH) compounds are one of 
the key building blocks found in medicinal chemistry. Due to their high binding affinity with 
a variety of biological targets, some researchers classify FMH structures such as rhodanine and 
thiazolidine-2,4-dione as ‘privileged scaffolds’ in drug discovery (Tomasic and Masic 2009). 
However, debate exists for the suitability of the FMH ring with the exocyclic C=S group in 
early stage drug development, as the exocyclic C=S in rhodanine often offers a particularly 
high density of interaction sites which results in a promiscuous binding behaviour (Mendgen, 
Steuer et al. 2012) . Despite this fact, FMH ring-bearing compounds remain a chemically 
attractive class of compounds  that possess various intermolecular interaction points due to the 
presence of nitrogen and or sulphur in its ring (Mendgen, Steuer et al. 2012). Among this class 
of compounds, derivatives of thiohydantoin, rhodanine, hydantoin and thiazolidine are 
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commonly used in drug discovery (Meusel and Gütschow 2004, Jain, Vora et al. 2013). 
However, issues regarding the metabolic stability and toxicity of sulphur containing FMH ring-
bearing compounds have been raised (Tang, Lee et al. 2015). Therefore, such compounds 
without any exocyclic C=S containing N-atom as the only heteroatom offer an alternative 
option for drug lead development.  
Among the FMH ring-bearing compounds with only nitrogen as the heteroatom, imidazolidine 
or triazole compounds have shown bioactivity against various targets. For instance, 
imidazolidine-2-4, dione has been tested as a novel class of selective cannabinoid receptor 
agonists (van der Stelt, Cals et al. 2011), fatty acid amide hydrolase inhibitors (Muccioli, Fazio 
et al. 2006) and for antinociceptive effects in mice (de Queiroz, de Carvalho et al. 2015). A 
range of benzyl triazole derivatives act as γ-secretase modulators which lower Aβ levels in vivo  
(Fischer, Zultanski et al. 2011), while diphenyl triazole derivatives act as probe for detecting 
Aβ in human brain (Qu, Kung et al. 2007).  However, the direct interaction of these FMH ring-
bearing compounds, where nitrogen and/or oxygen are the heteroatom, with Aβ and its 
aggregation related toxicity is not well understood. An interaction of imidazolidine, triazole or 
benzoxazole derivatives against the pathologically relevant Aβ protein target would provide 
further insight towards suitability of these five membered heterocycle compounds without 
exocyclic C=O or C=S bonds as new aggregation inhibitors and neuroprotectants. 
In view of this, the present study was aimed at identifying new FMH ring-bearing compounds 
with nitrogen and/or oxygen as the heteroatoms that can inhibit Aβ aggregation and toxicity. 
To address this, structure-based virtual screening by molecular docking was performed. ZINC 
is an open access database for commercially-available compounds, with a collection of many 
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millions of compounds. This database is designed to be suited for virtual screening, where the 
compounds have been divided into subsets based on their ‘ring’ structure. As a result, the  
ZINC database was well suited for the purpose of this study. Before conducting the structure-
based virtual screening, the database was filtered for:  
(a): FMH ring bearing compounds that have nitrogen and or oxygen as heteroatom and (b). No 
exocyclic C=O/S/N groups in the FMH ring.  
This study has identified five new ‘hit’ compounds with predicted high binding scores to Aβ 
via molecular docking. Out of the five, four compounds inhibited Aβ aggregation in the 
thioflavin T assay of fibril kinetics. 100µM of each compound was tested against 10µM of Aβ 
in the anti-aggregation study. Finally, two compounds bearing a novel dibenzyl imidazolidine 
scaffold demonstrated inhibition of Aβ aggregation and neurotoxicity in neuronal (PC-12) 
cells. 
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Aggregation and neurotoxicity of amyloid b (Ab) protein is a hallmark characteristic of Alzheimer's
disease (AD). In this study we compared the anti-aggregatory and neuroprotective effects of five syn-
thetic compounds against Ab protein; four of which possessed a five membered heterocycle ring scaffold
(two dibenzyl phenyl imidazolidines and two triazole sulfanyl acetamides) and one with a fused five
membered heterocycle (benzoxazole) ring, selected thorough virtual screening from ZINC database.
Molecular docking of their optimized structures was used to study Ab binding characteristics. As pre-
dicted frommolecular docking, strong steric binding of imidazolidines and H-bonding of both triazoles to
Ab were translated into anti Ab aggregation properties. Subsequent transmission electron microscopy
(TEM) was used to assess their effects on Ab1-42 fibril formation. Four compounds variably altered
morphology of Ab fibrils from long, intertwined fibrils to short, loose structures. Thioflavin T assay of Ab
fibrillisation kinetics demonstrated that one imidazolidine and both triazole compounds inhibited Ab
aggregation. Rat pheochromocytoma (PC12) cells were exposed to Ab1-42, alone and in combination with
the heterocyclic compounds to assess neuroprotective effects. Ab1-42-evoked loss of neuronal cell
viability was significantly attenuated in the presence of both imidazolidine compounds, while the tri-
azole acetamides and benzoxazole compound were toxic to PC12 cells. These findings highlight the Ab
anti-aggregative and neuroprotective propensity of a dibenzyl phenyl imidazolidine scaffold (Compound
1 and 2). While the triazole sulfanyl acetamide scaffold also possessed Ab anti-aggregation properties,
they also demonstrated significant intrinsic neurotoxicity. Overall, the predictive efficacy of in silico
methods enables the identification of novel imidazolidines that act both as inhibitors of Ab aggregation
and neurotoxicity, and may provide a further platform for the development of novel Alzheimer's disease-
modifying pharmacotherapies.
Crown Copyright © 2017 Published by Elsevier Masson SAS. All rights reserved.1. Introduction
Deposition of amyloid beta (Ab) protein is a pathological hall-
mark of Alzheimer's disease (AD), due to its high propensity for
self-aggregation and conversion into toxic conformations. Under
pathological conditions, the 42 residue amyloid beta (Ab1-42) pro-
tein rapidly converts into neurotoxic oligomers, protofibrils and
fibrils that lead to the deposition of b amyloid plaques [1,2]. Soluble
oligomers and protofibrillar forms of Ab1-42 are more toxic than
mature fibrils and associated with neurodegeneration [3].gy, Adelaide Medical School,
, Adelaide, SA 5005, Australia.
mid).
evier Masson SAS. All rights reservConsequently, disrupting the aggregative properties of Ab1-42 pro-
vides a potentially disease-modifying approach that merits the
intensive search for small molecules that can impede self-
aggregation and attenuate toxicity [4].
Various natural polyphenolic compounds such as EGCG, myr-
icetin and curcumin suppress Ab1-42 aggregation and are also
associated with a neuroprotective capacity [5e8]. However, there
are limitations for using natural polyphenolic compounds as lead
compound in structure-based drug discovery in this field. This is
often related to poor bioavailability [9,10], with several novel small
molecules, including natural compounds lacking conclusive out-
comes in clinical trials [4,11]. Hence, identification and further
development of new small molecules targeting Ab1-42 would be
highly desirable for AD therapy.ed.
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dictive information on small molecules that may favourably bind
Ab, and thus be used in the identification of compounds or mo-
lecular scaffolds for rational drug design targeting Ab aggregation.
Here we have studied the interaction of five such synthetic com-
pounds, termed as Compound 1e5, selected from the ZINC chem-
ical database through virtual screening methods. The database was
filtered and screened for compounds in the single and double ring
subsets; a five membered heterocycle ring (FMH) with nitrogen
heteroatom (N) and a fused double ring with either a nitrogen or a
nitrogen and an oxygen heteroatom in the FMH ring, but no het-
eroatom in its six membered ring and having no exocyclic C]O,S,N
group. From the screening, four of the selected compounds con-
tained either two or three N atoms in their FMH ring. They were an
imidazolidine ring (Compound 1 and 2) or a triazole ring (Com-
pound 3 and 4). Compound 5 containing a fused FMH; a benzox-
azole ring was also selected (Fig. 1). We then investigated their Ab1-
42 docking interactions and subsequently assessed the effects of
each of these compounds on Ab1-42 aggregation kinetics, fibril
morphology and neuroprotective capacity in vitro.
2. Materials and methods
2.1. Reagents and chemicals
Human amyloid-b 1e42 protein (Ab1-42) was obtained fromFig. 1. 2-D structure of five selected compound
Sukanya Das, PhD Thesis, 2018rPeptide (Bogart, GA, USA). Compound 1, 3 and 4were sourced from
Specs, a screening compound manufacturer (https://www.specs.
net) while Compound 2 and 5 were sourced from ChemDiv
(http://www.chemdiv.com). Compound 2 and 5 were assessed as
>90% pure by manufacturer. For Compound 1 and 4, purity was
assessed through 1H NMR analysis (supplementary material, Figs. 1
and 2). For cell culture experiments, thiazolyl blue tetrazolium
bromide (MTT), trypan blue, Thioflavin T, DMSO, Roswell Park
Memorial Institute 1640 (RPMI) medium and fetal calf serum (FCS)
were obtained from Sigma-Aldrich (St Louis, MO, USA). Non-
essential amino acids (NEAA), penicillin/streptomycin,
10  trypsin EDTA and phosphate buffered saline (PBS) at pH 7.4
were obtained from Thermo Fisher Scientific, (Scoresby, VIC,
Australia). Bovine serum albumin (BSA) was obtained from Bov-
ogen Biologicals (East Keilor, VIC, Australia).
2.2. Database selection, structure/ligand searching and selection
process
ZINC15 (http://zinc15.docking.org/) is a free database that con-
tains over 120 million commercially available “drug-like” com-
pounds from various suppliers in a ready-to-dock structural format
[12]. We began our search from its single ring subset using i) in
nature and ii) for-sale filters and subsequently consolidated into 11
different types of single ring five-membered heterocycles (FMH)
with only nitrogen heteroatom. Similarly, in the double rings with their chemical names and ZINC IDs.
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either only one nitrogen or a nitrogen and an oxygen fused with a
six membered ring. Each of these 16 types of ring-bearing com-
pound subsets were further filtered for i) anodyne compounds with
known non-reactivity and ii) bb, compounds commercially avail-
able in preparative quantity. Thereafter, each subset was screened
through docking using PLANTSPLP scoring function [13] in speed
mode 4 that uses a 3s average ligand docking timewith no iteration
(Fig. 2).
All ligand screening simulations, further molecular docking and
image collection were conducted in CLC Drug Discovery Work-
bench (CLC DDW), version 1.5.1 (http://resources.
qiagenbioinformatics.com/manuals/clcdrugdiscoveryworkbench/
current/index.php?manual¼Introduction_CLC_Drug_Discovery_
Workbench.html). The best 10 docking results from all subsets were
visually inspected and ranked based on score, binding pose and
region and molecular weight (300e500 g/mol). The number of
compounds from the 16 types of ring subsets used in the virtual
screening is also provided (Table 1, Supplementary Material).
2.3. Computational modelling of compound optimized
conformations and binding to Ab1-42
In order to gain further insights into the Ab1-42 binding in-
teractions for each selected compound from screening, all ligandFig. 2. Schematic of the VS protocol. The ring subsets of ZINC database was filtered for N-h
were further filtered for anodyne, bb, and for-sale and then docked with PLANTSplp scoring
interaction. Finally five compounds were selected and redocked with their optimized struc
Sukanya Das, PhD Thesis, 2018structures were first optimized and then individually re-docked to
both Ab1-42 monomer and oligomer with normal speed (docking
time as required) with 300 iterations per docking. For all five
compounds, equilibrium molecular geometries were optimized
using density functional theory (DFT) method [14] that utilizes
Becke-Lee-Yang-Parr three-parameter hybrid functional commonly
known by the acronym B3LYP. A large basis set, aug-cc-pVDZ was
used in approximation of optimized geometry for all fivemolecules.
DFT-B3LYP level of calculations combining with a larger basis set is
considered as standard and reliable method for estimating opti-
mized molecular geometry [17]. Prior to docking, DFT calculations
were used to ascertain the accurate bond distances, angles, di-
hedrals and optimized conformations in the lowest energy state of
each of the selected compounds in this study. All the computations
were carried out using Gaussian 09 package of codes (http://www.
gaussian.com/) at the Tizard supercomputer server of eResearch SA
(https://www.ersa.edu.au/tizard). Calculations were carried out in
no symmetry to facilitate full rearrangement and relaxation of the
structures to their most stable form.
Fully optimized ligand structures were then allowed to dock
with the model Ab1-42 monomer and oligomeric pre-fibrillar pen-
tamer b-sheet structures. The docking software used a PLANTSplp
empirical scoring function to identify the optimal solution from its
docking based on a hybrid search algorithm, denoted as guided
differential evolution [13,18]. Ab1-42 monomer structure in solutioneteroatom FMH single and double rings, found in nature. Subsequently, 16 ring subsets
function. Best 10 compounds from all subsets were visually inspected for their binding
tures.
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as determined by NMR (PDB ID: 1IYT) and Ab17-42 oligomer forming
parallel, in register beta-sheet structures as determined by NMR
(PDB ID: 2BEG) were used as model Ab structures without any
further modification. The Ab1-42 monomer structure possessed an
alpha helical conformation with a beta-turn in solution, which was
suggested to be associated with membrane poration [19]. The
oligomeric b-sheet structure showed a correlation with neurotox-
icity and provided a structural basis for studies with fibrillisation
inhibitors [20]. Ab1-42 does not have any known singular pharma-
cophore and no crystalized Ab1-42 structure with small molecule,
co-crystalized ligand was available. Therefore, a large search space
was created covering the whole protein for binding sites. During
docking, all ligand structures were kept flexible to allow rotation of
any bonds in order to bind Ab1-42. Out of the top ten docking results,
the best binding poses with a high score were analysed. The
docking scores of the Thioflavin T molecule, a known binder of Ab1-
42, was used as a standard value. Results were summarized as a
docking score and interacting residues in Tables 1 and 2.2.4. Thioflavin T assay and microscopy of Ab fibril and aggregate
formation
Thioflavin T (ThT) binds to b-amyloid fibrils, with fluorescence
increasing proportionally to the amount of fibrils present in solu-
tion. The ThT assay was used to confirm fibril formation over time
with b-amyloid in cell-free solution, in addition to determining if
fibril formation was directly affected by the test compounds. In
order to avoid any interference with the fluorescence output, all
compounds were first dissolved in DMSO at 37 C and vortexed
repeatedly until it dissolved fully. They were then further diluted inTable 1
Docking profile of test compounds with Ab1-42 monomer (PDB ID: 1IYT).
Ligand Interacting residues H-bond form
Compound 1 Lys 16, Leu 17, Val 18, Phe 20, Ala 21
Val 24, Gly 25, Ile 31, Leu 34, Met 35
e
Compound 2 His 14, Leu 17, Val 18, Phe 19, Ala 21
Glu 22, Val 24, Gly 25, Ser 26
Glu 22
Compound 3 Gln 15, Lys 16, Val 18, Phe 19, Glu 22 Lys 16
Compound 4 Asp 7, Ser 8, Gly 9, Glu 11, Val 12, Gln 15, Lys 16, Phe 19 Asp 7
Gln 15
Compound 5 His 6, Gly 9, Tyr 10, Val 12, His 13,14
Gln 15, Leu 17, Val 18, Ala 21
e
Thioflavin T Val 12, His 13, Gln 15, Lys 16, Phe 19 e
Table 2
Docking profile of test compounds with Ab17-42 oligomer (PDB ID: 2BEG).
Ligand Interacting residues H-bond forming residues
Compound 1 Leu 17A,B,C,D,E, Val 18A,B,C,D,E
Phe 19A,B,C,D,E, Gly 37C,D,E, Gly 38C,D,E
Val 39B,C,D,E, Val 40B,C,D,E, Ala 42D,E
e
Compound 2 Leu 17C,D,E, Val 18B,C,D,E, Phe 19B,C,D,E
Phe 20E, Gly 37D,E, Gly 38D,E
Val 39D,E, Val 40C,D,E
e
Compound 3 Leu 17A,B,C,D,E, Val 18A,B,C,D,E
Phe 19A,B,C,D,E, Gly 37D, Gly 38D,E
Val 39B,C,D,E, Val 40B,C,D,E
Leu 17C
Compound 4 Leu 17A,B,C,D,E, Val 18A,B,C,D,E
Phe 19A,B,C,D,E, Gly 37D,E
Gly 38D,E, Val 39B,D,E, Val 40B,C,D,E
Leu 17C
Compound 5 Leu 17A,B,C,D,E, Val 18A,B,C,D,E
Phe 19A,B,C,D,E, Gly 37D,E, Gly 38D,E
Val 39B,D,E, Val 40B,C,D,E
Leu 17C
Val 39E
Thioflavin T Leu 17C,D,E, Val 18B,C,D,E
Phe 19B,C,D,E, Gly 37C,D,E, Gly 38C,D,E
Val 39C,D,E, Val 40C,D,E
e
ukanya Das, PhD Thesis, 2018PBS to the desired working concentration. ThT (10 mM in PBS) was
added to wells on a microplate together with non-fibrillar Ab1-42
(10 mM) and the test compound (each at 100 mM). Fluorescence was
then measured at 37 C every 10 min for 48 h using a Synergy MX
microplate reader (Bio-Tek, Bedfordshire, UK) with excitation and
emission wavelengths at 446 nm and 490 nm respectively. ThT
output from all treatment groups was normalized to blank values
(ThT alone in PBS).
Transmission electron microscopy (TEM) was used to visualize
Ab aggregates and fibrils and to investigate the effects of selected
compounds on Ab morphology. Samples were prepared by incu-
bating native Ab1-42 (10 mM) in PBS, either alone or with test
compounds (100 mM each) for 48 h at 37 C. A 400 mesh formvar
carbon-coated nickel electron microscopy grid (Proscitech, Kirwan,
QLD, Australia) was first treated in a plasma cleaning system
(Solarus 950 Gatan Advanced Plasma System) to make it more
hydrophilic. Then a 5 ml sample was placed onto the grid and after
1 min this sample was blotted off using filter paper. 10 ml of contrast
dye containing 2% uranyl acetate was then placed onto the grid, left
for 1 min and blotted off with filter paper. Grids were then loaded
onto a specimen holder and then into a FEI Tecnai G2 Spirit
Transmission Electron Microscope (FEI, Milton, QLD, Australia).
Sample grids were then viewed using a magnification of
34000e92000. Grids were extensively scanned manually in
search of fibrils and representative images were taken.2.5. Neuronal cell culture
Rat Phaeochromocytoma cells (Ordway PC12) displaying a semi-
differentiated phenotype with neuronal projections were kindlying residues Docking score Steric interaction score H-bond score RMSD (Å)
58.01 61.29 0.00 8.46
54.52 54.03 4.00 9.47
46.21 46.79 2.00 9.43
49.26 51.28 0.00 10.42
50.84 54.51 0.00 15.11
41.80 43.32 0.00 8.48
Docking Score Steric interaction score H-bonding score RMSD (Å)
87.69 90.24 0.00 19.07
77.71 81.25 0.00 23.75
73.86 73.08 3.62 18.44
71.44 71.91 2.00 18.53
77.91 80.62 3.04 21.77
65.53 69.45 0.00 21.00
63
S. Das, S.D. Smid / European Journal of Medicinal Chemistry 130 (2017) 354e364358donated by Professor Jacqueline Phillips (Macquarie University,
NSW, Australia) [21]. Cells were maintained in RPMI-1640 media
with 10% fetal calf serum (FCS), 1% L-glutamine, 1% non-essential
amino acids and 1% penicillin/streptomycin. Cells were seeded at
2 104 cells per well in RPMI-1640 with 10% FCS. PC12 cells were
equilibrated for 24 h before treatment with test compounds and/or
Ab1-42.
2.6. Ab and compound preparation
Native, non-fibrillar Ab1-42 was prepared by dissolving in 1%
DMSO to yield a protein concentration of 3.8 mM. Sterile PBS was
added to prepare a final concentration of 100 mM. Amyloid was then
dispensed into aliquots and immediately frozen at 70 C until
required. All test compounds were initially diluted in DMSO and
then in PBS to their final stock concentrations prior to addition to
cells.
2.7. Neuronal cell treatment and viability measurements
Undifferentiated PC12 cells were treated with each of these
compounds at 100 mM, 15 min prior to incubation with Ab1-42
(0e0.5 mM). Cells were then incubated for 48 h at 37 C, 5% CO2
prior to measurement of cell viability. To assess each of the test
compound's direct effects on cell viability, each compound was
incubated with PC12 cells for 48 h at 37 C, 5% CO2 along with a
vehicle over a concentration range 0e100 mM. After 48 h, PC12 cell
viability was determined using the thiazolyl blue tetrazolium bro-
mide (MTT) assay. After incubation, 96-well plates had all media
removed and replaced with serum-free media containing 0.25 mg/
ml of MTT. The plate was further incubated for 2 h at 37 C with 5%
CO2, then MTT solution was removed and cells were lysed with
DMSO. Absorbance was measured at 570 nm using a Synergy MX
microplate reader (Bio-Tek, Bedfordshire, UK).
2.8. Statistical analysis
Data obtained from the MTT assay was analysed via a two-way
analysis of variance (ANOVA) to assess neuronal cell viability
arising from incubation in Ab1-42, alone or in the presence of test
compounds, with a Bonferroni's post-hoc test used to determine
the significance level for each test compound treatment interac-
tion at each Ab1-42 concentration. Area under the curve analysis
for Thioflavin T (ThT) fluorescence data was analysed using one
way ANOVA with a Dunnett's multiple comparisons test used for
determining the significance of these tested compounds effects
versus Ab1-42. A significance value of p < 0.05 was used for all
experiments. Data analysis and production of graphs was per-
formed in GraphPad Prism 6 for Windows (GraphPad Software,
San Diego, USA).
3. Results
3.1. Selection of compounds by virtual screening method
In this study we attempted to identify compounds which bear a
N-heteroatom five membered heterocycle (FMH) ring without any
exocyclic C]O, C]S or C]N group, as opposed to common five
membered multi-heterocyclic (FMMH) lead-like molecules, which
may bind and alter Ab1-42 aggregation. The 16 type of rings filtered
from ZINC contained FMH rings bearing between 1 and 4 nitrogen
heteroatoms. Out of their best 10 screening results, the five highest
scoring ligands from three subsets were selected. These subsets
were imidazolidine (2 nitrogen FMH), triazole (3 nitrogen FMH)
and benzoxazole (1 nitrogen, 1 oxygen fused FMH) groups.Sukanya Das, PhD Thesis, 2018Extensive molecular docking screening simulations demonstrated
that the saturated 2-nitrogen rings such as imidazolidine, followed
by pyrazolidine, exhibited higher docking scores than unsaturated
ring types. Between the 2-nitrogen ring ligands, the dibenzyl
phenyl imidazolidine structures with the FMH at the center and
both N atoms bonded to dibenzyl side chains exhibited the highest
binding scores. Both Compound 1 and 2 were selected in order to
understand i) whether the dibenzyl phenyl imidazolidine scaffold,
present in both compounds, would render anti-aggregation prop-
erties as predicted from docking, and ii) the impact of an extra O-
methyl group in the phenyl group with respect to this scaffold's
effects on Ab1-42 aggregation and associated neurotoxicity. Since
they both possessed a common scaffold, a positive in vitro result for
both compounds would corroborate the anti Ab1-42 potential of this
scaffold. The triazole compounds (triazole sulfanyl acetamide
scaffold of Compound 3 and 4) were the next subset that displayed
high binding scores against both Ab1-42 conformations (Table 1).
They were selected to in order to gain an understanding of the 3-
nitrogen FMH scaffold and any role of an extra terminal methyl
group related to effects on Ab1-42 aggregation. Thereafter, we were
interested in selecting compounds with 1-nitrogen in the FMH. Of
these, benzoxazole ligands showed favourable binding scores when
compared to other 1-nitrogen FMH ligands. Compound 5, being a
fused benzoxazole ring provided a docking score similar to Com-
pound 2 and so provided insights into how such structural varia-
tions comparatively affected Ab1-42 aggregation.
3.2. Molecular modelling of compounds optimized structures:
effects on binding to Ab monomer and oligomer
The optimized structure of Compound 1 and 2 revealed that
Compound 2 had a different ground state conformation than
Compound 1 (supplementary material, Fig. 3). Compound 1 was
more planar than Compound 2, with the terminal benzene ring
puckered and sitting out of plane in Compound 2. The optimized
structures of each of the five compounds were allowed to dock to
the model Ab1-42 monomer and oligomer. In the monomer, Com-
pound 1 bound near the hinge region of the protein (Fig. 3a, nearby
residues were shown). Compound 2 bound to the front of the
protein (Fig. 3b, nearby residues were shown). One functionality of
the docking algorithm PLANTS is ‘ligand torsional potential’ as
implemented in the Tripos force field that is calculated for all the
rotatable bonds available in the ligandmolecule, with the exception
of terminal hydrogen bond-donating groups [22]. Since Compound
1 had 8 rotatable bonds and Compound 2 had 9 rotatable bonds,
they were likely to undergo a higher torsional optimization of their
molecular geometry as calculated by the DFTmethod after docking.
As seen in Fig. 3aeb and Fig. 4aeb, the docked conformations of
both Compound 1 and 2 were more twisted when compared to
their optimized 3D conformation (Fig. 3, Supplementary Material).
Compound 3 and 4 bound to the same region underneath the
protein surface (Fig. 3c and d, nearby residues were shown).
Compound 3 was positioned in the binding pocket and formed H-
bonding with Lys 16, whereas Compound 4 bound in the pocket by
bending at the sulfanyl group (Fig. 3c and d, nearby residues are
shown). Compound 5 docked in a binding pocket anterior to the
protein (Fig. 3e, nearby residues are shown).
The oligomeric Ab17-42 conformationwas made up of five chains
of Ab (chain A,B,C,D,E), aligned side by side to form a b-sheet like
structure. All the compounds boundwith different docking poses to
the hydrophobic pocket formed by chain B,C,D,E; residues Leu 17,
Val 18, Phe 19 and Gly 37, Gly 38, Val 39, Val 40 (Fig. 4aee). Com-
pound 1 bound inside this pocket with a benzyl ring posing out-
ward and parallel to the plane of the protein (Fig. 4a), therefore
interacting with most of the residues in the pocket but without64
Fig. 3. Binding of each of the five optimized compound conformations to Ab1-42 monomer (PDB ID: 1IYT): (a) Compound 1, (b) Compound 2, (c) Compound 3, (d) Compound 4 and
(e) Compound 5. Binding properties are provided in Table 1.
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its phenyl group, but its dibenzyl imidazolidine moiety was placed
outside the protein structure (Fig. 4b). Like Compound 1, it did not
form any hydrogen bonding. Compound 3 and 4 bound inside the
pocket, forming hydrogen bonding (Fig. 4c, Table 2). Compound 5
bound across the pocket with its phenyl group connected to ben-
zoxazole ring, positioned outside the oligomer (Fig. 4d). Among the
five compounds, Compound 1 showed the highest docking score
(Table 2). Compound 2 and 5 had similar scores, but with different
poses. Compound 3 and 4 had similar scores, while Compound 3
showed higher H-bond score than Compound 4.
3.3. Thioflavin T fluorescence of Ab1-42 fibrillisation kinetics
Thioflavin T (ThT)-based fibrillisation kinetics of Ab1-42
demonstrated a gradual increase in fluorescence output until
approximately 600 min (10 h), indicative of maximum fibril and
aggregate formation (Fig. 5a). Thereafter, ThT fluorescence levels
increased steadily up to 1560 min (26 h) and stabilized over theSukanya Das, PhD Thesis, 2018duration of the assay, up to 2880 min (48 h). Among the five test
compounds, Compound 2, 3 and 4 (imidazolidine and triazole
acetamides respectively) notably inhibited the development of ThT
fluorescence from the initial period of fibrillisation and continuing
over the duration of assay. Area under the curve analysis showed
extensive and significant overall inhibition of fibril formation in the
presence of each of Compound 2, 3 and 4 (each at 100 mM) over this
time course (Fig. 5b). By contrast, Compound 1, another imidazo-
lidine, did not affect the ThT fluorescence output over the duration
of assay (Fig. 5c). Compound 1 itself did not generate auto fluo-
rescence, either alone or with ThT (data not shown). Interestingly
however, when Compound 5 was incubated with Ab1-42, it showed
markedly higher fluorescence output than Ab1-42 alone (Fig. 5c).
Further examination revealed that even in absence of Ab1-42,
Compound 5 and ThT yielded higher fluorescence output than
Compound 5, Ab1-42 and ThT combined (Fig. 5c). Whereas, Com-
pound 5 alone, in the absence of ThT, produced very low fluores-
cence. This indicated a possible spectroscopic/fluoroscopic
interaction between Compound 5 and Thioflavin T.65
Fig. 4. Binding of each of the five compounds optimized conformations to Ab17-42 oligomer (PDB ID: 2BEG): (a) Compound 1, (b) Compound 2, (c) Compound 3 and 4 together in the
same binding region, (d) Compound 5. Binding properties are provided in Table 2.
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On microscopic evidence, the morphology of b amyloid fibrils
was affected by incubation with each of the compounds to varying
degrees. For Ab1-42 alone, the fibrils were relatively long, slightly
rough edged and intertwined in a rope-like manner (Fig. 6a). In the
presence of Compound 1, the fibrils appeared to be thinner, shorter
in length and loosely attached to each other (Fig. 6b). Compound 2
also elicited thinner, loosely attached and relatively shorter fibrils
(Fig. 6c). However, in Compound 1 treated samples, the fibrils
appeared to be smoother, whereas in Compound 2 treated samples,
the fibrils appeared to be relatively uneven. Fibrils in Compound 3
and 4 treated samples appeared to be thinner, uneven and with
some mesh-like structures indicative of small and punctate ag-
gregates (Fig. 6dee). With the exception of Compound 5, overall
fibril appearance was less dense when compared to Ab1-42 control
samples. In contrast, treatment with Compound 5 showed visibly
more fibrils than Ab1-42 control samples (Fig. 6f). These fibrils were
more prevalent than control with an extended length and
smoothened appearance.
3.5. Effects of compounds on neuronal cell viability
The MTT assay of cell viability demonstrated that Compounds 1
and 2 did not elicit significant toxicity to PC12 cells over the full
concentration range of 1e100 mM after 48 h (Fig. 7). By contrast,
Compound 3 exhibited moderate (20%e25%) toxicity and Com-
pound 4 caused comparatively higher toxicity (60%) than Com-
pound 3 after 48 h at 100 mM. Compound 5 demonstrated the
highest toxicity among the five compounds, with 35% toxicity at
10 mM increasing in a concentration-dependent manner to over
87% at 100 mM.
3.6. Effects of test compounds on Ab1-42 mediated neurotoxicity
Incubation with Ab1-42 (0.1e0.5 mM) over 48 h evoked aSukanya Das, PhD Thesis, 2018significant decrease in cell toxicity by a maximum of 35% (Fig. 8).
Notably, treatment with Compound 1 and 2 (100 mM) provided a
significant degree of neuroprotection against Ab exposure over the
full concentration range of Ab1-42. Treatment with Compound 3
(100 mM) maintained 73%e78% cell viability over the full concen-
tration range of Ab1-42, consistent with its intrinsic modest toxicity
profile as demonstrated in Fig. 6. The effects of Compounds 4 and 5
against Ab-mediated neuronal toxicity on PC12 cells could not be
measured, due to their intrinsic toxicity to PC12 cells. However, the
toxicity of Compound 3, 4 and 5 did not increase in combination
with Ab exposure (data only shown for Compound 3).
4. Discussion
These studies have successfully applied virtual screening
methods and identified and compared the Ab1-42 anti-aggregative
properties of five synthetic heterocyclic compounds. Among
them, two (Compound 1 and 2) were neuroprotective against Ab
induced toxicity in vitro. All of these compounds bear an N-con-
taining five membered heterocycle ring, without exocyclic C]S/O/
N groups. Both Compound 1 and 2 possessed a dibenzyl phenyl
imidazolidine scaffold and Compound 3 and 4 possessed a triazole
sulfanyl acetamide scaffold. Compound 5 possessed a benzoxazole
piperidine propanamide scaffold. To the best of our knowledge,
these five membered heterocyclic scaffolds, such as an imidazoli-
dine linked with a di-benzyl group, or triazole linked with a sul-
fanyl acetamide group, have not been reported previously for their
potential as Ab1-42 aggregation inhibitors. In silico virtual screening
simulations have been used to identify potential Ab1-42 inhibitors
from a chemical database containing desired functional groups
previously [24]. In the present study, the in silico modelling was
also used to compare the probable binding sites and affinity in the
Ab monomer and oligomer as a predictive tool for the interaction
with Ab1-42 protein that may mitigate aggregation and toxicity.
Compound 1 and 2 both exhibited higher binding scores with
monomeric as well as oligomeric Ab, blunted the elongated fibril66
Fig. 5. (a) Thioflavin T (ThT) fluorescence indicative of amyloid Ab1-42 fibrillisation
kinetics, alone and in the presence of each of the Compound 2, 3 and 4 (100 mM each)
over 48 h in cell-free PBS solution. Each of Compound 2, 3 and 4 significantly inhibited
ThT fluorescence throughout 48 h. (b) Area under the curve analysis of ThT kinetics
demonstrated significant overall inhibition of amyloid fibrillisation from incubation
with Compounds 2, 3 and 4. (c) ThT fluorescence indicative of amyloid Ab1-42 fibril-
lisation kinetics, alone and in the presence of each of the Compound 1 and 5 (100 mM
each) over 48 h in cell-free PBS solution. Additional curves in absence of Ab1-42,
exhibited ThT fluorescence of Compound 5 with ThT, Compound 5 alone and ThT alone
over 48 h in cell free PBS solution. Compound 1 did not inhibit ThT fluorescence.
Compound 5 with Ab1-42 increased ThT fluorescence and fluorescence was the highest
with only ThT, excluding Ab1-42. (****P < 0.0001; mean ± SEM of n ¼ 4 experiments).
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morphology and demonstrated significant neuroprotection against
Ab1-42 mediated neurotoxicity in PC12 cells. Compound 2 signifi-
cantly inhibited ThT fluorescence, however Compound 1 had no
influence on ThT fluorescence. DFT-B3LYP level of calculation for
structure optimization revealed that although Compound 1 and 2
are structurally similar in possessing a dibenzyl phenyl imidazoli-
dine scaffold, the addition of one methoxy group and displacement
of the benzoxy group from C7 to C8 in the phenyl ring disrupted the
planarity of Compound 2 (Fig. 3, supplementary material), possibly
due to two vicinal oxygen atoms. Compound 1 was relatively more
planar with regards to the phenyl extension from the imidazolidine
ring than Compound 2. Co-planarity of aromatic moieties have
been considered important for actions against amyloid fibril for-
mation and attributed to favourable hydrophobic and p-stacking
interactions in some natural compounds [23]. It was likely that the
planarity of Compound 1 facilitated binding to Ab in a way that
altered toxic fibril formation, but did not impede Thioflavin Tukanya Das, PhD Thesis, 2018integration into the developing fibrils. While Compound 1 bound to
a similar pocket as Thioflavin T in the b-sheet oligomer, Compound
2 bound to a different pocket (Fig. 4aeb, supplementary material).
Conversely, Compound 2 had multiple binding pockets in that hy-
drophobic region making it a more flexible binder. As discussed by
Murugan et al. [24], having similar binding regions in the hydro-
phobic core of the Ab oligomer increased the possibility of cross
interaction between a highly specific binder and a tracer molecule.
As a result, interpretation of Ab binding from a tracer molecule like
ThT should be carefully evaluated. It was possible that Compound 1
was unable to displace ThT within the competing binding pocket of
Ab, which resulted in no inhibition of ThT fluorescence. In contrast,
Compound 2, as a flexible binder, was less prone to a competing
cross interaction with ThT and therefore still able to bind in mul-
tiple sites of Ab and inhibit fluorescence [25]. Compound 1
exhibited a high steric interaction score to the Ab17-42 pentamer
(Table 2), indicating the formation of a stable, bound complex with
the oligomeric form of the protein. Avid binding to the Ab pentamer
is of particular importance in terms of reducing toxicity, as the
oligomeric form has been suggested to be the most neurotoxic [26].
Other modes of neuroprotection against Ab1-42 exposure are the
stabilization of oligomers rather than complete ablation of aggre-
gation, diverting alloforms into off-target pathways that abrogate
neurotoxicity [27]. A similar phenomenon may have also occurred
to mitigate Ab neurotoxicity in the present study.
In the case of the other dibenzyl phenyl imidazolidine (Com-
pound 2), a clear correlation was observed related to its favourable
molecular binding to Ab protein and its anti-fibrillar action. This
was inferred by both the extensive inhibition of ThT fluorescence
andmorphological evidence of fibril modification via TEM imaging,
with its Ab anti-aggregatory activity also translating to a neuro-
protective capacity. The non-planar conformation of Compound 2
might contribute to its ability to bind at multiple sites in the Ab1-42
monomer and oligomer. Hydrogen bonding did not seem to play a
major role for the Ab interaction with each of these two imidazo-
lidine compounds. From this study, we can infer that with respect
to neuroprotection against Ab, that i) non-planar conformation of
dibenzyl phenyl imidazolidine scaffold might assist in attenuating
ThT kinetics but are not important for neuroprotection, and ii)
Compound 1 might have other modes of protection against Ab1-42-
mediated neurotoxicity than solely via anti-aggregation. These
findings, combined with a lack of intrinsic neurotoxicity, suggest
that the dibenzyl phenyl-imidazolidine scaffold is a useful template
for further development.
The other two structurally related triazole sulfanyl acetamides,
Compound 3 and 4 also exhibited a correlation related to the
favourable molecular binding to Ab protein and its effect on fibril
morphology and aggregate formation. This was ascertained by
both the extensive inhibition of ThT fluorescence and evidence of
fibril morphology modification via TEM imaging. The appearance
of Ab1-42 in the presence of Compound 3 resembled thin, unevenly
textured fibrils. Additionally, in the presence of Compound 4, some
small mesh-like structures were also observed. Such fibrillar
structures were likely to undergo the loss of surface area present
in the longer ‘rope-like’ Ab fibrils in which ThT binds to account
for these significant reduction in fluorescence output [28].
Appearance of these thin fibrillar structures after co-incubation
with triazoles somewhat resembled that of another noted Ab ag-
gregation inhibitor, the N-containing heterocyclic aromatic (ben-
zotrizinone) compound by Catto et al. [29]. Reviewing the docking
study showed both Compound 3 and 4 demonstrated high binding
scores, however, unlike the imidazolidines, H-bonding interactions
played a key role in their binding. With the monomer, Compound
3 formed H-bond with residue Lys 16. A study on natural poly-
phenol binding to Ab had shown that residue Lys 16 appears to be67
Fig. 6. Representative transmission electron micrographs of Ab1-42 fibrils, alone and following 48 h incubation with all five compounds (each at 100 mM): (a) Ab1-42, (b) Ab1-42 and
compound 1, (c) Ab1-42 and compound 2, (d) Ab1-42 and compound 3, (e) Ab1-42 and compound 4 and (f) Ab1-42 and compound 5. Scale bar: 100 nm.
Fig. 7. MTT assay representing neuronal PC12 cell viability following 48 h incubation
with Compounds 1e5 (1e100 mM). Compound 1 and 2 did not have any significant
toxicity at any of the test concentrations. Compound 3 had moderate toxicity at 10 mM
or higher concentration. Compound 4 showed significant toxicity from 25 mM. Com-
pound 5 was the most toxic among these compounds. (****P < 0.0001 for each com-
pounds vs. control; mean ± SEM of n ¼ 4 experiments).
Fig. 8. MTT assay representing PC12 cell viability following 48 h of Ab1-42 incubation,
alone or with each of Compounds 1e3 (100 mM). Compound 1 and 2 exerted significant
neuroprotection over the full concentration range of Ab1-42. Increase in cell viability
seen with Compound 3 was not significant. Compound 4 and 5 was not shown due to
their significant toxicity to PC12 cells. (****P < 0.0001 for each compounds vs Ab1-42
(0.1e0.5 mM); mean ± SEM of n ¼ 4 experiments).
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an important factor in promoting Ab1-42 toxicity [30]. Neverthe-
less, it was not possible to predict whether the resultant triazole
sulfanyl acetamide-modified Ab was benign or toxic to neuronal
cells solely from the cell viability assay. Individually Compound 3
displayed moderate toxicity to PC12 cells at test concentration of
100 mM. Compound 4, which shared the same structure with
compound 3 except for an additional terminal methyl group, was
found to be substantially more toxic to PC12 cells. This may be due
to the sulfanyl 1,2,4 triazole group's anti-proliferative property, as
seen with several other structurally related amino sulfanyl 1,2,4
triazole derivatives [31]. Thus, while the Ab anti-aggregative
property of this triazole sulfanyl acetamide scaffold was mecha-
nistically insightful, further development may be hampered by its
intrinsic toxicity.
Among the five selected compounds, Compound 5 was the most
unique due to its size and presence of various functional groups,
including the fused benzoxazole ring. It showed reasonably high
binding scores to both forms of Ab from the docking data. However,
its unusually high background ThT fluorescence output (even in the
absence of Ab1-42) and its enhancement of Ab1-42 fibrillisation,
together with marked neurotoxicity, limited its further utility in
this study. The direct fluoroscopic interaction with ThT might have
been due to steric hindrance to the intramolecular rotation of ThT.
Additionally, the benzoxazole group in Compound 5 might behave
like the benzothiazole group in ThT, both by binding to Ab1-42 and
generating fluorescence [33]. TEM imaging in Compound 5 also
revealed both a greater amount and extended length of fibrils
compared to Ab1-42 control. From docking of Compound 5 to Ab
oligomer, we hypothesized that the phenyl group placed outside
the oligomer promoted further fibril elongation as seen in the TEM
imaging, by attracting hydrophobic elements of the monomer
which might in part contribute to higher ThT fluorescence than Ab
alone. Other compounds bearing a similar phenyl benzoxazole
moiety as Compound 5 exhibited DNA intercalating and pro-
apoptotic properties in a melanoma cell line [34]. This property of
the phenyl benzoxazole moiety might in part contribute to its cell
toxicity. So, while collectively the fibril-promoting and fluorophoric
nature of Compound 5 was interesting, its marked neurotoxicity
limited its further investigation.
5. Conclusions
In conclusion, imidazolidines and triazole acetamide scaffolds
have demonstrated anti-aggregatory properties against Ab1-42.
Their varying affinity and binding sites differentially affected Ab1-42
fibrillisation kinetics and morphology in addition to a spectrum of
effects on cell viability. Nonetheless, we have identified a novel
dibenzyl phenyl imidazolidine scaffold that was shown to be
favourable for both Ab1-42 anti-aggregatory and neuroprotective
actions, and as such might be a promising pharmacotherapeutic
lead for further development in Alzheimer's disease.
Acknowledgements
The authors would like to thank Dr. Tara Pukala, School of
Chemistry and Physics, The University of Adelaide for access to
Gaussian’09 software and assistance with purity assessment of
compounds through NMR analysis and Lyn Waterhouse, Micros-
copist, Adelaide Microscopy for assistance with TEM.
Appendix A. Supplementary data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.ejmech.2017.02.057.ukanya Das, PhD Thesis, 2018References
[1] M. Ahmed, J. Davis, D. Aucoin, T. Sato, S. Ahuja, et al., Structural conversion of
neurotoxic amyloid-[beta]1-42 oligomers to fibrils, Nat. Struct. Mol. Biol. 17
(2010) 561e567.
[2] D.M. Walsh, I. Klyubin, J.V. Fadeeva, W.K. Cullen, R. Anwyl, M.S. Wolfe,
M.J. Rowan, D.J. Selkoe, Naturally secreted oligomers of amyloid [beta] protein
potently inhibit hippocampal long-term potentiation in vivo, Nature 416
(2002) 535e539.
[3] W.L. Klein, G.A. Krafft, C.E. Finch, Targeting small Ab oligomers: the solution to
an Alzheimer's disease conundrum? Trends Neurosci. 24 (2001) 219e224.
[4] A.J. Doig, P. Derreumaux, Inhibition of protein aggregation and amyloid for-
mation by small molecules, Curr. Opin. Struct. Biol. 30 (2015) 50e56.
[5] B.S. Harvey, I.F. Musgrave, K.S. Ohlsson, Å. Fransson, S.D. Smid, The green tea
polyphenol ()-epigallocatechin-3-gallate inhibits amyloid-b evoked fibril
formation and neuronal cell death in vitro, Food Chem. 129 (2011)
1729e1736.
[6] S. Das, L. Stark, I.F. Musgrave, T. Pukala, S.D. Smid, Bioactive polyphenol in-
teractions with [small beta] amyloid: a comparison of binding modelling,
effects on fibril and aggregate formation and neuroprotective capacity, Food &
Funct. 7 (2016) 1138e1146.
[7] D.E. Ehrnhoefer, J. Bieschke, A. Boeddrich, M. Herbst, L. Masino, R. Lurz,
S. Engemann, A. Pastore, E.E. Wanker, EGCG redirects amyloidogenic poly-
peptides into unstructured, off-pathway oligomers, Nat. Struct. Mol. Biol. 15
(2008) 558e566.
[8] K. Ono, K. Hasegawa, H. Naiki, M. Yamada, Curcumin has potent anti-
amyloidogenic effects for Alzheimer's b-amyloid fibrils in vitro, J. Neurosci.
Res. 75 (2004) 742e750.
[9] C. Manach, A. Scalbert, C. Morand, C. Remesy, L. Jimenez, Polyphenols: food
sources and bioavailability, Am. J. Clin. Nutr. 79 (2004) 727e747.
[10] D. Mereles, W. Hunstein, Epigallocatechin-3-gallate (EGCG) for clinical trials:
more pitfalls than promises? Int. J. Mol. Sci. 12 (2011) 5592e5603.
[11] S. Molino, M. Dossena, D. Buonocore, F. Ferrari, L. Venturini, G. Ricevuti,
M. Verri, Polyphenols in dementia: from molecular basis to clinical trials, Life
Sci. 161 (2016) 69e77.
[12] T. Sterling, J.J. Irwin, ZINC 15eligand discovery for everyone, J. Chem. Inf.
Model. 55 (2015) 2324e2337.
[13] O. Korb, T. Stützle, T.E. Exner, Empirical scoring functions for advanced Pro-
teinLigand docking with PLANTS, J. Chem. Inf. Model. 49 (2009) 84e96.
[14] W. Kohn, A.D. Becke, R.G. Parr, Density functional theory of electronic struc-
ture, J. Phys. Chem. 100 (1996) 12974e12980.
[17] A.A. El-Azhary, H.U. Suter, Comparison between optimized geometries and
vibrational frequencies calculated by the DFT methods, J. Phys. Chem. 100
(1996) 15056e15063.
[18] R. Thomsen, M.H. Christensen, MolDock: a new technique for high-accuracy
molecular docking, J. Med. Chem. 49 (2006) 3315e3321.
[19] O. Crescenzi, S. Tomaselli, R. Guerrini, S. Salvadori, A.M. D'Ursi, P.A. Temussi,
D. Picone, Solution structure of the Alzheimer amyloid beta-peptide (1-42) in
an apolar microenvironment. Similarity with a virus fusion domain, Eur. J.
Biochem. 269 (2002) 5642e5648.
[20] T. Luhrs, C. Ritter, M. Adrian, D. Riek-Loher, B. Bohrmann, H. Dobeli,
D. Schubert, R. Riek, 3D structure of Alzheimer's amyloid-beta(1-42) fibrils,
Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 17342e17347.
[21] D.N. Dixon, R.A. Loxley, A. Barron, S. Cleary, J.K. Phillips, Comparative studies
of PC12 and mouse pheochromocytoma-derived rodent cell lines as models
for the study of neuroendocrine systems, In Vitro Cell. Dev. Biol. - Animal 41
(2005) 197e206.
[22] M. Clark, R.D. Cramer, N. Van Opdenbosch, Validation of the general purpose
tripos 5.2 force field, J. Comput. Chem. 10 (1989) 982e1012.
[23] J.A. Carver, P.J. Duggan, H. Ecroyd, Y. Liu, A.G. Meyer, C.E. Tranberg, Carbox-
ymethylated-k-casein: a convenient tool for the identification of polyphenolic
inhibitors of amyloid fibril formation, Bioorg. Med. Chem. 18 (2010) 222e228.
[24] N.A. Murugan, C. Halldin, A. Nordberg, B. Långstr€om, H. Ågren, The culprit is in
the cave: the core sites explain the binding profiles of amyloid-specific
tracers, J. Phys. Chem. Lett. 7 (2016) 3313e3321.
[25] I.I.I.H. Levine, Multiple ligand binding sites on Ab(1e40) fibrils, Amyloid 12
(2005) 5e14.
[26] M. Ahmed, J. Davis, D. Aucoin, T. Sato, S. Ahuja, S. Aimoto, J.I. Elliott, W.E. Van
Nostrand, S.O. Smith, Structural conversion of neurotoxic amyloid-[beta]1-42
oligomers to fibrils, Nat. Struct. Mol. Biol. 17 (2010) 561e567.
[27] Q.I. Churches, J. Caine, K. Cavanagh, V.C. Epa, L. Waddington, C.E. Tranberg,
A.G. Meyer, J.N. Varghese, V. Streltsov, P.J. Duggan, Naturally occurring poly-
phenolic inhibitors of amyloid beta aggregation, Bioorg. Med. Chem. Lett. 24
(2014) 3108e3112.
[28] R. Khurana, C. Coleman, C. Ionescu-Zanetti, S.A. Carter, V. Krishna, R.K. Grover,
R. Roy, S. Singh, Mechanism of thioflavin T binding to amyloid fibrils, J. Struct.
Biol. 151 (2005) 229e238.
[29] M. Catto, A.A. Berezin, D. Lo Re, G. Loizou, M. Demetriades, A. De Stradis,
F. Campagna, P.A. Koutentis, A. Carotti, Design, synthesis and biological
evaluation of benzo[e][1,2,4]triazin-7(1H)-one and [1,2,4]-triazino[5,6,1-jk]
carbazol-6-one derivatives as dual inhibitors of beta-amyloid aggregation and
acetyl/butyryl cholinesterase, Eur. J. Med. Chem. 58 (2012) 84e97.
[30] M. Sato, K. Murakami, M. Uno, Y. Nakagawa, S. Katayama, K.-i. Akagi,
Y. Masuda, K. Takegoshi, K. Irie, Site-specific inhibitory mechanism for69
S. Das, S.D. Smid / European Journal of Medicinal Chemistry 130 (2017) 354e364364amyloid b42 aggregation by catechol-type flavonoids targeting the Lys resi-
dues, J. Biol. Chem. 288 (2013) 23212e23224.
[31] Y.J. Shi, X.J. Song, X. Li, T.H. Ye, Y. Xiong, L.T. Yu, Synthesis and biological
evaluation of 1,2,4-triazole and 1,3,4-thiadiazole derivatives as potential
cytotoxic agents, Chem. Pharm. Bull. (Tokyo) 61 (2013) 1099e1104.
[33] S. Stefansson, D.L. Adams, C.M. Tang, Common benzothiazole and benzoxazole
fluorescent DNA intercalators for studying Alzheimer Abeta1-42 and prionSukanya Das, PhD Thesis, 2018amyloid peptides, Biotechniques 52 (2012).
[34] A. Kamal, K.S. Reddy, M.N.A. Khan, R.V.C.R.N.C. Shetti, M.J. Ramaiah,
S.N.C.V.L. Pushpavalli, C. Srinivas, M. Pal-Bhadra, M. Chourasia, G.N. Sastry,
A. Juvekar, S. Zingde, M. Barkume, Synthesis, DNA-binding ability and anti-
cancer activity of benzothiazole/benzoxazoleepyrrolo[2,1-c][1,4]benzodiaze-




















































































































































































































































































Appendix A: Supplementary material
Supplementary Figure 1. 1H-NMR of Compound 1 (1,3-dibenzyl-2-[3-(benzyloxy)phenyl]imidazolidine) in DMSO.




































































































































Sample Name Compound 4 






































































































Supplementary Figure 2. 1H-NMR of Compound 4 (2-{[5-(4-aminophenyl)-4-methyl-4H-1, 2, 4-triazol-3-yl] sulfanyl}-N-(4-methylphenyl) acetamide) in 
DMSO.






























































































































Integral start(ppm) end value
1 10.3872 10.0893 4.412
2 8.1964 7.86339 0.301
3 7.62679 7.18863 17.376
4 7.18863 6.96078 8.793
5 6.82057 6.49633 8.784
6 5.66382 5.43598 3.415
7 4.16531 3.84984 8.814
8 3.75344 3.24517 24.976
9 2.60546 2.36885 8.294
10 2.36885 2.00956 13.499
11 1.32603 0.984259 1.261
12 0.922917 0.712599 0.075
Plotname: PRESAT_TPacetomide_dmso_20150525_500_01_plot01
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Supplementary material
Figure. 3: Optimised structures (following DFT-B3LYP calculation) of Compounds 1 and 2. 
3-D interactive structure files in .pdb format.
Figure 4:  Binding of three ligands: optimised conformations of Compound 1, 2 and ThT to the Aβ17-
42 oligomer and Aβ1-42 monomer. (a) Binding sites of Compound 1 and ThT in oligomer (b) Binding 
sites of Compound 2 and ThT in oligomer (c) Compound 1, 2 and ThT bound to Aβ1-42 monomer. 
Compound 1=purple, Compound 2=blue and ThT=green. 
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Single ring type Total purchasable 
compounds 
Anodyne, bb, ready for sale 
Tetrazole 2180726 86430 
1H, 1_2_4 triazole 10193186 293256 
2H triazole 3350821 163705 
Imidazole 7445052 423322 







Imidazolidine 30802 876 
Pyrazolidine 8521 1048576 
Pyrrole 3985252 166055 
Pyrrolidine 36456053 1048576 
Double ring type Total purchasable 
compounds 
Anodyne, bb, ready for sale 
Indole 4160299 79320 
Isoindole 487759 6376 
1H indole 414276 16508 
Indoline 1912779 40285 
Benzoxazole 1136373 34754 
Table 1: Type of rings after filtering the ZINC database, ring subsets. 11 single FMH rings with only 
N-heteroatom and 5 double rings, having single N-heteroatom FMH fused with a six membered ring.
Total number of purchasable compounds from each ring is further filtered for anodyne, bb and
compounds ready for sale. These filtered list of compounds from each ring was used in virtual screening.
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Chapter 4: Exploring the structural diversity in inhibitors of α-synuclein 
amyloidogenic folding, aggregation and neurotoxicity 
Das, S., Pukala, TL. and Smid, SD. (2018) ‘Exploring the structural diversity in inhibitors of 
α-synuclein amyloidogenic folding, aggregation and neurotoxicity’ Frontiers in Chemistry – 
Medicinal and Pharmaceutical Chemistry, 6: (181- 192) doi: 10.3389/fchem.2018.00181   
Author’s proof reprinted following Frontiers Copyright Statement, 2018. 
The main purpose of this study is to investigate the effect of various structural features within 
a diverse set of molecules on αS (αSA53T) amyloidogenic folding, aggregation and exogenous 
toxicity to PC-12 cells. This study compared the effect of a flavone bearing B-ring 
trihydroxylation and a flavone with both A and B-ring dihydroxylation on αSA53T 
amyloidogenic folding, aggregation and toxicity. This was compared with the flavone 
myricetin, which has hydroxylation in all A, C and B-rings and is a known inhibitor of αSA53T 
aggregation (Liu, Graetz et al. 2015). The other aim of this study is to investigate the effect of 
the biphenyl neolignan, honokiol on αSA53T amyloidogenic folding, aggregation and 
neurotoxicity. The effect of large and extensively hydroxylated polyphenol such as ellagitannin 
is also addressed in this study, by characterising the punicalagin molecule’s interaction with 
αSA53T and its effects on aggregation and toxicity. These molecules are comparatively studied 
to identify new flavone structures as well as non-flavone bioactive polyphenolic inhibitor of 
αSA53T toxic amyloidogenic aggregation. Additionally, this study has been aimed at 
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characterizing the effects of synthetic dibenzyl imidazolidine compounds, identified from 
virtual screening as ‘hits’ from our previous study (Chapter 3) on αSA53T amyloidogenic 
folding, aggregation and toxicity. An understanding of the impact of these inhibitors on the 
various conformations of αSA53T would be insightful to probe the early structural 
polymorphism observed during amyloidogenic aggregation. Thus, the IM-MS analysis 
presented in this study is aimed at improving our understanding of each molecule’s effect on 
αSA53T conformational ensembles. In addition, their proposed direct binding interactions are 
studied by molecular docking with model αSA53T to understand their binding affinity.  
This study demonstrated the inhibitory effect of B-ring trihydroxylation in flavone 
(exemplified by the semi-synthetic flavone 2-D08) on αSA53T amyloidogenic folding, 
aggregation and toxicity. The comparative analysis of three flavones here, showed that only B-
ring trihydroxylation has a distinct effect on αSA53T amyloidogenic aggregation and toxicity. 
Furthermore, this study identified that honokiol impacted αSA53T amyloidogenic aggregation 
in a comparable manner to the studied flavones. This study also highlighted the importance of 
the dibenzyl imidazolidine scaffold against αSA53T amyloidogenic aggregation. Additionally, 
punicalagin has also been identified for the first time as inhibitor of αSA53T amyloidogenic 
aggregation and toxicity. Overall, this study has demonstrated important structural elements, 
including the neolignan biphenyl structure, of flavone B-ring trihydroxylation, the dibenzyl 
imidazolidine scaffold and the bulky ellagitannin structure are all capable of inhibiting αSA53T 
amyloidogenic aggregation by preserving its native conformation, hence reducing its 
amyloidogenic aggregation and exogenous toxicity in vitro.  
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Aggregation of α-Synuclein (αS) protein to amyloid fibrils is a neuropathological hallmark
of Parkinson’s disease (PD). Growing evidence suggests that extracellular αS aggregation
plays a pivotal role in neurodegeneration found in PD in addition to the intracellular αS
aggregates in Lewy bodies (LB). Here, we identified and compared a diverse set of
molecules capable of mitigating protein aggregation and exogenous toxicity of αSA53T, a
more aggregation-prone αSmutant found in familial PD. For the first time, we investigated
the αS anti-amyloid activity of semi-synthetic flavonoid 2′, 3′, 4′ trihydroxyflavone or
2-D08, which was compared with natural flavones myricetin and transilitin, as well as
such structurally diverse polyphenols as honokiol and punicalagin. Additionally, two
novel synthetic compounds with a dibenzyl imidazolidine scaffold, Compound 1 and
Compound 2, were also investigated as they exhibited favorable binding with αSA53T.
All seven compounds inhibited αSA53T aggregation as demonstrated by Thioflavin
T fluorescence assays, with modified fibril morphology observed by transmission
electron microscopy. Ion mobility-mass spectrometry (IM-MS) was used to monitor the
structural conversion of native αSA53T into amyloidogenic conformations and all seven
compounds preserved the native unfolded conformations of αSA53T following 48 h
incubation. The presence of each test compound in a 1:2 molar ratio was also shown
to inhibit the neurotoxicity of preincubated αSA53T using phaeochromocytoma (PC12)
cell viability assays. Among the seven tested compounds 2-D08, honokiol, and the
synthetic Compound 2 demonstrated the highest inhibition of aggregation, coupled with
neuroprotection from preincubated αSA53T in vitro. Molecular docking predicted that
all compounds bound near the lysine-rich region of the N-terminus of αSA53T, where
the flavonoids and honokiol predominantly interacted with Lys 23. Overall, these findings
highlight that (i) restricted vicinal trihydroxylation in the flavone B-ring is more effective in
stabilizing the native αS conformations, thus blocking amyloidogenic aggregation, than
dihydroxylation aggregation in both A and B-ring, and (ii) honokiol, punicalagin, and
the synthetic imidazolidine Compound 2 also inhibit αS amyloidogenic aggregation by
stabilizing its native conformations. This diverse set of molecules acting on a singular
pathological target with predicted binding to αSA53T in the folding-prone N-terminal
region may contribute toward novel drug-design for PD.
Keywords: α-synuclein, amyloid inhibition, 2-D08, transilitin, honokiol, punicalagin, dibenzyl imidazolidine
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INTRODUCTION
Parkinson’s disease (PD) neuropathology is characterized by
loss of dopaminergic neurons, and in most cases, deposition of
Lewy bodies in the brain (Hughes et al., 1992). Aggregation and
amyloid formation of the cytosolic protein α-Synuclein (αS), in
both intracellular and extracellular areas, have been implicated
in the formation of Lewy pathology (LP) and degeneration of
dopaminergic neurons in the substantia nigra pars compacta
region of the brain (Baba et al., 1998; Volpicelli-Daley et al., 2011;
Luk et al., 2012; Iyer et al., 2014). Human αS is a 140-amino acid
residue polymorphic protein consisting of a membrane binding
N-terminal region, a non-amyloid β component (NAC) region
and an acidic C-terminal tail. This protein is associated with key
biological activities such as vesicle trafficking, maintenance of
the synaptic SNARE complex and vesicle pools, and regulation
of dopamine (DA) metabolism (Cabin et al., 2002; Sidhu et al.,
2004; Chandra et al., 2005; Cooper et al., 2006). Along with
the sporadic form of PD caused by wild type αS, a missense
point mutation in the snca gene results in the more aggregation
prone mutant αSAla53Thr (αSA53T), which has been found
to be associated with a familial form of PD (Polymeropoulos
et al., 1997; Narhi et al., 1999; Li et al., 2001; Papadimitriou
et al., 2016). Since current treatments for PD aim only at
replacing DA loss, and provide only transient symptomatic relief,
there is an urgent need for treatments that can directly modify
disease progression. Therefore, inhibition of αS aggregation, or
its pathological mutant αSA53T, provides a disease-modifying
therapeutic approach for PD, inclusive of its familial form.
The amyloidogenic aggregation of an intrinsically disordered
protein (IDP) such as αS involves formation of heterogeneous
and transient assemblies early in its aggregation pathway, that act
as a precursor for fibrillization (Bousset et al., 2013). Considering
the difficulty in gaining structural information on these
conformational assemblies, ionmobility-mass spectrometry (IM-
MS) is employed to monitor soluble αS conformations during the
early aggregation process. IM-MS is a sensitive tool for structural
study of conformational folding and other characterization
(Lanucara et al., 2014), and has been used for high-throughput
screening of amyloid inhibitors (Young et al., 2014). It allows
measurement of both the mass and collision cross section
(CCS) of an ion, and thereby can provide information on the
structural changes of amyloidogenic proteins such as αS during
aggregation and binding of small molecules (Bernstein et al.,
2004; Vlad et al., 2011; Liu et al., 2015). Combined with kinetic
analysis of fibrillization (such as from thioflavin T fluorescence
assays) and visualization of the fibrils using transmission electron
microscopy (TEM), IM-MS provides insights on the effect of
exogenous compounds on native αSA53T conformations in vitro.
This can inform on how such compounds interact during the
early stage of toxic amyloidogenic aggregation. Evaluation of
αSA53T neurotoxicity also provides valuable information on
the toxic nature of the observed aggregation products, and
possible neuroprotective effects of small molecule aggregation
inhibitors.
Various natural compounds have been shown to inhibit αS
aggregation or participate in remodeling of its fibrillization
pathway (Zhu et al., 2004; Masuda et al., 2006; Bieschke
et al., 2010; Morshedi et al., 2015). The polyphenolic flavonoids
baicalein and epigallo-catechin-3-gallate (EGCG) are amongst
these (Hong et al., 2008; Bieschke et al., 2010). Structurally,
baicalein possesses vicinal trihydroxyl groups only in the flavone
A-ring, whereas EGCG possesses vicinal trihydroxylation in
the B-ring and in the gallic acid moiety. Gallic acid, by itself,
also demonstrated inhibition of αSA53T aggregation (Liu et al.,
2014). A comprehensive study on flavonoid-induced inhibition
of αS aggregation has shown that vicinal dihydroxylation or
trihydroxylation improves inhibition irrespective of ring position
(Meng et al., 2009). However, except for baicalin, other reported
flavonoid inhibitors lack the localized single ring vicinal di
or tri hydroxyl groups. Thus, the importance of position and
extent of hydroxylation of flavonoids involved in inhibiting
αS aggregation and neurotoxicity is unclear. In this study,
we have investigated the anti-amyloid effect of semi-synthetic,
2′, 3′, 4′ trihydroxy flavone (2-D08) that has only vicinal
trihydroxylation in the B-ring. This flavone has shown improved
inhibition of amyloid β (Aβ) aggregation and toxicity through
its localized B-ring trihydroxylation (Marsh et al., 2017). We
compared it with myricetin, a known inhibitor of αS aggregation
(Meng et al., 2010; Liu et al., 2015) which also has vicinal
trihydroxylation in the B-ring along with -OH groups at flavone
3, 5, and 7 positions. Transilitin was also investigated here
to compare the effect of dihydroxylation in both A and B
rings. Our study provides information on the role of select
B-ring trihydroxylation for modulation of αS aggregation and
toxicity.
Other bioactive polyphenols investigated here for the
first time are the natural lignan compound honokiol and
ellagitannin punicalagin. Honokiol has demonstrated anti-
amyloid effects against amyloid beta (Aβ) (Hoi et al., 2010;
Das et al., 2016). Punicalagin, found in pomegranate, is
also a known inhibitor of Aβ protein aggregation and has
antioxidant and anti-inflammatory properties (Yaidikar et al.,
2014; Yaidikar and Thakur, 2015; Das et al., 2016). Extending
the structural diversity of molecules that can act on a
common target of pathological αS aggregation, we also included
two synthetic imidazolidine compounds, termed Compound
1 (1,3-dibenzyl-2-[3-(benzyloxy) phenyl] imidazolidine) and
Compound 2 (1,3-dibenzyl-2-[4-(benzyloxy)-3-methoxyphenyl]
imidazolidine), both bearing a five-membered heterocyclic
(FMH) imidazolidine ring scaffold. We previously identified
these compounds through virtual screening of the ZINC
chemical database and highlighted the importance of this
molecular scaffold with regards to preventing amyloid β
aggregation (Das and Smid, 2017). A summary of the compounds
investigated here is provided in Figure 1.
MATERIALS AND METHODS
Reagents and Chemicals
Myricetin, 2-D08, honokiol, and punicalagin were obtained
from Sigma-Aldrich (Castle Hill, VIC, Australia). Transilitin
was kindly provided by Dr. Peter Duggan at CSIRO
Materials Division (Clayton South, VIC, Australia). Synthetic
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FIGURE 1 | Chemical structures of (1) myricetin, (2) 2′, 3′, 4′ trihydroxy flavone or 2-D08, (3) transilitin, (4) honokiol, (5) punicalagin, (6) 1,3-dibenzyl-2-[3-(benzyloxy)
phenyl] imidazolidine or Compound 1, and (7) 1,3-dibenzyl-2-[4-(benzyloxy)-3-methoxyphenyl] imidazolidine or Compound 2.
imidazolidine Compound 1 and Compound 2 were sourced from
Specs (The Netherlands) and ChemDiv (U.S.A.) respectively,
both screening compound manufacturers. Purity of Compound
1 was assessed to be >97% through 1H NMR analysis
(Supplementary Figure 1), Compound 2 was certified with
a purity of >97%.
Thioflavin T, thiazolyl blue tetrazolium bromide (MTT),
trypan blue, DMSO, Roswell Park Memorial Institute 1640
(RPMI) medium and fetal calf serum (FCS) were obtained
from Sigma-Aldrich (St Louis, MO, USA). Non-essential amino
acids (NEAA), penicillin/streptomycin, 1× trypsin EDTA, and
phosphate buffered saline (PBS) at pH 7.4 were obtained from
Thermo Fisher Scientific, (Scoresby, VIC, Australia). Bovine
serum albumin (BSA) was obtained from Bovogen Biologicals
(East Keilor, VIC, Australia). Ammonium acetate was obtained
from Sigma-Aldrich (Castle Hill, VIC Australia).
Protein Expression and Purification
αSA53T was expressed and purified as previously described
(Volles and Lansbury, 2007). Cells were grown in normal
lennox broth (LB) medium. Protein was purified by size
exclusion chromatography using a Superdex 200 SEC column
(Bio Rad), with a flow rate of 0.5 ml/min, in 20mM ammonium
acetate buffer. The purity of αSA53T was confirmed by mass
spectrometry and samples were lyophilized and stored at −80◦C
until required.
Preincubation of αSA53T and Compound
Preparation
αSA53T was dissolved in 50mM ammonium acetate buffer (pH
not adjusted) to make 1mM stock solution, dispensed into
aliquots and immediately frozen at−80◦C until required. All test
compounds were initially diluted in DMSO and then in 50mM
ammonium acetate to their final stock concentrations prior to
incubation with αSA53T. The final concentration of DMSO in
each experiment was <1%. For the cell viability assay, 50µM
αSA53T alone or in the presence of each compound (100µM)
in 50mM ammonium acetate buffer was shaken at 300 rpm for
72 h at 37◦C.
Thioflavin T Fluorescence Assay
Thioflavin T (ThT) binds to β sheet rich structures present in
amyloid fibrils, with fluorescence increasing proportionally to the
quantity of fibrils present in solution. ThT (final concentration
100µM) was added to wells in a Greiner 96-well plate together
with αSA53T (100µM), in the absence or presence of each test
compound (either at 200 or 100µM) in 50mM ammonium
acetate buffer to a total volume of 100 µl in each well.
Fluorescence was measured at 37◦C every 30min for 100 h
using a Fluostar Optima plate reader (BMG Lab technologies,
Australia) with a 440/490 nm excitation/emission filter. The ThT
assay was performed in duplicate and repeated three times.
Results were normalized to blank values (ThT alone in 50mM
ammonium acetate buffer).
Transmission Electron Microscopy (TEM)
Imaging
TEM was used to visualize αSA53T aggregates and fibrils
and investigate the effects of selected compounds on fibril
morphology. Samples were prepared by adding 5–10 µl of
protein solution taken directly from the ThT assay after 100 h to a
400mesh formvar carbon-coated nickel electronmicroscopy grid
(Proscitech, Kirwan, QLD, Australia). After 1min, this sample
was blotted using filter paper. Ten microliters of contrast dye
containing 2% uranyl acetate was then placed on the grid, left
for 1min and blotted with filter paper. Grids were then loaded
Frontiers in Chemistry | www.frontiersin.org 3 May 2018 | Volume 6 | Article 181
Sukanya Das, PhD Thesis, 2018 82
Das et al. Diverse Inhibitors of α-Synuclein Aggregation
onto a specimen holder for analysis using a FEI Tecnai G2
Spirit Transmission Electron Microscope (FEI, Milton, QLD,
Australia). Sample grids were viewed using a magnification of
34,000–92,000X. Grids were extensively scanned manually in
search of fibrils and representative images were taken.
Ion Mobility-Mass Spectrometry (IM-MS)
Fifty micromolar αSA53T was prepared for IM-MS experiments
in 50mM ammonium acetate buffer in the absence and presence
of each compound at a molar ratio of 1:2 (protein: compound).
Samples were allowed to fibrillize by incubation at 37◦C with
constant shaking at 300 rpm. IM-MS analysis was performed
on an Agilent 6560 Ion Mobility Q-ToF spectrometer with
samples introduced by nanoelectrospray ionization through
platinum-coated capillaries (made in-house). Ions were analyzed
in the positive mode, with parameters systematically selected
to achieve optimal signal while avoiding any analysis induced
structural transitions (full details of optimization will be reported
in a manuscript currently in preparation). Typical instrument
parameters included; capillary voltage 1,700V, fragmentor
voltage 400V, gas temperature 0◦C, gas flow 2 l/min, trap fill time
20000.0 µs, trap release time 4000.0 µs and CCS measurement
was made using a multifield approach varying the IM drift tube
voltage between 1,200 and 1,700V. The acquired spectra were
processed using Qualitative Analysis B.07.00 and IM-MS browser
B.07.01 (both Agilent, Santa Clara, USA).
Neuronal Cell Culture, Treatment, and
Viability Measurements
Rat phaeochromocytoma cells (Ordway PC12) displaying a semi
differentiated phenotype with neuronal projections were kindly
donated by Professor Jacqueline Phillips (Macquarie University,
NSW, Australia) [21]. Cells were maintained in Roswell Park
Memorial Institute 1640 (RPMI) media with 10% fetal calf serum
(FCS), 1% L-glutamine, 1% non-essential amino acids, and 1%
penicillin/streptomycin. Cells were seeded at 2 × 104 cells per
well in RPMI with 10% FCS. PC12 cells were equilibrated for
24 h before treatment with preincubated αSA53T or preincubated
αSA53T in presence of each test compound. Cells were then
incubated for 48 h at 37◦C, 5% CO2 prior to measurement
of cell viability. After 48 h, PC12 cell viability was determined
using the thiazolyl blue tetrazolium bromide (MTT) assay. After
incubation, 96-well plates had all media removed and replaced
with serum-free media containing 0.25 mg/ml of MTT. The
plate was further incubated for 2 h at 37◦C with 5% CO2,
then the MTT solution was removed and cells were lysed with
DMSO. Absorbance wasmeasured at 570 nm using a SynergyMX
microplate reader (Bio-Tek, Bedfordshire, UK).
Statistical Analysis
Area under the curve analysis for Thioflavin T (ThT) fluorescence
data was interrogated using a one-way analysis of variance
(ANOVA) with a Dunnett’s multiple comparisons test to
determine the significance of each tested compound’s effect vs.
αSA53T alone. Data obtained from the MTT assay was analyzed
via a one-way ANOVA to assess neuronal cell viability with
a Holm–Sidak’s multiple comparison test used to determine
the significance level for each test compound interacting with
αSA53T. A significance value of p < 0.05 was used for
all experiments. Data analysis and production of graphs was
performed in GraphPad Prism 6 for Windows (GraphPad
Software, San Diego, USA).
Molecular Docking of Compound
Optimized Structure Binding to α Synuclein
To gain insight into the binding interactions of each selected
compound (ligand) with αSA53T, all ligand structures were first
optimized and then individually docked to αSA53T with 300
iterations per docking. Previous experimental evidence suggested
that the flavonoid binding site in α synuclein is near the lysine-
rich region of the N-terminus, with Lys21 or Tyr39 playing a
pivotal role (Meng et al., 2009). Therefore, the docking search
space was created centering this binding site with a radius of
25 Å covering these N-terminus residues. Ligand equilibrium
molecular geometries were optimized using a density functional
theory (DFT) method that utilizes the Becke-Lee-Yang-Parr
three-parameter hybrid functional (B3LYP) to ascertain accurate
bond distances, angles, dihedrals and optimized conformations
in the lowest energy state, using the Gaussian09 package of
codes (Frisch et al., 2016). A large basis set, aug-cc-pVDZ,
was used in approximation of optimized geometry for each
ligand. DFT-B3LYP level of calculations combined with a larger
basis set is considered as a standard and reliable method for
estimating optimized molecular geometry (El-Azhary and Suter,
1996). Fully optimized ligand structures were then allowed
to dock with the model αSA53T. Since the full sequence
αSA53T structure was not available, the solid-state NMR of
pathogenic α synuclein fibril (PDB ID: 2N0A) was obtained
from protein data bank and residue 53 mutated from alanine
to threonine to generate the model protein monomer of
αSA53T (Tuttle et al., 2016). The resultant αSA53T protein
conformation, without any further adjustment, was used for
docking, which employed CLC drug discovery workbench,
version 2.4.1 using a PLANTSplp empirical scoring function
(Korb et al., 2009).
RESULTS
Significant Inhibition of αSA53T Amyloid
Fibril Formation by All Test Compounds
The amyloid fibrillization of αSA53T was measured by a ThT-
based kinetic assay, which demonstrated a gradual increase
in fluorescence (relative fluorescence unit or RFU) up to the
first 50 h and then stabilized over the remainder of the assay,
indicating αSA53T underwent a conformational transition to a
cross-β-sheet rich structure characteristic of amyloid fibrils and
aggregates (Figure 2A). All test compounds: 2-D08, myricetin,
transilitin, honokiol, punicalagin, Compound 1 and Compound
2 inhibited the ThT fluorescence over the entire 100 h time
course of the assay at a 1:2 (protein: compound) molar ratio.
Area under the curve analysis showed extensive and significant
overall inhibition of fibril formation in the presence of each of
the test compounds at a 1:2 (protein: compound) molar ratio
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FIGURE 2 | (A) ThT fluorescence assay representing kinetics of (100µM)
αSA53T fibrillisation over 100 h, alone and in the presence of each test
compound at a 1:2 (protein: compound) molar ratio. (B) Representative area
under the curve (AUC) measurements demonstrating significant reductions in
ThT fluorescence for each test compound at a 1:2 (protein: compound) molar
ratio. [****p < 0.0001, F (7, 17) = 15.96; mean ± SEM of n = 3 experiments].
(Figure 2B). Further ThT assays at a 1:1 (protein: compound)
molar ratio also exhibited significant fibril inhibition, though
Compound 1 was the least effective among all compounds
tested (Supplementary Figures 2a,b). The mean RFU along with
the respective standard error of mean (SEM) values for each
compound are provided as Supplementary Table 1.
Transmission Electron Microscopy of
αSA53T Fibrils and Aggregates
False positives for ThT inhibition can occur when some
polyphenols undergo spontaneous oxidation in aqueous solution
and strongly quench ThT fluorescence, and this also might have
resulted in negative RFU for myricetin and punicalagin (Coelho-
Cerqueira et al., 2014). Therefore, the inhibition of fibrillization
observed in ThT assays was further confirmed by TEM, an
essential qualitative technique to characterize the morphology
of amyloid fibril and aggregate formation. The morphology
of αSA53T fibrils and aggregates appeared to be affected by
incubation with each of the test compounds at a 1:2 (protein:
compound) molar ratio, after 100 h incubation (Figures 3a–h).
TEM evidence demonstrated that αSA53T alone formed dense
fibrillar aggregates where several fibrils were intertwined and
arranged as rope-like mature amyloid fibrils, similar to those
observed previously (Bharathi et al., 2007; Figure 3a). Incubation
with Compound 2, myricetin and transilitin resulted in shorter,
thinner, and loosely attached fibrils, but in low abundance
(Figures 3c,e,h). Incubation with honokiol produced loosely
attached, short and long fibrils while punicalagin incubation
produces loosely attached, thin fibrils that were comparatively
longer (Figures 3f,g). Incubation with 2-D08 resulted in
amorphous aggregates of very short fibrils (Figure 3d), while
incubation with Compound 1 produce short fibrils and small
dense aggregates (Figure 3b). In the presence of all test
compounds, no rope-like aggregates were observed compared to
αSA53T alone. Additional TEM images following 50 h incubation
highlighted the formation of pre-fibrillar structures by αSA53T
alone. In the presence of all compounds except punicalagin, small
aggregate-like structures were observed. Punicalagin incubation
resulted in a few protofibrillar αSA53T structures similar to those
that were observed following 100 h incubation (Supplementary
Figure 3).
Preservation of Early αSA53T
Conformations by Test Compounds
Monitored Using IM-MS
IM-MS was utilized to investigate the αSA53T conformational
changes occurring early during aggregation in the presence and
absence of each test compound. An effective amyloid inhibitor
compound would not only prevent fibril formation, but also
preserve the protein in its natively unfolded state. IM-MS has
important application for investigating the early aggregation
phenomena of amyloidogenic proteins, since the unfolded native
proteins convert into a compact folded conformation that
precedes fibrillization (Smith et al., 2010; Liu et al., 2014). The
mass spectrum of αSA53T prior to incubation displayed a broad
charge state distribution consistent with a natively unstructured
protein (Konermann and Douglas, 1998; Figure 4A). The
measured CCSs for monomeric αSA53T ions prior to incubation
were plotted in Figure 4B, and are in agreement with previously
reported IM-MS measurements of the αSA53T monomer (Liu
et al., 2011). Lower charge states having a lower CCS represent
the population of ions with more compact structure, while from
charge states+8 to+9 the CCS measured increases significantly,
indicative of a transition from compact to extended structures.
A similar observation was reported previously for wild type
α-synuclein (Bernstein et al., 2004).
Following 48 h incubation, IM-MS analysis showed that
αSA53T ions of both lower and higher charge states from
+7 to +12 underwent a structural collapse as indicated by a
notable decrease in measured CCSs. Notably, when αSA53T was
incubated in the presence of inhibitor compounds, the measured
CCS values of the monomers revealed that the protein mostly
remained in its native conformation after 48 h, with honokiol
or 2-D08 shown to be most effective (Figure 4B). Among the
flavones, CCSs of αSA53T in the presence of myricetin or 2-D08
or transilitin were comparable.
To simplify the analysis of αSA53T conformations in the
presence of each test compound, we selected a single charge
state, +11, for comparison of CCSs based on the data shown
in Figure 4B. This charge state was selected as ion populations
at higher charge states tend to display a single, narrow feature
in the arrival time distribution and it showed remarkable
collapse of unfolded conformations, from 2,937 to 2,520 Å2
following 48 h of incubation. Incubation of αSA53T in the
presence of punicalagin, myricetin, transilitin, Compound 2
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FIGURE 3 | Representative transmission electron micrographs of αSA53T fibril and aggregate formation, following 100 h incubation alone and with each test
compound at a 1:2 (protein: compound) molar ratio; (a) αSA53T alone and in presence of (b) Compound 1, (c) Compound 2, (d) 2-D08, (e) myricetin, (f) honokiol,
(g) punicalagin, and (h) transilitin. Scale bar: 200 nm.
FIGURE 4 | (A) IM-MS spectrum of αSA53T (50µM) in 50mM ammonium acetate. (B) Plot of CCS vs. charge state for the dominant peaks in the IM-MS spectrum
measured for αSA53T at 0 h (circles) and following incubation in the absence (squares) and presence of 1:2 (protein: compound) honokiol (triangles) or 2-D08
(diamonds). Where multiple features were observed in the ATD, CCS is plotted for each feature. (C) Experimentally derived CCSs for the +11-charge state (m/z 1,317)
of αSA53T following 48 h incubation at 37◦C with shaking at 300 rpm.
and Compound 1 preserved the CCS of the 11+ ions close to
the preincubation measurement after 48 h (Figure 4C). Detailed
CCSs measurements of all these compounds for each charge state
is provided in Supplementary Figures 4a–e. Overall, all seven
test compounds demonstrated inhibition of the early structural
collapse of αSA53T during aggregation, with honokiol and 2-D08
being the most effective as evidenced by preventing the decrease
in CCSs.
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FIGURE 5 | Cell viability of PC12 cells described by an MTT assay following
48 h incubation of preincubated (for 72 h) 50µM αSA53T alone or with each
test compounds at a 1:2 (protein: compound) molar ratio. [****p < 0.0001;
F (3, 11) = 21.61 for Compound 1, Compound 2, and punicalagin and ****p <
0.0001; F (4, 17) = 21.77 for 2-D08, myricetin, honokiol, and transilitin; mean ±
SEM of n = 4 experiments].
Effects of Compounds on Fibrilar αSA53T
Mediated Neuronal Toxicity
Analysis of cell viability as determined by the MTT assay
demonstrated that preincubated αSA53T (50µM) alone evoked
about 50% loss of cell viability over 48 h (Figure 5). In contrast,
preincubated αSA53T in the presence of each test compound
at a 1:2 (protein: compound) molar ratio prevented the loss
of cell viability significantly (Figure 5). PC12 cells exposed to
preincubated αSA53T in the presence of 2-D08, myricetin, or
honokiol (100µM each) did not show any loss of cell viability.
This finding implies that interaction of these compounds with
αSA53T inhibited the neurotoxicity of the resultant fibrils toward
PC12 cells in vitro. The two synthetic imidazolidines, Compound
1 and Compound 2 also significantly mitigated the loss of cell
viability compared to αSA53T alone, however, the degree of
neuroprotection was not as pronounced as the other natural test
compounds (Figure 5). In a 1:1 (protein: compound) molar ratio,
only Compound 2, 2-D08, myricetin, honokiol, and punicalagin-
treated significantly reversed the loss of cell viability from
αSA53T (Supplementary Figure 5). The mean percentage cell
viability along with respective SEM values for each compound
are provided as Supplementary Table 2.
Molecular Modeling of Optimized
Conformations of Test Compounds to αS
A53T
Results from docking studies indicated that all the test
compounds bound near the lysine-rich hinge area ranging from
residue Ala 17 to Gly 36 in the predefined docking search space
(Figures 6A–D and Supplementary Figures 6a–c). Both synthetic
imidazolidines Compound 1 and Compound 2 displayed higher
docking scores and steric interactions than the rest of the
ligands; however, neither formed any H-bonding interactions
(Table 1; Figures 6A,B). The two trihydroxy flavones, 2-D08 and
myricetin, yielded similar scores, with myricetin forming more
H-bonding interactions than 2-D08. Transilitin, a dihydroxy
flavone, had similar docking and H-bonding scores as myricetin.
The lignan honokiol had the highest score among the natural
compounds, indicating strong interaction and H-bonding to
Lys 23 and Thr 33 while the ellagitannin punicalagin had
the lowest score, implying punicalagin might be a poor
binder to αSA53T. H-bonding with key Lys residues, especially
Lys 23 and Lys 21 was found in the case of all tested
natural ligands.
DISCUSSION
A growing number of studies have emphasized that
accumulation or aggregation of α-synuclein plays a key
role in neurodegeneration via mitochondrial and lysosomal
dysfunction (Hashimoto et al., 2003; Mazzulli et al., 2016).
A search for αS aggregation inhibitors possessing different
molecular scaffolds, other than the commonly used dopamine
analogs would be insightful for rational drug design. This study
has identified and compared the neuroprotective properties
of common and novel flavones as well as other polyphenols,
along with two synthetic imidazolidine compounds, which
can attenuate the toxic aggregation of αSA53T in vitro. The
seven compounds studied here can be broadly divided into
four categories, based on their structures; (i) the flavones:
myricetin, 2-D08 and transilitin, (ii) neolignan: honokiol,
(iii) ellagitannin: punicalagin, and (iv) synthetic dibenzyl
phenyl imidazolidines: Compound 1 and Compound 2.
Molecular docking provided additional insight into their
probable binding sites and the nature of interactions that
might contribute to structural modification of αSA53T
during fibrillization, to result in the formation of non-toxic
aggregates.
Interaction of Flavones and Their Effect on
αSA53T Conformation, Fibrillization, and
Neurotoxicity
The three flavones studied here possessed a catechol-type vicinal
tri-hydroxylation in the B-ring (myricetin and 2-D08) and di-
hydroxylation in both A and B-rings (transilitin). A major aim
of this study was to investigate how restricted tri-hydroxylation
in the flavone B-ring (2-D08) impacts αS amyloid aggregation.
TEM imaging revealed that 2-D08 altered the fibril morphology
more significantly than myricetin or transilitin, despite similar
ThT fluorescence outputs, in particular, TEM images after 50 h
incubation revealed that 2-D08 modified the αSA53T active
fibrillisation phase differently than myricetin or transilitin. The
amorphous αSA53T aggregates arising from incubation with 2-
D08 are likely to possess a reduced hydrophobic surface that
is critical for ThT micellar binding, thus lowering fluorescence
(Khurana et al., 2005). These amorphous aggregates resemble α-
Synuclein treated with baicalein as observed in a previous study
(Hu et al., 2016). Notably, 2-D08 showed an exclusive interaction
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FIGURE 6 | Binding modes of the four strongest inhibitor optimized ligand structures to αSA53T monomer: (A) Compound 2, (B) 2-D08, (C) honokiol, and
(D) punicalagin.
with Lys 23, followed by Thr 33 and unlike transilitin and
myricetin. Therefore, restriction of the O-quinone forming three
-OH side groups in either the A or B-ring of the flavone might
be favorable for binding to inhibit αS fibrillization as previously
observed with baicalein (Hong et al., 2008). Nevertheless, the
primary interaction of 2-D08 with αSA53T could be a low
affinity, transient interaction between the protein and ligand
rather than covalent modification of the Lys and Thr residues
in the binding region, as we did not observe significant adduct
formation in our IMMS study. Gallic acid had been shown to
inhibit αSA53T structural collapse in a similar manner (Liu et al.,
2014).
We previously reported that 2-D08 exerted a novel anti-
aggregatory and neuroprotective effect against Aβ compared
to transilitin and quercetin, which have A and C-ring
hydroxylation (Marsh et al., 2017). In the present study, 2-
D08 induced inhibition of αS aggregation and neuroprotection
was as pronounced as myricetin, a generic amyloid aggregation
inhibitor, and supports the idea that restricted B-ring tri-
hydroxylation is adequate for targeting both αS and Aβ (Ono
and Yamada, 2006; Hirohata et al., 2007; Zelus et al., 2012;
Liu et al., 2015). From the TEM imaging, it appeared that
transilitin modified the αSA53T fibrils in a similar way to
myricetin, where only loose fibrils but no amorphous aggregates
were seen. It is likely that these two flavones with A-ring
hydroxylation share a common mechanism for inhibiting
aggregation by reducing toxic amyloidogenic fibrils, whereas
2-D08 may inhibit amyloid fibrillization through formation
of non-toxic amorphous aggregates. Consequently, within the
flavone molecular scaffold, both 2-D08 and transilitin appear
to be generic inhibitors of αSA53T and Aβ aggregation,
similar to myricetin. Comparing the strong inhibitory effect
of transilitin with the flavonoid G-500 suggests that additional
hydroxyl groups other than the two pairs in the A and C-
rings might be redundant (Meng et al., 2010). Together, our
findings emphasize the previously reported idea that vicinal
trihydroxylation in the flavone is favorable for strong inhibition
of αS aggregation, coupled with its precise position in the B-ring
(Meng et al., 2010).
IM-MS is an emerging analytical method that retains weak
non-covalent interactions in the gas-phase andmaintains protein
conformations from solution phase (Konermann and Douglas,
1998; Sarni-Manchado and Cheynier, 2002; Wyttenbach and
Bowers, 2011; Abzalimov et al., 2012). The IM-MS study
presented here reinforces that soluble αSA53T undergoes a
structural transition from natively unfolded to more compact
amyloidogenic conformations at an early stage of aggregation, as
measured by changes in CCSs. This is consistent with our ThT
results, where the increasing fluorescence reaches its maximum
by ∼50 h, indicating the fibril plateau phase is reached in this
time frame. Stabilization of unfolded αSA53T conformations
to prevent amyloid formation was observed by IM-MS in the
presence of all three flavones tested and was further supported
by inhibition of ThT fluorescence during this early aggregation
period.
No loss in PC12 cell viability was observed in vitro by
preincubated αSA53T in the presence of 2-D08, even at
an equimolar concentration, corroborating that the loose
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TABLE 1 | Docking profiles of seven test compounds to αSA53T monomer.
Ligand Docking score H-bond forming residues H-bond score Steric interaction score RMSD (Å)
Compound 1 −69.23 − 0.00 −73.48 133.13
Compound 2 −65.53 − 0.00 −68.25 136.99
2-D08 −44.89 Lys 23, Thr 33 −6.00 −40.88 137.15
Myricetin −41.82 Ala 19, Lys 21, 23, Thr 22, Gln 24, Gly 25 −10.45 −32.68 129.40
Honokiol −58.36 Lys 23, Thr 33 −6.00 −55.55 137.42
Punicalagin −38.00 Lys 21, Lys 23 −5.83 −38.28 131.27
Transilitin −50.09 Lys 23, Lys 32, Thr 33, Lys 34 −10.00 −44.82 136.70
amorphous aggregates formed under these conditions are
not amyloidogenic or toxic. The prevention of structural
collapse by 2-D08 effectively inhibited the toxic amyloid
formation of αSA53T, providing a degree of neuroprotection
as pronounced as myricetin. Transilitin, on the other hand,
was less effective in halting αSA53T amyloidogenic aggregation
and neurotoxicity at an equimolar concentration. Since there
is some degree of αSA53T folding as measured by CCSs in
the presence of transilitin, this might account for the reduced
neuroprotection at a lower concentration. Combining the
anti-aggregation and neuroprotection results, we can infer
that flavone tri-hydroxylation is more effective against toxic
αSA53T amyloidogenic aggregation than di-hydroxylation. An
understanding of the precise flavone structural requirements for
strong inhibition of αS toxic aggregation would facilitate
improved drug design. As exemplified with quercetin,
hydroxylation in the flavone 3 and 7 positions are susceptible
to thiol formation with cellular proteins rather than being
neutralized in the cellular antioxidant network (Jacobs et al.,
2011). Therefore, not having any hydroxylation in these positions
while retaining a strong inhibitory effect seems a valuable strategy
for improved drug design. Consequently, 2-D08 would be more
favorable than myricetin to serve as a template for flavone-based
inhibitors of αS toxic aggregation.
Lignan Interaction With αSA53T During
Fibrillization and Neurotoxicity
Outside the flavonoid class of compounds, other small molecule
polyphenolics such as lignans have recently gained attention
for amyloid inhibition. In the present study, honokiol showed
a profound effect on αSA53T aggregation, as indicated by
the TEM imaging and ThT assay. TEM images of honokiol-
treated αSA53T fibrils to some extent resembled analogous
samples with punicalagin when comparing the long fibrils, and
transilitin when comparing the short fibrils. These modified
fibrils might account for the residual ThT fluorescence. As a
strong inhibitor, honokiol prevented the structural collapse of
native monomeric αSA53T at a very early stage of aggregation,
as observed for 2-D08, although treatment with honokiol did
not produce any amorphous aggregates. TEM images following
50 h incubation suggested that honokiol effectively inhibited
αSA53T fibrillization at an early stage, in agreement with the
ThT and IM-MS results. The demonstrated neuroprotection
by preincubated αSA53T fibrils in the presence of honokiol
highlights the non-toxic and non-amyloidogenic nature of the
detached fibrils observed. Molecular docking results indicated
that honokiol has the highest overall and steric binding scores
among the natural compounds, while interacting strongly with
key residues Lys 23 and Thr 33 through hydrogen-bonding,
a similar interaction observed in the docking profile of 2-
D08. This indicated a more sterically favorable interaction
with this binding region to stabilize the unfolded αSA53T
monomer. Nonetheless, honokiol lacks any O-quinone forming
vicinal dihydroxyl structure like 2-D08 or other catechol-type
flavones. Therefore, it might not covalently modify the target
but interact throughπ-π stacking. Presumably, honokiol and tri-
hydroxyflavones such as 2-D08 or myricetin might have different
modes of interacting with αSA53T, nevertheless, they all result
in similar degree of inhibition of amyloidogenic aggregation.
Previously, honokiol was reported to be effective against toxicity
related to Aβ and calcitonin aggregation (Guo et al., 2015; Das
et al., 2016), and shown to be as effective as resveratrol and EGCG
in an in vivo model of Aβ toxicity, inhibition of cholinesterase
and metal chelation (Kantham et al., 2017). Together, honokiol
has as pronounced an effect as the two tri-hydroxyflavones
on inhibiting αSA53T aggregation and toxic amyloidogenic
formation. Nonetheless, the molecular mechanism underlying
this lignan based inhibition of αS aggregation is yet to be fully
understood.
Effect of Ellagitannin on αSA53T
Fibrillization and Neurotoxicity
Punicalagin, being the largest molecule tested, presents
interesting information on the role of steric bulk. Like the
flavones and honokiol, punicalagin also maintained the natively
unfolded structure of αSA53T in its early stage of aggregation.
Seemingly, the thin, long fibrils arising from punicalagin-
treated αSA53T might not be toxic amyloid fibrils, as it exerted
significant neuroprotection to αSA53T-exposed PC12 cells.
These fibrils might have undergone a loss of hydrophobic
surface area where ThT micelles could bind, thus diminishing
fluorescence output (Khurana et al., 2005). Not surprisingly,
molecular docking predicted that punicalagin was a poor binder
to αSA53T, possibly due to steric hindrance as a result of its bulky
size, however, it was predicted to form H-bonding interactions
with key Lys 21 and 23 like other natural polyphenols tested here.
Having multiple vicinal hydroxylation sites across the molecule,
it is highly probable that punicalagin has several interaction
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modes with polar residues in an unfolded protein. Therefore,
it is possible that punicalagin interacted with these predicted
residues to preserve an unfolded conformation that resulted in
non-amyloidogenic fibril formation. This was further supported
by the TEM study following 50 h incubation. Due to the bulky
size, punicalagin might have weak, non-specific interactions,
not binding to a particular pocket unlike other small molecule
polyphenolics. There is a correlation between the antioxidant
activity of flavonoids and their in vitro inhibitory effect on αS
fibrillization (Meng et al., 2009). We previously showed that
punicalagin was capable of inhibiting amyloid β aggregation
and neurotoxicity (Das et al., 2016). Given punicalagin has
some similarities in terms of being an extensively hydroxylated
polyphenol, its high antioxidant activity might also contribute
toward its inhibitory effect.
Novel Dibenzyl Imidazolidine Scaffold
Effect on αSA53T Fibrillization and
Neurotoxicity
Our previous study employing structure-based virtual screening
for Aβ1−42 inhibitors identified two compounds with anti-
aggregatory and neuroprotective roles in vitro (Das and Smid,
2017). These two synthetic compounds bearing a novel dibenzyl
imidazolidine scaffold could provide insight on the effect of
this scaffold on αSA53T aggregation in comparison with natural
polyphenolics. TEM imaging suggests that the αSA53T fibril
morphology, modified by both compounds, is different than that
induced by the polyphenolics. Nonetheless, the TEM study after
50 h incubation showed that αSA53T modified by Compound
2 resembled the morphology of myricetin-incubated samples.
Furthermore, there is variable effect on fibril morphology
between these two compounds. In the presence of Compound
1, the small dense aggregates look different than the amorphous
aggregates produced by 2-D08. The presence of both aggregates
and short fibrils indicate that Compound 1might have more than
one mechanism of interaction with αSA53T during aggregation.
The docking study predicted no polar interactions between
Compound 1 and αSA53T and showed higher docking scores,
suggesting a non-stable protein-ligand interaction. The reduction
of CCSs for some αSA53T charge states in the presence of
Compound 1 indicates it is less effective in stabilizing the native
αSA53T unfolded state. Therefore, interaction of Compound 1
with αSA53T might not completely prevent its amyloidogenic
aggregation, especially at lower concentration, unlike the natural
polyphenolics and Compound 2. This was further supported
by the comparative neurotoxicity observed in PC12 cells, and a
higher ThT fluorescence at equimolar concentrations of protein:
compound.
In the case of Compound 2, the appearance of thin, long fibrils
but no dense aggregates points toward a different mechanism
of interaction with αSA53T than Compound 1. There is
some degree of similarity between αSA53T fibrils formed by
Compound 2 andmyricetin. However, Compound 2 had amostly
sterically favorable binding to αSA53T, while myricetin has both
steric and polar interactions observable from the docking study.
Compound 2 demonstrated significant neuroprotection and low
ThT fluorescence at an equimolar concentration of protein:
compound. Improved inhibition of αSA53T toxic amyloid
aggregation by Compound 2 over Compound 1 is feasibly
attributable to the additional -OCH3 functional group adjacent
to the phenyl group in the dibenzyl imidazolidine scaffold in
Compound 2. This finding is consistent with our previous study
on these compounds against Aβ1−42, where we found that
Compound 2 significantly inhibited Aβ1−42 aggregation in both
ThT and TEM analysis, whereas Compound 1 was not able to
inhibit ThT fluorescence (Das and Smid, 2017). Considering
the novel aspect and effectiveness of both compounds bearing
this dibenzyl imidazolidine scaffold, our findings highlight
the potential of this molecular scaffold when targeted against
pathological amyloidogenic proteins.
CONCLUSION
Among the seven compounds tested and compared here,
polyphenols such as 2-D08, honokiol, myricetin, punicalagin,
and the synthetic imidazolidine, Compound 2 are the most
effective inhibitors of αSA53T toxic amyloidogenic aggregation,
while transilitin and other synthetic imidazolidines, such as
Compound 1, were less effective. All of these compounds
inhibited toxic amyloidogenic aggregation by stabilizing the
native unfolded αSA53T conformations, which in turn altered
αSA53T fibril morphology. This structurally diverse group of
molecules could potentially facilitate improved drug design
targeting the complexity of progressive neurodegenerative
diseases associated with amyloidogenic protein aggregation.
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Appendix A: Supplementary material
Supplementary Figure 1. 1H-NMR of Compound 1 (1,3-dibenzyl-2-[3-(benzyloxy)phenyl]imidazolidine) in DMSO.
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Chapter 5: Inhibition of α-synuclein and amyloid β aggregation by diverse 
bioactives reveals a common antiaggregative role of magnolol  
5.1  Introduction 
Protein aggregation in the form of amyloid fibrils is associated with the neuropathology of both 
PD and AD. In AD, the extracellular protein amyloid β (Aβ) misfolds into neurotoxic β-sheet 
rich fibrils, whereas in PD it is the cytosolic protein α synuclein (αS) that aggregates into 
neurotoxic amyloid fibrils eliciting cellular dysfunction. The αSA53T mutant form of αS is 
more aggregation-prone and associated with familial PD (Narhi, Wood et al. 1999). 
Consequently, studies have focused on identifying bioactive molecules capable of directly 
disrupting and remodelling amyloid fibrils of both Aβ and αS into non-toxic conformations as 
part of their neuroprotective action, exemplified by the green tea flavonoid EGCG, flavone 
myricetin and saffron bioactive crocin (Papandreou, Kanakis et al. 2006, Bieschke, Russ et al. 
2010, Inoue, Shimizu et al. 2017). A diverse array of natural polyphenols has been ascribed 
neuroprotective properties in a number of models of neuronal damage and neurodegeneration, 
with potential for the development of neuroprotective drugs (Koppel and Davies 2008, 
Fernandez-Ruiz, Garcia et al. 2010). Bioactive polyphenols such as flavonoids been shown to 
mediate neuroprotection against the neurotoxic Aβ found in AD via anti-aggregation and other 
mechanisms (Smid, Maag et al. 2012).  
Previous studies presented in this thesis have highlighted the inhibitory activity of the 
neolignan honokiol for both αSA53T and Aβ amyloidogenic aggregation. Honokiol and 
magnolol have very similar chemical structures (found in the same plant genus Magnolia) and 
in the molecular docking studies showed a favourable binding profile comparable to honokiol.  
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Additionally, magnolol displayed neuroprotection against Aβ induced toxicity, in a previous 
study (Hoi, Ho et al. 2010). Other than Aβ, magnolol demonstrated neuroprotective and anti-
aggregative properties against calcitonin, another amyloidogenic protein (Guo, Ma et al. 2015). 
Therefore, magnolol has been selected to study its direct effect on αSA53T and Aβ 
amyloidogenic aggregation and fibril morphology. Neferine, an alkaloid from lotus seed 
embryo, reduces amyloidogenic huntingtin protein levels and toxicity through inducing 
autophagy (Wong, Wu et al. 2015). It has been found to inhibit the BACE1 enzyme resulting 
in lower Aβ production (Jung, Jin et al. 2010). Neferine generated a lower docking score 
against both targets, hence this was selected for comparison. Tanshinone I, an abietane 
diterpene found in the medicinal herb Danshen, has been found to offer neuroprotection in PD 
pathology through antioxidant action and selectively suppressing pro-inflammatory gene 
expression associated with neurodegeneration (Wang, Jing et al. 2015, Jing, Wei et al. 2016). 
Similarly, cryptotanshinone, another abietane diterpenes, has been found to alleviate memory 
decline following Aβ injection in mice and reduce neuroinflammation (Maione, Piccolo et al. 
2018). Both cryptotanshinone and tanshinone I have been shown to be neuroprotective against 
Aβ (Hanaki, Murakami et al. 2016). The chalcone structural scaffold has been used for 
developing imaging molecules for αS and Aβ aggregation (Kotzbauer, Tu et al. 2017, Chauhan, 
Tiwari et al. 2018). Phloretin, a dihydrochalcone found in apple leaves, has been associated 
with protecting cells from Aβ toxicity by blocking attachment to lipid bilayers (Hertel, Terzi 
et al. 1997). The flavone galangin, has reduced Aβ generation in vitro by inhibition of the 
BACE1 enzyme (Zeng, Huang et al. 2015). Our previous studies have shown that B-ring 
hydroxylation in the flavone is a favourable structural feature for inhibiting αSA53T and Aβ 
amyloidogenic aggregation and fibril morphology (Chapter 4 and (Marsh, Das et al. 2017). As 
galangin has no hydroxyl group in the B-ring, it enables us a useful comparator to further study 
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structure-activity relationships towards αSA53T and Aβ amyloidogenic aggregation and fibril 
morphology.  
While previous studies highlight multiple sites of neuroprotection of naturally-occurring 
bioactives, a direct interaction of many of these bioactives with the common elements of toxic 
amyloidogenic proteins, such as Aβ and αSA53T has not been systematically documented. In 
this way, the study aims to better understand the structural features by which bioactive 
inhibitors may interact with the aggregation-prone and amyloidogenic proteins αSA53T and 
Aβ. 
Figure 1. Chemical structures of the bioactive compounds used in this study. 
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5.2  Materials and Methods 
5.2.1  Reagents and Chemicals 
Human amyloid-β 1-42 protein (Aβ1-42) was obtained from Abcam (Cambridge, MA, USA). 
Select bioactives used in this study were the flavonoid galangin, the lignin magnolol, the 
chalcone phloretin, alkaloid neferine and diterpenes tanshinone I and cryptotanshinone. All 
were sourced from Sigma-Aldrich (St Louis, MO, USA). thioflavin T, DMSO were also 
obtained from Sigma-Aldrich. Phosphate buffered saline (PBS) at pH 7.4 were obtained from 
Thermo Fisher Scientific, (Scoresby, VIC, Australia). Foetal calf serum (FCS) was obtained 
from Bovogen Biologicals (East Keilor, VIC, Australia).  
5.2.2  αSA53T Protein expression and purification 
αSA53T was expressed and purified as previously described (Volles and Lansbury Jr 2007). 
Cells were grown in normal Lennox broth (LB) medium. Protein was purified by size exclusion 
chromatography using a Superdex 200 SEC column (Bio Rad), with a flow rate of 0.5ml/min, 
in 20mM ammonium acetate buffer. The purity of αSA53T was confirmed by Q-ToF mass 
spectrometry on an Agilent 6560 Ion Mobility Q-ToF spectrometer with samples introduced 
by nanoelectrospray ionisation through platinum-coated capillaries (made in-house). Ions were 
analysed in the positive mode with typical instrument parameters included; capillary voltage 
1700 V, fragmentor voltage 400 V, gas temperature 0°C, gas flow 2 l/min, trap fill time 20000.0 
μs, trap release time 4000.0 μs. Protein was stored at −80ºC until required.  
5.2.3  Thioflavin T kinetic assay of αSA53T and Aβ1-42 fibrillisation 
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The dye thioflavin T (ThT) binds to the β-sheet of amyloid fibrils, with fluorescence increasing 
proportionally to the amount of fibrils present in solution. The ThT assay was used to confirm 
fibril formation over time by αSA53T and Aβ1-42 in cell-free solution, in addition to 
determining if the fibril formation was directly affected by the bioactive compounds. For 
αSA53T fibrillisation kinetics, ThT (100μM in PBS) was added to wells on a microplate 
together with non-fibrillar αSA53T (100μM) and test bioactive compounds at a 1:5 (protein: 
compound) molar ratio. Fluorescence was measured at 37°C every 30 minutes for 100 hours 
using a Fluostar Optima plate reader (BMG Lab technologies, Australia) with a 440/490 nm 
excitation/emission filter. For the Aβ1-42 fibrillisation study, ThT (10µM in PBS) was added to 
wells on a microplate together with non-fibrillar Aβ1-42 (10µM) and the test bioactive 
compounds (each at 100μM). Fluorescence was then measured at 37°C every 10 minutes for 
48 hours using a Synergy MX microplate reader (Bio-Tek, Bedfordshire, UK) with excitation 
and emission wavelengths at 446nm and 490nm respectively. ThT output from all treatment 
groups were normalised to blank values (ThT alone in PBS). 
5.2.4  Transmission Electron Microscopy of Aβ fibrils and aggregates 
Transmission electron microscopy (TEM) was used to visualise the effects of selected 
bioactives on αSA53T and Aβ1-42 fibril and aggregate morphology. For αSA53T imaging, 
samples were directly taken from the ThT assay on completion (100 hrs). For Aβ imaging, 
samples were prepared by incubating native Aβ1-42 (10 µM) in PBS, either alone or with each 
of the bioactive compounds (100μM) for 48 hours at 37°C. For both proteins, a 5μl sample was 
then placed onto a 400 mesh formvar carbon-coated nickel electron microscopy grid 
(Proscitech, Kirwan, QLD, Australia). After 1 minute this sample was blotted off using filter 
paper and 10µl of contrast dye containing 2% uranyl acetate was then placed onto the grid, left 
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for one minute and blotted off with filter paper. Grids were then loaded onto a specimen holder 
and then into a FEI Tecnai G2 Spirit Transmission Electron Microscope (FEI, Milton, QLD, 
Australia). Sample grids were extensively scanned manually in search of fibrils using a 
magnification of 34000-92000 and representative images taken. 
5.2.5 Computational modelling of bioactive optimized conformation binding to Aβ1-42 and 
αSA53T 
For the bioactive ligands, equilibrium geometries were optimized using density functional 
theory (DFT) approach that utilizes Becke’s three-parameter hybrid functional known as 
B3LYP (Kohn, Becke et al. 1996). A large basis set, aug-cc-pVDZ was used for approximation 
of molecular orbitals in optimized geometry for all three molecules. All the computations were 
carried out using Gaussian 09 package of codes (M. J. Frisch 2016). Calculations were carried 
out in no symmetry to facilitate full rearrangement and relaxation of the structures to their most 
stable form.  
Fully optimized ligand structures were studied for their prospective binding interactions 
according to docking model Aβ1-42 fibrillar β-sheet structure (PDB ID: 2BEG) using the CLC 
Drug Discovery Workbench, version 2.4.1, that uses a PLANTSplp empirical scoring function 
(Thomsen and Christensen 2006). This NMR structure of Aβ oligomer has been shown to be 
toxic and serves as a good model for understanding the structural basis of fibrillisation 
inhibitors (Lührs, Ritter et al. 2005). As Aβ does not have any singular pharmacophore, a large 
search space was created covering the whole protein. For docking studies with αSA53T, the 
docking search space was created near the NAC (non-amyloid β component of AD amyloid) 
region of its lipid binding domain since this region is crucial for its aggregation (Rodriguez, 
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Ivanova et al. 2015). Since the full αSA53T structure was not available, the solid-state NMR 
of pathogenic α synuclein fibril (PDB ID: 2N0A) was obtained from the protein data bank and 
the residue 53 mutated from alanine to threonine to generate the model protein monomer of 
αSA53T (Tuttle, Comellas et al. 2016). The resultant αSA53T protein conformation was used 
for docking without any further adjustment. All ligand structures were kept flexible to allow 
rotation of any bonds to bind αSA53T or Aβ1-42. There were 100 iterations performed for each 
docking simulation for each bioactive ligand. Results are summarized as a docking score in 
Table 1 and 2.  
The compound structures were screened for PAINS (pan assay interference compound) 
moieties using the filter http://zinc15.docking.org/patterns/home/. No PAINS moiety was 
detected.  
5.2.6  Statistical Analysis 
Area under the curve analysis for thioflavin T (ThT) fluorescence data was analysed using one-
way ANOVA with a Dunnett's multiple comparisons test used for determining the significance 
of bioactive effects versus αSA53T or Aβ1-42. A significance value of p<0.05 was used for all 
experiments. Data analysis and production of graphs was performed in GraphPad Prism 7 for 
Windows (GraphPad Software, San Diego, USA). 
5.3  Results 
5.3.1  Effects of bioactives on αSA53T and Aβ1-42 fibrillisation 
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The mass spectrum of αSA53T confirmed the purity of the expressed protein (Fig. 2). 
Thioflavin T (ThT) fibrillisation kinetics of αSA53T demonstrated a gradual increase in 
fluorescence from 24 hours (hrs) and reached at its highest at 70 hrs. This indicated that 
αSA53T underwent a conformational transition to a cross-β-sheet rich structure characteristic 
of amyloid fibrils and aggregates (Fig. 3a). Thereafter, the fluorescence stabilised over the 
remainder of the assay. Out of the six bioactive compounds tested at a 1:5 (protein: compound) 
molar ratio, only magnolol and cryptotanshinone significantly inhibited ThT fluorescence (Fig. 
3a, b). Magnolol markedly suppressed fibril kinetics, while cryptotanshinone showed a small 
degree of residual fluorescence (Fig. 3a, b). Neferine showed a partial inhibition of ThT 
fluorescence, however, this was not statistically significant (Fig. 3a, b). Galangin, phloretin 
and tanshinone I had only a marginal and non-significant effect on the ThT fluorescence of 
αSA53T overall (Fig. 3a, c).   
Figure 2. Mass spectrum of αSA53T (50μM) in 50mM ammonium acetate. 
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Figure 3: (a) ThT fluorescence assay representing kinetics of αSA53T (100 µM) fibrillisation over 100 
hrs, alone and in the presence of each test compound at a 1:5 (protein: compound) molar ratio. (b) Area 
under the curve (AUC) measurements demonstrating significant reductions in ThT fluorescence for 
each test compound at a 1:5 (protein: compound) molar ratio. **p<0.01 for magnolol and 
cryptotanshinone and p>0.05 for galangin, phloretin, tanshinone I and neferine. Mean ± SEM of n=3 
experiments. 
The thioflavin T (ThT)-based fibrillisation kinetics of Aβ1-42 demonstrated a gradual increase 
in fluorescence from 770 mins (~13 hrs) and reached a maximum at about 2250 minutes (mins) 
equivalent to 37 hrs, indicative of fibril and aggregate formation (Fig. 4a). Thereafter, ThT 
levels were mostly stable over the duration of the assay, up to 2880 mins (48 hrs). Initially, 
there was a minor increase in Aβ1-42 fluorescence and a higher increase in fluorescence for all 
the test bioactives were observed. However, this increased fluorescence was diminished from 
around 800 mins (~13 hrs) when the Aβ1-42 showed a persistent increase in fluorescence output 
(Fig. 4a). All the bioactives tested (each at 100 μM) inhibited the development of ThT 
fluorescence significantly after around 13 hrs and continuing over the full 48 hr time course of 
incubation. Area under the curve analysis showed extensive and significant overall inhibition 
of fibril formation in the presence of each of the bioactive polyphenols (Fig. 4b). Galangin had 
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the most profound inhibition of Aβ1-42 fluorescence, followed by cryptotanshinone, magnolol, 
neferine, tanshinone I and phloretin.  
Figure 4: (a) Thioflavin T (ThT) fluorescence indicative of amyloid Aβ1-42 (10μM) fibrillisation 
kinetics, alone and in the presence of each of the six bioactives (100μM each) over 48hrs in cell-free 
PBS solution. (b) Area under the curve analysis of ThT kinetics demonstrating significant overall 
inhibition of amyloid fibrillisation from incubation with each of the bioactives (****P< 0.0001; mean 
SEM of n=3 experiments). 
5.3.2  Transmission Electron Microscopy of αSA53T and Aβ1-42 fibrils and aggregates 
The inhibition of αSA53T fibrillisation observed in the ThT assay was further confirmed by 
transmission electron microscopy (TEM), an essential qualitative technique to directly 
visualise the morphology of amyloid fibril and aggregate formation. αSA53T alone formed 
dense fibrillar aggregates in high abundance following 100 hrs incubation (Fig. 5a), as observed 
previously (Liu, Carver et al. 2014). The morphology of αSA53T fibrils and aggregates was 
markedly altered after 100hrs incubation with magnolol, forming small amorphous aggregates 
at a 1:5 (protein: compound) molar ratio (Fig. 5d). Incubation with cryptotanshinone resulted 
in shorter, smoother and loosely attached fibrils in relatively low density and abundance (Fig. 
5b). For the remainder of the bioactives, the density and abundance were only modestly 
reduced compared to control, with a meshwork of aggregates still present (Fig. 5c, e-g). 
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Overall, incubation with either galangin, neferine, phloretin or tanshinone I did not alter the 
overall morphology and abundance of dense fibrillar aggregates of αSA53T. 
Figure 5: Representative transmission electron micrographs of αSA53T fibril and aggregate formation, 
following 100 hr incubation, alone and with each bioactive compound at a 1:5 (protein: compound) 
molar ratio; (a) A53TαS alone, and in presence of (b) cryptotanshinone, (c) galangin, (d) magnolol, (e) 
neferine, (f) phloretin and (g) tanshinone I (each at 100 µM). Scale bar: 500 nm. 
On microscopic evidence, the morphology of Aβ1-42 fibrils and aggregates was affected by 
incubation with each of the bioactives, but to varying extents on both density and morphology. 
Aβ1-42 alone formed dense aggregates, resembling a ‘meshwork’ after 48 hrs of incubation (Fig. 
6a). Magnolol markedly reduced Aβ1-42 aggregation, with the appearance of small and dense 
amorphous aggregates (Fig. 6d). Cryptotanshinone and tanshinone I altered Aβ1-42 aggregate 
morphology into thin, long fibrils that were loosely attached and less dense than Aβ1-42 alone 
(Fig. 6b, g). Incubation with neferine produced relatively thin and loosely attached fibrils, while 
no aggregates were observed (Fig. 6e), while phloretin did not visibly alter the morphology of 
Aβ1-42 aggregates (Fig. 6f). In contrast to the other bioactives tested, incubation with galangin 
resulted in the presence of both dense aggregates and longer, interconnected fibrils in 
abundance (6c).   
Figure 6: Representative transmission electron micrographs of Aβ1-42 fibril and aggregate formation, 
(a) alone and (b-g) following 48hrs incubation with each of the bioactives (each at 100μM): (a) Aβ1-42
(b) cryptotanshinone (c) galangin (d) magnolol (e) neferine (f) phloretin (g) tanshinone I. scale bar:
200nm.
5.3.3  Molecular modelling of bioactive prospective interactions with αSA53T and Aβ17-42 
Results from docking studies indicated that all the test compounds bound near the hinge region 
of αSA53T, surrounded by residue Ala 85 to Ile 88 and Phe 94 to Glu 105 of the NAC (non-
Aβ component) region, a critical part of the protein responsible for amyloidogenic aggregation, 
in the lipid binding domain (Fig. 7a-f) (Rodriguez, Ivanova et al. 2015). Due to the relatively 
larger size of the protein, only binding site with interacting residues are shown. Magnolol 
showed the lowest docking score, which was due to proposed shape complementarity within 
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this NAC region binding pocket, interacting with the Lys and Glu residues (Fig. 7c). Neferine 
had the second lowest docking score and interacted mostly with Gly residues (Fig 7d). 
Cryptotanshinone and Tanshinone I had similar docking scores and proposed hydrogen (H-
bonding) interactions with similar binding poses (Fig. 7a, f). Galangin, having a high docking 
score, bound to a different pocket than rest of the bioactives and interacted with Ala 78 to Glu 
83 residues (Fig. 7b). Phloretin had the highest docking score but a low H-bonding score and 
bound in a similar region to tanshinone I (Fig. 8e).    










cryptotanshinone -40.84 -6.01 Asn 103, Glu 104, 105 -34.83 171.99 
galangin -36.14 -6.0 Gln 79, Glu 83 -30.98 163.99 
magnolol -51.55 0.00 - -54.41 170.61 
neferine -47.21 0.00 - -56.02 185.45 
phloretin -35.04 -7.36 Gly 101, Asn 103, Glu 
104,105 
-34.59 172.75 
Tanshinone I -39.74 -6.0 Asn 103, Glu 104, 105 -33.74 170.84 
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Figure 7: Modelled bioactive ligand binding of each of the optimised bioactives conformations to 
αSA53T (PDB ID: 2N0A) (a) cryptotanshinone, (b) galangin, (c) magnolol, (d) neferine (e) phloretin 
and (f) tanshinone I. Binding properties of each bioactives are provided in Table 1.  
Molecular docking of each of the bioactives with the Aβ17-42 oligomer suggested that all the 
test compounds bound in the hydrophobic binding pocket formed by Leu 17, Val 18, Phe 19 
and Gly 38, Val 39, 40 of all chains (Fig. 8a-f). Due to the small size of Aβ12-42 oligomer, the 
whole protein structure can be shown with interacting residues for all bioactives. Neferine had 
the lowest docking score which was primarily due to proposed shape complementarity, as it 
was able to interact with all the chains in the binding pocket according to docking model (Fig. 
8d). Tanshinone I bound within this same pocket and had the second highest score with a high 
H-bond score (Fig. 8f). Despite having similar docking scores, magnolol binding was suggested
to be through shape complementarity primarily, whereas galangin was suggested to have a 
higher probability of forming H-bond interactions in this pocket according to the docking 
model (Fig. 8b, c). Cryptotanshinone was predicted to have a different binding pose than 
Tanshinone I and displayed a weak binding score, with predicted less H-bond interactions 
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according to the docking model (Fig. 8a). Phloretin bound inside the pocket with a proposed 
high H-bond interaction; however, the overall docking score was high (Fig. 8e).  









cryptotanshinone -50.29 -1.57 Val 39E -48.72 21.42 
galangin -64.95 -14.08 Leu 17D, E, Val 18C, D, 
Phe 19D 
-51.73 20.34 
magnolol -65.24 -1.76 Leu 17C -67.86 17.66 
neferine -82.91 -3.53 Leu 17C  -88.56 22.05 
phloretin -56.21 -10.78 Leu 17A, C, D, Val 18A, C -53.33 17.01 
Tanshinone I -68.84 -10.8 Leu 17D, E, Val 18C, D, 
Phe 19D  
-58.04 21.10 
Figure 8: Modelled bioactive ligand binding of each of the optimised bioactives conformations to Aβ17-
42 polymer (PDB ID: 2BEG) (a) cryptotanshinone, (b) galangin, (c) magnolol, (d) neferine (e) phloretin 
and (f) tanshinone I. Binding properties of each bioactives are provided in Table 2  
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5.4.  Discussion 
This study compared the capacity of selected natural bioactives to structurally modify the 
aggregation of the major neurotoxic α-synuclein (A53T) and β amyloid fragment 1-42 in vitro. 
In silico modelling was also used to compare the likely binding sites of such bioactives to the 
α-synuclein (A53T) and β amyloid oligomer, as a further tool in which to investigate the most 
effective binding parameters that may predict the structural modification of α-synuclein and β 
amyloid protein to potentially non-aggregative and non-neurotoxic conformations. 
The ThT and TEM study of αSA53T aggregation suggests that magnolol is capable of 
significantly inhibiting αSA53T fibrillisation by forming small amorphous aggregates. These 
small amorphous aggregates are likely to undergo loss of an extensive surface area present in 
the ‘meshwork’ of Aβ fibrils in which ThT binds to account for these marked reductions in 
fluorescence output  (Khurana, Coleman et al. 2005). In a previous study, Rekas et al. (2004) 
observed that αB-crystallin inhibited the aggregation of A53T α-synuclein by converting it into 
amorphous aggregates. The docking study of magnolol and αSA53T indicates strong steric 
interaction between magnolol and the binding site of αSA53T. This interaction might have 
resulted in formation of less abundant amorphous aggregates, rather than highly abundant long 
αSA53T fibrils present in control samples. The compounds inhibited αSA53T fibrillation at a 
relatively high compound concentration of 500 μM. Therefore, it is possible that other 
mechanisms in addition to the reversible binding of an inhibitor molecule could contribute to 
inhibition of αSA53T aggregation.   
Similar to αSA53T, magnolol inhibited Aβ1-42 aggregation via ThT kinetics and resulted in the 
formation of small, amorphous aggregates as seen from TEM. The initial increase in ThT 
fluorescence for Aβ1-42 in the first few hours of incubation with bioactives, including magnolol, 
may indicate that initial nucleation or elongation of amyloid oligomers can still occur, but that 
at a specific stage, Aβ1-42 fibrils are exposed or vulnerable to small ligand interactions in which 
selected bioactive polyphenols seem particularly effective at inhibiting further progression. It 
is previously shown that ThT fluorescence can vary due to the addition of endogenous 
compounds such as polyphenols (Hudson et al. 2009). It should be noted that ThT fluorescence 
can over-represent fibril inhibition, as electron microscopy demonstrated that fibrils and 
aggregates can still be present even with markedly reduced ThT output. Magnolol, due to its 
small size and favourable intramolecular position of aliphatic/side chains, is able to fit 
efficiently within the binding pocket, resulting in a comparatively lower docking score. As 
observed in our docking simulations, the binding interaction of magnolol with both αSA53T 
and Aβ oligomeric conformation is essentially one of shape complementarity. Therefore, it can 
be asserted that the biphenyl structure of the neolignan is favourable for sterically interacting 
with amyloidogenic proteins, leading to anti-aggregative activity. Our previous study with 
honokiol, a structurally similar neolignan, indicated that the neolignan biphenyl scaffold had a 
favourable shape for interacting with Aβ and was a potent inhibitor of aggregation and may 
provide neuroprotection through multiple pathways (Das, Stark et al. 2016) (Kantham, Chan 
et al. 2017). Interestingly, magnolol was also demonstrated to inhibit calcitonin aggregation 
(Guo, Ma et al. 2015), suggestive of further potential as a small molecule template for anti-
amyloid drug development.  
The finding that galangin is ineffective in arresting αSA53T aggregation, as evidenced by both 
ThT and TEM, is probably due to the absence of vicinal di-or tri-hydroxylation in either of its  
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flavone A or B ring. Previous studies on αSA53T aggregation by various flavones have found 
that the presence of vicinal hydroxylation improves α synuclein aggregation inhibition (Meng, 
Munishkina et al. 2009, Meng, Munishkina et al. 2010). Our docking scores also indicate that 
galangin is a poor binder to αSA53T, which also might account for its ineffectiveness against 
αSA53T aggregation. In the docking study, the binding of galangin to Aβ was most favourable 
on the hydrophobic part of the pentamer, surrounded by key residues Leu17, Val18, Phe19, 
Gly38 and Val39. This occurs in a groove running parallel with the long axis of fibrils, which 
is also associated with ThT binding (Krebs, Bromley et al. 2005). While the ThT inhibition via 
galangin in presence of Aβ has been unexpected, other flavones without B ring hydroxylation 
have been shown previously to inhibit thioflavin T fluorescence, such as baicalein (Zhu, Choi 
et al. 2007, Espargaró, Ginex et al. 2017). However, as the TEM images still showed 
fibrils/aggregates, this is indicative that galangin may have quenched ThT fluorescence or 
otherwise displaced ThT from fibrils without impeding fibrillisation (Lee, Kerr et al. 2016). 
This may also explain why some polyphenolic compounds exert a strong degree of inhibition 
of ThT fluorescence without necessarily inhibiting fibril formation, via displacement of ThT 
from its amyloid binding site (Janefjord, Maag et al. 2014).  
Cryptotanshinone, being anti-aggregative against αSA53T, modified fibrils in a similar manner 
to phloretin. However, these were relatively lower in abundance. Tanshinone I modified 
αSA53T fibril morphology to a minor extent, where the moderately abundant αSA53T fibrillar 
‘meshwork’ was still evident from microscopic analysis. Although their docking profile to 
αSA53T was very similar, they may possess a different mode of interaction with αSA53T. Both 
tanshinones altered Aβ aggregation by producing loose fibrils, with no aggregates observed.  
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The alkaloid neferine demonstrated significant Aβ aggregation inhibition and visibly altered 
Aβ fibril morphology and reduced overall aggregation. This property, coupled with a 
favourable docking profile against Aβ oligomer, suggests that the size of the neferine molecule 
is amenable for interaction with a small amyloid protein such as the Aβ oligomer. Neferine, 
however, did not significantly inhibit αSA53T aggregation, albeit its docking profile pointed 
towards a weak interaction.  
Phloretin had a modest effect on Aβ aggregation. Although, the TEM imaging implied no 
visible modification in appearance of aggregates in comparison to control, the overall 
abundance of aggregates was lower. A previous study demonstrated that phloretin prevented 
Aβ association to negatively charged lipid vesicles by means of electrostatic interactions, as a 
means of mitigating Aβ cytotoxicity (Hertel, Terzi et al. 1997). Our docking of phloretin with 
the Aβ oligomer also highlighted a high degree of electrostatic interaction between phloretin 
and the hydrophobic core of Aβ. In addition to electrostatic interaction, phloretin might also 
increase Aβ oligomerization as a result of direct interactions (Efimova, Zakharov et al. 2015). 
Phloretin modified αSA53T fibrils in a manner comparable to cryptotanshinone; however, the 
overall abundance of fibrils was much higher, suggesting that phloretin exerted a marginal 
effect on αSA53T aggregation and this was also reflected in the high docking scores.  
5.5  Conclusion 
Diverse naturally-occurring bioactives are variably able to disrupt the aggregative propensity 
of αSA53T and Aβ. Of all the bioactives tested, the neolignan magnolol and cryptotanshinone 
were the best in this regard, inhibiting both α Synuclein and β amyloid aggregation. In a 
preliminary cell viability study, both cryptotanshinone and tanshinone I displayed intrinsic 
neurotoxicity to PC-12 cells after 48 hour exposure at 50 µM, but not magnolol (unpublished 
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data). Therefore, these findings suggest that magnolol may have the most potential among the 
six compounds tested and provide a favourable template for further drug development targeting 
amyloidogenic protein aggregation.   
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Chapter 6: Molecular docking guided design of novel amyloid binding 
ligands using natural polyphenols and a synthetic heterocyclic ring system 
as templates  
6.1 Introduction and background 
In silico drug design collectively represents various computational methods used at different 
stages of drug design and development in modern drug discovery. In silico approaches play an 
essential role in the ‘hit’ to ‘lead’ generation and ‘lead optimization’ process (Zoete, Grosdidier 
et al. 2009, Koutsoukas, Simms et al. 2011). Depending on the available knowledge of a drug 
target and molecules that bind to that target, different in silico methods can be applied in order 
to design a novel ligand. When the structure of the target binding site is well understood, de 
novo drug design and structure-guided methods can be employed for generating novel ligands 
(Honma, Hayashi et al. 2001, Honma 2003, Ji, Zhang et al. 2003).  In the absence of adequate 
information of a drug target, other in silico methods such as ligand-based drug design and 
virtual screening have been shown to be able to successfully guide the drug discovery 
endeavour (Knehans, Schüller et al. 2011).  
6.1.1 Ligand-based drug design 
Ligand-based drug design is of great importance when there is a lack of information about the 
3D structure of a target. It can provide valuable insight into the nature of interaction between a 
ligand and its target, which further reveal predictive optimization of the ligand structure is 
possible. For example, there is no clear understanding of the potential small molecule ligand 
binding sites in amyloid β or α synuclein proteins, or even if they have potential 
 Sukanya Das, PhD Thesis, 2018              118 
pharmacophores. Therefore, ligand-based drug design would be an effective strategy in the 
case of these aggregation-prone amyloidogenic proteins, which can be additionally complex 
when considering their polymorphic propensity during aggregation (Kodali and Wetzel 2007). 
Ligand-based drug design can be broadly divided into two approaches: a) pharmacophore-
based design and b) 3D quantitative structure activity relationship (QSAR) computations 
(Table 1).   
Table 1. Two major approaches for in silico ligand-based drug design. 
Ligand-based drug design 
Pharmacophore-based design 
Ligands are designed based on 
pharmacophores: IUPAC defines 
a pharmacophore as ‘an 
ensemble of steric and electronic 
features that is necessary to 
ensure the optimal 
supramolecular interactions with 
a specific biological target and to 
trigger (or block) its biological 
response’. (Wermuth, Ganellin et 
al. 1998). 
3D-Quantitative Structure Activity Relationship (QSAR) 
Comparative Molecular Field Analysis (COMFA)- This 
involves i) representing ligands by their steric and 
electrostatic fields in a three-dimensional lattice, ii) a new 
‘field fit’ technique by statistical calculation, iii) analysis 
by partial least squares, PLS and iv) graphic 
representation of results  (Cramer, Patterson et al. 1988). 
Comparative Molecular Similarity Indices Analysis 
(CoMSIA) – finds common features important in binding, 
by analysis of i) steric, ii) electrostatic features and 
hydrogen bond acceptor and donor properties using a 
Gaussian function in the similarity indices equation 
Aq F,K,(j) = −Σ Wprobe,k Wik e−αγ2iq 
(Klebe, Abraham et al. 1994, Zheng, Kong et al. 2014) 
6.1.2 Application of pharmacophore-based drug design for Aβ 
Aβ has several conformations that have been associated with its toxicity (Crescenzi, Tomaselli 
et al. 2002, Luhrs, Ritter et al. 2005). A diverse set of natural bioactives ranging from flavonoid, 
curcuminoid, lignan, chalcone, alkaloid and terpenoid structures have been characterized as 
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inhibitors of Aβ aggregation by directly interacting and modifying Aβ fibrils and aggregate 
morphology (Luo, Smith et al. 2002, Reinke and Gestwicki 2007, Bieschke, Russ et al. 2010, 
Kraziński, Radecki et al. 2011, Das, Stark et al. 2016, Fosso, McCarty et al. 2016). Among 
these natural bioactives, curcuminoid or curcumin structures have been extensively modified 
in order to design novel and improved Aβ binders (Yanagisawa, Shirai et al. 2010, Yanagisawa, 
Taguchi et al. 2015). Some studies have successfully developed flavonoid derivative 
compounds with improved Aβ binding, leading to anti-aggregation and neuroprotection (Li, 
Wang et al. 2013, Singh, Gaur et al. 2014), whereas chalcone derivatives have been designed 
as superior binders to Aβ for imaging and diagnostic purposes (Ono, Hori et al. 2007, Ono, 
Ikeoka et al. 2010, Fosso, McCarty et al. 2016). In contrast, the lignan structure has not been 
well investigated for use as an active scaffold or pharmacophore in ligand-based drug design 
targeting Aβ or other amyloidogenic proteins such as αSA53T, despite a recently identified 
anti-amyloidogenic action in vitro (Das, Stark et al. 2016, Kantham, Chan et al. 2017).  
6.1.3 Virtual screening 
As described in Chapter 1, virtual screening (VS) is an in silico, inexpensive and quicker 
alternative to traditional high throughput screening (HTS). It is applicable in the case of both 
known or unknown binding sites of a target. VS can further complement a de novo drug design 
approach by increasing chemical accessibility or the design of a compound library (Schneider, 
Clément‐Chomienne et al. 2000, Katarkar, Haldar et al. 2015). For the ligand-based drug 
design method, structure-based VS can play an important role in pharmacophore-based drug 
design by generating hits bearing the desired pharmacophore(s) (Schneider, Neidhart et al. 
1999, Knehans, Schüller et al. 2011).  
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6.1.4 A combined approach: pharmacophore-based drug design with virtual screening 
In this Chapter, a combination of both drug design strategies has been employed in order to 
develop novel amyloid β1-42 (Aβ1-42) binders. Modelling natural polyphenolic bioactives 
revealed that honokiol, a small molecule lignin, is structurally amenable for further 
development through molecular docking simulations. Additionally, the VS study of the ZINC 
chemical database identified a dibenzyl imidazolidine as a promising scaffold for structure-
based drug design against Aβ (Das and Smid 2017). Likewise, honokiol and the dibenzyl 
imidazolidine scaffold bearing compounds demonstrated direct interaction and inhibition of α 
Synuclein A53T (αSA53T) aggregation, a more aggregation-prone mutant of α Synuclein (αS) 
associated with PD (Li, Uversky et al. 2001). A common ligand binding with higher affinity to 
Aβ or αSA53T would be beneficial either from a drug discovery perspective or for amyloid 
imaging purposes with clinical applications. Therefore, in this work these molecular scaffolds 
or pharmacophores have been combined with the aim of designing novel and improved Aβ 
binder(s), which were then docked against αSA53T for characterizing the generic amyloid 
binding affinity. A set of derivative molecules have been designed utilizing computational 
methods such as molecular docking and molecular geometry optimization, which consolidate 
the structural features of honokiol and the dibenzyl imidazolidine scaffold. Low docking score 
was used as a guide for in silico development. The steric interaction score as computed by the 
PLANTSPLP docking algorithm provided information about the shape complementarity during 
docking interactions (Korb, Stützle et al. 2009). Lipinski’s rule of five was also used as a guide 
for evaluating ligand structures, however, a marginal increase in log P value was considered to 
be advantageous where the ligand target would require access to the central nervous system 
(CNS).   
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6.1.5. The neolignan biphenyl pharmacophore as a template for anti-Aβ ligand design 
Honokiol and magnolol are two structurally similar lignans, possessing the neolignan biphenyl 
or the biphenyl-hydroxy-propenyl molecular scaffold. Both of these molecules demonstrated 
direct interaction and inhibition of Aβ experimentally, with favourable docking profiles in 
molecular modelling (Chapter 5, (Das, Stark et al. 2016). Likewise, they both inhibited 
αSA53T aggregation, where honokiol inhibited the toxic conversion of unfolded αSA53T 
(Chapter 4). They have almost identical chemical structures except for one -OH group; 
however, their ground state conformations are slightly different (Fig. 1). Honokiol has both of 
its -OH groups on the same side of the biphenyl ring, while in magnolol, they are on the 
opposite sides. The docking studies presented in the earlier chapters of this thesis have shown 
that both honokiol and magnolol are strong binders to Aβ, while honokiol had a relatively 
higher score than magnolol (Chapter 2 and 4). This could be due to the conformation of 
honokiol. Additionally, honokiol obtained a lower docking score than other bioactive 
polyphenols such as myricetin, luteolin and punicalagin, particularly with oligomeric Aβ1-42 
(Das, Stark et al. 2016). Since the oligomeric structure of Aβ1-42 was representative of an anti-
parallel beta-sheet conformation that is associated with neurotoxicity, a lower docking score 
would be a desirable  starting point for designing an improved Aβ1-42 binder (Lührs, Ritter et 
al. 2005).  
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Figure 1. Chemical structures of (a) honokiol and (b) magnolol. Optimized conformations of (c) 
honokiol and (d) optimized conformation of magnolol.  
Moreover, the structure of honokiol is more tractable for pharmacophore-based development 
than other Aβ inhibitors such as punicalagin, EGCG or other catechol-type flavones. Being a 
small molecule with a molecular weight of 266.33 g/mol, it resembles a fragment which could 
be developed further using in silico design. Therefore, the neolignan biphenyl molecular 
scaffold of honokiol (partially shared by magnolol too) was chosen as the initial 
pharmacophore for designing novel ligands that may be potentially superior binders to Aβ and 
other amyloidogenic proteins like αS. 
Molecular stability of honokiol is higher than other noted amyloidogenic protein aggregation 
inhibitors such as EGCG and resveratrol (Kantham, Chan et al. 2017). Honokiol has been found 
to be stable over 48 hrs in phosphate buffered saline at 37 deg. C, whereas both EGCG and 
resveratrol showed degradation over this time period (Kantham, Chan et al. 2017). Aqueous 
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solubility is of high interest for enhancing bioavailability during the drug development process. 
Although honokiol is essentially a hydrophobic molecule with poor aqueous solubility, its 
nanoparticle formulation has been demonstrated to have  dispersibility in water that may make 
it more amenable to an efficient drug-delivery system (Gou, Dai et al. 2008). Therefore, the 
biphenyl-hydroxy-propenyl fragment/scaffold of honokiol has been used as a pharmacophore 
for further development of novel derivatives targeting Aβ and αS amyloidogenic protein 
structures in this study.  
6.2 Methodology 
6.2.1 Design strategy for honokiol-derivatives using molecular docking 
Molecular docking against Aβ monomer and oligomer structures were used as guide to design 
ligands with improved low docking scores and predicted H-bonding as part of their binding. 
The aim of this study was to enhance and improve the docking profile (low scores, electrostatic 
interaction and shape complementarity) as compared to honokiol. Using the biphenyl-hydroxy-
propenyl pharmacophore, an iterative fragment growing strategy was employed to improve 
docking scores, which has  been applied for other drug discovery strategies previously (Shang, 
Yuan et al. 2014). The oligomeric form of Aβ (PDB ID: 2BEG) is associated with toxicity and 
has been used in many in silico modelling studies to understand various small molecular 
suggested interactions with Aβ (Lührs, Ritter et al. 2005). Additionally, the monomeric form 
of Aβ serves as good model for docking, due to the full length (residues 1–42) and association 
with toxicity (Crescenzi, Tomaselli et al. 2002). In addition to Aβ, a high-resolution NMR 
structure of αS (PDB ID: 2N0A) was mutated from Ala to Thr at residue 53 to generate the 
structure of αSA53T (Tuttle, Comellas et al. 2016).   
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6.2.2 Computational methods 
All the structural modifications and design of new ligand structures was performed in 
GaussView5.0 of the Gaussian’09 program (http://gaussian.com/) (Frisch, Trucks et al. 2016). 
For each of the new ligand, the structural geometry was optimized using a density functional 
theory (DFT) approach that utilizes Becke’s three-parameter hybrid functional, commonly 
known by the acronym B3LYP (El-Azhary and Suter 1996). A large basis set, cc-pVDZ was 
used for optimized geometry of each designed ligand. All computations were carried out using 
Gaussian’09. Optimized ligands underwent molecular docking analyses in CLC Drug 
Discovery Workbench, version 1.5.1 using a PLANTSPLP scoring function (Korb, Stützle et al. 
2009). The molecular properties related to their drug-likeness were calculated for each 
derivative, using the docking software. The first ligand structure, modified from the honokiol-
based pharmacophore, was called Derivative 1. From Derivative 1, Derivative 2 was designed 
and this iterative fragment growing strategy continued until the design of Derivative 7. Scaffold 
hopping, another popular concept in drug design, was then used on Derivative 6 and 7 
structures to develop other promising ligands (Böhm, Flohr et al. 2004). Each derivative ligand 
was docked to both the Aβ and αSA53T targets. This ‘design – structure optimization – 
docking’ loop was repeated for several rounds to ensure improved binding.  
The whole design process was guided by rational intervention without any automated input 
from the docking software.  
6.2.3 Design of Derivative 1, 2, 3 and 4 
The main rationale behind modifying the structure of honokiol was to explore whether any 
derivative structure of this biphenyl neolignan scaffold can further improve binding probability 
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to amyloid targets. This, in turn, would inform a novel design of honokiol-derived amyloid 
binding ligands. Several strategies for modifying the honokiol structure were tried 
computationally which indicated that the structural modification followed in Derivative 1 
would be favourable. In the first step, the A-ring of the neolignan biphenyl molecular scaffold 
of honokiol was modified. The -OH group at position 4 of the A-ring and the propenyl chain 
at position 3 were replaced by a conjugated alkene (buta-1,3-diene) chain at position 4 (Fig. 
2a, b). This structure was called Derivative 1 (Fig 2). Next, a phenyl group was introduced to 
the conjugated buta-1,3-diene chain of Derivative 1 (Fig. 4). This resulted in the structure of 
Derivative 2. Derivative 3 was designed by introducing two -OH groups in the 1 and 3 positions 
of the buta-1,3-diene chain of Derivative 3 (Fig. 6). In the next step, an attempt was taken to 
investigate the effect of introducing a nucleophile such as O, N or S atom with the conjugated 
chain. Therefore, the two -OH groups of Derivative 3 were removed, and the phenyl group was 
converted into phenoxy group, which made the ligand structure of Derivative 4 (Fig. 8). This 
modification had the phenyl buta-1,3-diene-1,3-diol chain of Derivative 3 converted into a 
phenoxybuta-1,3-dien-1-yl chain of Derivative 4 (Fig. 8).  
6.2.4 Design of Derivative 5,6 and 7: combining virtual screening hit with existing ligand 
The structure-based virtual screening study using molecular docking used in Chapter 3 
identified a novel dibenzyl imidazolidine scaffold with a phenyl group as an anti-aggregative 
and neuroprotective ligand against Aβ (Das and Smid 2017). This scaffold was additionally 
effective against αSA53T toxic aggregation (Chapter 4).  For simplicity and to use less ring 
systems, only the ‘dibenzyl phenyl imidazolidine’ fragment was used from the ‘benzoxy phenyl 
imidazolidine scaffold’ of the virtual screening hits.  Both of the ‘hit’ molecules possessed this 
fragment and showed low docking scores with a predicted favourable shape. Therefore, this 
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molecular scaffold was used in further design of derivative ligands to improve the docking 
scores. This combined approach of ligand-design by introducing fragments from screening 
‘hits’ allowed us to search new chemical spaces and maintain a novel molecular design.  
Since the structural modification from Derivative 3 to Derivative 4 did not yield any significant 
advantage in terms of the docking profile with Aβ, the structure of Derivative 3 was used for 
further modification. To design the next series of ligands, the dibenzyl (methoxy) phenyl 
imidazolidine fragment was introduced to the conjugated buta-1,3-diene chain, which was 
Derivative 5 (Fig. 10). Subsequently, the structure of Derivative 5 was further simplified in the 
design of Derivative 6, where the (methoxy)phenyl group from the imidazolidine ring was 
removed (Fig. 12). In the final stage of ligand optimization, the imidazolidine ring of Derivative 
6 was replaced with an imidazole group, which resulted in the design of Derivative 7 (Fig. 14). 
6.2.5 Other Derivatives 
Several other derivatives were designed by changing the five-membered heterocyclic (FMH) 
imidazole ring into other FMH rings of the Derivative 7 structure (Table 4). These other FMH 
rings were selected from the top 100 most frequently occurring rings in small molecule traded 
drugs, as listed by the FDA (Taylor, MacCoss et al. 2014).  
6.2.6 The core fragment of the derivatives 
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After docking all the derivative ligands, it was identified that the ‘core fragment’ of the high 
scoring derivative ligands shared the dibenzyl imidazole or other FMH ring scaffolds (Fig. 16). 
This ‘core’ fragment was also individually docked with Aβ.   
6.3 Results and Discussion 
6.3.1 Honokiol and Derivative 1 molecular properties and interaction with Aβ 
The optimized ground state conformation of honokiol was non-planar. Introduction of a buta-
1,3-diene chain at position 4 of the A-ring, by replacing the -OH and propenyl chain, made 
Derivative 1 more planar at the ground state optimized conformation, except for the other 
propenyl chain at position 5' of B-ring (Fig. 2c, d). The calculated molecular properties 
indicated that the structural modification from honokiol to Derivative 1 increased the LogP 
(Table 1). However, the hydrogen donor and hydrogen acceptor groups had been reduced to 1 
from 2 in honokiol. The ability of honokiol to cross the blood brain barrier and act on various 
targets in the CNS, such as in gliosarcoma and neuroblastoma is attributed to essentially 
hydrophobic nature of honokiol (Wang, Duan et al. 2011, Lin, Chen et al. 2012).   
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Figure 2. Development of Derivative 1 (b, d) ligand molecular structure from the neolignan 
biphenyl molecular scaffold of honokiol (a, c). The A-ring of honokiol (a) has been modified 
in Derivative 1 (b). 
The docking study of Derivative 1 with the Aβ monomer did not show any significant 
difference from the docking profile of honokiol (Table 2), although the binding pose of 
Derivative 1 was slightly shifted from Asp 23 to Asn 27 (Fig 3a, b). In docking with the Aβ 
oligomer, the structural modification from honokiol to Derivative 1 did not change the overall 
docking score. Nonetheless, it is proposed to have increased interactions with the backbone 
amides group of key residues within this target as summarized by proposed H-bonding 
interactions (Table 3, Fig 3c, d). This predicted improvement in backbone amides interaction 
was possibly due to the conformational change, as planarity in some polycyclic compounds 
might appropriately orient the hydrogen donor or acceptor group of a ligand against Aβ 
(Churches, Caine et al. 2014). Backbone amides participate in stabilizing the overall protein 
conformation (Yang, Wang et al. 2004). A previous study on replacing the backbone amides 
with ester groups in islet amyloid polypeptide (IAPP) made the protein more stable in a 
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monomeric form (Cao and Raleigh 2010). However, the effect of this proposed increased 
interaction with backbone amides by a small molecular ligand is yet to be investigated for Aβ. 
Figure 3. Comparison of docking binding poses between honokiol and Derivative 1 in Aβ (a) 
honokiol, (b) Derivative 1 bound to Aβ monomer, (c) honokiol and (d) Derivative 1 bound to 
Aβ oligomer. Only interacting residues are shown.  
6.3.2 Derivative 2 molecular properties and interaction with Aβ 
Derivative 2 had a mostly planar conformation, like Derivative 1 (Fig. 4). Not surprisingly, the 
introduction of an aromatic ring, a phenyl group to the buta-1,3-diene chain, markedly 
increased the LogP value (Table 1). The hydrophobic structure of Derivative 2 decreased the 
overall docking score against both Aβ monomer and oligomer, along with proposed increased 
H-bonding interactions to its binding pocket according to the docking model (Fig. 5a-d).  In
the case of the monomer, it is predicted to form H-bonding with Lys 16, a key residue 
responsible for Aβ toxicity (Table 2) (Sato, Murakami et al. 2013). The docking poses of 
Derivative 2 suggested that the terminal phenyl group improved the ligand orientation while 
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enabling the -OH group to interact with key residues (Fig. 5b, d). Therefore, in the subsequent 
steps, modifications were made either to this phenyl group or the linker buta-1,3-diene chain.  
Figure 4. (a) Chemical structure and (b) ground state optimized structure of Derivative 2. 
Figure 5. Docking poses of Derivative 2 with Aβ; (a) monomer, (b) Derivative 2 showing 
proposed binding interaction residues of monomer, (c) oligomer and (d) Derivative 2 showing 
proposed binding interaction residues of oligomer.  
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6.3.3 Derivative 3 interaction with Aβ 
In Derivative 3, the introduction of two -OH groups at position 1 and 3 of the buta-1,3-diene 
chain (Fig. 6) partially reduced the LogP; nevertheless, it increased H-bond donor and acceptor 
counts (Table 1). Interestingly, Derivative 3 had a higher docking score than Derivative 2 
against both Aβ monomer and oligomer (Table 2, 3). Despite having more polar groups as H-
bond donor/acceptors, it showed no H-bonding interaction while docked to the Aβ monomer 
(Fig. 7a, b). However, within the Aβ oligomer binding pocket it was predicted to have the 
highest H-bonding interactions with multiple residues from amongst all derivatives according 
to the docking result (Table 3). This suggested that the hydroxy buta-1,3-diene chain of 
Derivative 3 favours electrostatic interactions with many residues across the binding pocket of 
Aβ oligomer (Fig. 7c, d), whereas Derivative 2 interacted essentially through shape 
complementarity based on the docking model. A comparison of their binding poses also 
suggested that Derivative 2 fitted well within the binding pocket, a characteristic of favourable 
shape (Fig. 5c), while Derivative 3 spanned across the binding pocket in a different orientation 
(Fig. 7c).   
Figure 6. (a) Chemical structure and (b) ground state optimized structure of Derivative 3. 
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Figure 7. Docking poses of Derivative 3 with Aβ; (a) monomer, (b) Derivative 3 showing 
proposed binding interaction residues of monomer, (c) oligomer and (d) Derivative 3 showing 
proposed binding interaction residues of oligomer. 
6.3.4 Derivative 4 interaction with Aβ 
The alternative approach taken in the design of Derivative 4 altered its geometry and disrupted 
the planarity of the molecular structure (Fig. 8a). However, there was a marginal increase in 
the LogP value and the ether group increased the number of H-bond acceptors (Table 1). 
Docking with the monomer suggested a marginal increase in score compared to Derivative 3, 
while the binding pocket and H-bond preference shifted to residue Glu 22 (Fig. 9a, b, Table 2). 
In regard to oligomer docking, no significant improvement was observed compared to either 
Derivative 2 or 3 (Fig. 9c, d, Table 3). Since the interaction with Lys residues would be a 
desirable property of an anti-Aβ ligand due to its impact on Aβ toxicity, the Derivative 4 
structure was not considered suitable for further design (Sato, Murakami et al. 2013).  
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Figure 8. (a) Chemical structure and (b) ground state optimized structure of Derivative 4. 
Figure 9. Docking poses of Derivative 4 with Aβ; (a) monomer, (b) Derivative 4 showing 
proposed binding interaction residues of monomer, (c) oligomer and (d) Derivative 4 showing 
proposed binding interaction residues of oligomer. 
6.3.5 Derivative 5 interaction with Aβ 
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The merging of the Derivative 2 structure with the virtual screening ‘hit’ dibenzyl 
imidazolidine scaffold, as described previously, altered the molecular geometry from a mostly 
planar Derivative 2 to a non-planar Derivative 5 (Fig. 10). This marginally increased the LogP 
value as more hydrophobic groups were introduced (Table 1), but it also increased the H-bond 
acceptors in the ligand with more rotatable bonds. The lower docking score with Aβ monomer 
than previous Derivatives was probably due to more ring systems along with rotatable bonds 
in this ligand (Fig. 11, Table 2, 3). The virtual screening ‘hits’ Compound 1 and 2 bearing this 
scaffold demonstrated slightly lower docking scores compared to Derivative 5 (Das and Smid 
2017). Docking of Derivative 5 to the Aβ oligomer resulted in a higher docking score than 
Compound 1. Nonetheless, it was predicted to have moderate interactions with the backbone 
amide groups of the key residues as summarized by proposed H-bonding interactions within 
the binding pocket of the Aβ oligomer according to the docking model (Fig. 11c, d, Table 3). 
This suggested that Derivative 5 was capable of both prospective H-bond and hydrophobic 
interactions, unlike Compound 1 and 2 according to docking model. Additionally, having a 
phenyl group such as the B-ring of honokiol connected to the dibenzyl group, seemed an 
effective design strategy for balancing polar and hydrophobic interactions with the Aβ 
monomer and oligomer.  
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Figure 10. (a) Chemical structure and (b) ground state optimized structure of Derivative 5. For 
clarity no hydrogen atoms are shown.  
Figure 11. Docking poses of Derivative 5 with Aβ; (a) monomer, (b) Derivative 5 showing 
proposed binding interaction residues of monomer, (c) oligomer and (d) Derivative 5 showing 
proposed binding interaction residues of oligomer. 
6.3.6 Derivative 6 interaction with Aβ 
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Removal of the methoxyphenyl group from the dibenzyl imidazolidine fragment of Derivative 
5 and addition of the -OH and -OCH3 groups to the terminal phenyl group (as in Derivative 4) 
simplified the molecular geometry of Derivative 6 when compared to Derivative 5 (Fig. 12). 
Derivative 6 also possessed improved drug-likeness, as LogP was within the range of most 
approved drugs and it contained multiple H-bond acceptors, donors and flexible bonds (Table 
1). Derivative 6 had the lowest docking score with the Aβ monomer, showing H-bonding to 
the key Lys 16 residue (Table 2). It was predicted to bind in a favourable region where it 
interacted with the majority of the hydrophobic residues along with Lys 28 and Met 35, 
responsible for Aβ toxicity (Fig. 13a, b) (Bitan, Tarus et al. 2003, Sato, Murakami et al. 2013). 
In the oligomer docking, Derivative 6 also displayed the highest score, yet not many 
prospective interactions with the key residues occurred, except for that with Gly 37 (Fig. 13c, 
d). This indicates towards a proposed non-polar interaction and a favourable shape of ligand 
according to docking model. Although Derivative 2 also displayed favourable shape for fitting 
within the Aβ oligomer binding pocket, the structure of Derivative 6 would be preferable in 
drug design, since more saturated carbons in a structure are associated with successful drug 
discovery (Lovering, Bikker et al. 2009).   
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Figure 12. (a) Chemical structure and (b) ground state optimized structure of Derivative 6. 
Figure 13. Docking poses of Derivative 6 with Aβ (a) monomer, (b) Derivative 6 showing 
proposed binding interaction residues of monomer, (c) oligomer and (d) Derivative 6 showing 
proposed binding interaction residues of oligomer. 
6.3.7 Derivative 7 interaction with Aβ 
Derivative 7 represented the final structural modification from the molecular docking guided 
and pharmacophore-based in silico design approach. Replacing the imidazolidine group of 
Derivative 6 with an imidazole group, as in Derivative 7, increased LogP > 6 (Table 1), while 
also increasing the H-bond donor count and marginally altering the molecular geometry (Fig. 
14a). This modification improved the H-bond interaction while docked to Aβ monomer; 
however, the binding pocket was shifted and the interaction with the key Lys residues and 
overall score was decreased (Fig. 15a, b, Table 2). Therefore, Derivative 6 was considered as 
the optimized ligand from this in silico study against the Aβ monomer target. 
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Proposed interactions with the Aβ oligomer suggested that Derivative 7 engaged in prospective 
interactions with the backbone amide groups of the key residues as summarized by H-bonding 
interactions, as well as possessing a favourable shape for binding to the Aβ target, according 
to docking result (Table 3, Fig 15c, d).  The minor change in molecular geometry from 
Derivative 6 to Derivative 7 probably positioned the lignan -OH groups well within the binding 
pocket (Fig. 15c). As a result, Derivative 7 seemed to be an optimized ligand for an improved 
docking profile showing both polar and hydrophobic interaction to the Aβ oligomer.    
Figure 14.  (a) Chemical structure and (b) ground state optimized conformation of Derivative 
7.
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Figure 15. Docking poses of Derivative 7 with Aβ (a) monomer, (b) Derivative 7 showing 
proposed binding interaction residues of monomer, (c) oligomer and (d) Derivative 7 showing 
proposed binding interaction residues of oligomer. 
In drug design, Lipinski’s rule of five is commonly used as a guide to assess the drug-likeness 
of a small molecule from its physicochemical properties. These are - i) not more than 5 
hydrogen bond donors (nitrogen or oxygen atoms with one or more hydrogen atoms), ii) not 
more than 10 hydrogen bond acceptors (nitrogen or oxygen atoms), iii) a molecular mass less 
than 500 daltons, iv) an octanol-water partition coefficient log P not greater than 5. Lipinski’s 
rule also states that no more than one violation of this rule is found in most orally bioavailable 
drugs (Lipinski, C. A. et al. 1997, 2001). Table 1 describes these physicochemical properties 
of honokiol and the derivative compounds. All the derivatives have one violation (LogP>5) of 
this rule of five and honokiol satisfies all of the rules.  
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Table 1. Molecular properties of honokiol and its derivatives as calculated using the CLC Drug 
Discovery Workbench (version 2.4.1).   
Table 2. Molecular docking profiles of honokiol and its derivative ligands with Aβ1-42 











Honokiol 266.34 5 2 2 4.98 0 
Derivative 1 262.35 5 1 1 5.68 1 
Derivative 2 338.45 6 1 1 7.17 1 
Derivative 3 370.45 6 3 3 6.04 1 


























H-bonding residue Steric 
interaction 
score 
Honokiol -45.96 0.00 - -48.33 
Derivative 1 -45.19 0.00 - -48.26 
Derivative 2 -53.97 -2.00 Lys 16 -54.88
Derivative 3 -47.73 0.00 - -58.31
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Table 3. Molecular docking profiles of honokiol and its derivative ligands with Aβ17-42 
oligomer (PDB ID: 2BEG). 
6.3.8 Docking of derivatives with α Synuclein A53T 
All the derivatives, except Derivative 1 and 3, were identified as having a favourable docking 
profile within the binding region of αSA53T (Table 4). The initial structural modification from 
honokiol to Derivative 1 did not improve its docking profile and the score was marginally 
reduced, indicating a weaker interaction at the binding pocket (Fig. 16b). In case of Derivative 
2, the addition of another benzene ring might have improved its binding through interaction 
with Thr 33 (Fig. 16c), whereas, in Derivative 3, the two additional -OH groups shifted the 
ligand orientation towards residue Lys 34, with more predicted H-bonding (Fig. 16d). Absence 
of these -OH groups and introduction of the -oxy group on the linker chain in Derivative 4’s 
structure improved the docking score, with H-bonding to Lys 23 (Fig. 16e). Derivative 5 had a 





H-bonding residue Steric 
interaction 
score 
Honokiol -72.31 -3.87 Leu 17C, Gly 38E -72.77
Derivative 1 -72.13 -7.65 Leu 17D, Val 18C, D, Phe 19D -68.68
Derivative 2 -79.87 -4.45 Leu 17E, Val 18D, Phe 19D -90.61
Derivative 3 -73.02 -13.59 Leu 17E, Val 18D, E, Phe 19D, E, Gly 
38E 
-66.10










Leu 17E, Val 18 D, Phe 19D 
Gly 37E 




 Sukanya Das, PhD Thesis, 2018              142 
16f). Derivative 6 displayed superior H-bonding with three residues in this binding pocket (Fig. 
16g). Finally, Derivative 7 was found to have the lowest docking score, along with H-bonding 
to the Lys residues (Fig, 16h, Table 5). The pharmacophore-based ligand design strategy used 
for Derivative 6 and 7 improved the docking profile, where interestingly, replacing the 
imidazolidine ring with imidazole ring altered the binding poses and access to Lys 21 and 23 
residues (Fig. 16g, h). Lys 21 was previously reported to be a target residue for ligand binding 
and anti-aggregatory effects towards αS, although Lys 23 and 34 were also involved in this 
process (Meng, Munishkina et al. 2009). Therefore, Derivative 6 would be the more favourable 
ligand structure targeting αSA53T than the other Derivatives proposed here.  





H-bonding residue Steric interaction 
score 
Honokiol -53.69 -2.00 Lys 23 -55.04
Derivative 1 -50.86 -2.00 Lys 23 -51.97
Derivative 2 -54.22 -3.35 Lys 23, Thr 33 -53.19
Derivative 3 -50.81 -6.00 Lys 34 -51.64











Lys 21, 23, Thr 33, 
Lys 34 




 Sukanya Das, PhD Thesis, 2018              143 
Figure 16. Docking poses of (a) honokiol, (b) Derivative 1, (c) Derivative 2, (d) Derivative 3, 
(e) Derivative 4, (f) Derivative 5, (g) Derivative 6 and (h) Derivative 7 with αSA53T.
6.3.9  Core fragment and scaffold hopping 
This study used molecular docking to derive new ligand structures based on previously known 
pharmacophores with amyloidogenic affinity and by searching new chemical spaces. By 
studying the prospective binding interactions of Derivative 6 and 7 in the docking model, a 
novel scaffold called the ‘core’ structure was designed (Fig. 17). This consisted of a FMH ring 
connected to a dibenzyl group on both sides (Fig. 17). The FMH ring in the core structure could 
be either an aromatic ring, such as the imidazole of Derivative 7 or a saturated ring such as the 
imidazolidine of Derivative 6. This ‘core’ scaffold showed a favourable docking profile against 
both the Aβ monomer and oligomer, with an overall score of -43.47 and -73.55 respectively.   
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Figure 17. Structure of the ‘core’ scaffold with an imidazole as the FMH ring.  
6.3.10 General considerations 
The applications of the novel amyloid binding ligands presented here extend beyond those 
targeting pathological misfolded proteins in the brain such as Aβ and αS. A previous study has 
shown that aminoimidazole analogs having a comparable shape with the ‘core’ structure, act 
as non-toxic inhibitors of Pseudoalteromonas sp. bacterial biofilm formation (Linares, 
Bottzeck et al. 2011). Amyloidogenic proteins such as curli are associated with biofilm 
production in uropathogenic bacterial infections (Cegelski, Pinkner et al. 2009). Moreover, the 
curli functional amyloid system was found in some Pseudoalteromonas species (Dueholm, 
Albertsen et al. 2012). This provides some support to the concept that the pharmacophore-
based design of the derivative ligands bearing the ‘core’ fragment might show a generic anti-
aggregatory activity against amyloidogenic proteins. Interestingly, a previous study focusing 
on screening various drugs and natural products structures proposed a ‘BioCore’ scaffold for 
novel drug design, a similar concept to the ‘core’ scaffold presented here (Kombarov, Altieri 
et al. 2010).   
Imidazole rings have been widely used in medicinal chemistry to discover drugs in the area of 
cancer chemotherapy, microtubule polymerization inhibitors and kinase inhibitors, in addition 
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to antifungal drugs (Bukowski, Sheeler et al. 1984, Zhang, Peng et al. 2014). However, the role 
of imidazole rings for binding to amyloidogenic proteins has not been well documented. 
Furthermore, a scaffold hopping approach of the ‘core’ FMH ring would enable additional 
design of novel derivative ligands targeting Aβ (Table 5). Scaffold hopping has been a 
commonly practised approach in medicinal chemistry for changing the central chemical 
template (Böhm, Flohr et al. 2004). In many drug discovery attempts, scaffold hopping led to 
the design of successful leads, such as for protein-protein interactions, design of peptide 
mimetics or selective antagonist of adenosine receptor A2A (Olson, Bolin et al. 1993, Ongini, 
Monopoli et al. 2001, Böhm, Flohr et al. 2004, Rush, Grant et al. 2005). The 11 FMH ring 
systems shown in Table 5 were recorded among the most frequently used ring systems in small 
molecule drugs listed in the FDA Orange Book (Taylor, MacCoss et al. 2014). They were 
incorporated into docking studies here, where out of these 11 different FMH ring-containing 
scaffolds, the thiazole moiety at the central core showed the lowest docking scores towards 
both the monomer and oligomer of Aβ. This is reflected in the benzothiazole core of thioflavin 
T structure, a commonly used molecule with high binding affinity towards amyloid fibrils, as 
used in this thesis. Since thiazoles are present in many drugs and possess various bioactivities 
desirable for CNS-targeted drug design, the proposed derivative with a thiazole scaffold could 
be a valuable novel Aβ ligand in this regard (Mishra, Kumari et al. 2015). Thiazole rings as the 
benzothiazole group are also present in the FDA approved positron emission tomography 
(PET) scanning radiopharmaceutical, flutemetamol, that is used clinically to bind Aβ 
deposition in AD patients (Curtis, Gamez et al. 2015).  
 Sukanya Das, PhD Thesis, 2018              146 
Table 5. Molecular docking profiles of derivatives bearing commonly used FMH rings in small 
molecule drugs with Aβ. 
There are a set of natural alkaloid compounds found mostly in red marine sponge species 
Leucetta chagosensis and Lepidium meyenii that have partial structural similarity with the 
FMH rings in 
Derivative 7 











Pyrrolidine -49.93 -2.00 -79.10 -6.43
Oxolane -50.12 0.00 -76.83 -6.43
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dibenzyl imidazole ‘core’ structure presented here (Cui, Zheng et al. 2003, Hassan, Al-Taweel 
et al. 2009, Koswatta, Kasiri et al. 2017). However, in those natural alkaloids the nitrogen 
atoms of the imidazole group are connected to the side chains whereas in the ‘core’ structure 
of this study, the nitrogens are not connected to any group, which accounts for its structural 
uniqueness. In another study searching for Aβ inhibitors by a HTS approach, a nitrogen FMH 
fused ring was identified, namely the indole derivative compound (D737), which has partial 
similarity with the shape of the ‘core’ structure presented here (McKoy, Chen et al. 2012).  
The present study of pharmacophore-based ligand design focused on the presence of nitrogen 
atoms either as imidazole, imidazolidine or thiazole in the iterative derivation of amyloid 
binding ligands. These groups possessed an improved docking profile, indicating they might 
be avid binders to amyloidogenic proteins.  
6.4 Conclusion and future direction 
This study has introduced a computationally guided drug-design approach from 
pharmacophores of natural as well as synthetic origin. Beginning from the neolignan biphenyl 
molecular scaffold of honokiol and later incorporating the dibenzyl imidazolidine scaffold, this 
study has designed several novel structures along with a novel molecular ‘core’ fragment that 
was predicted to have a superior binding to amyloidogenic proteins. In order to test this drug-
design method as a proof of concept study, a synthetic plan for one or more of these novel 
derivatives is currently being investigated. 
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Chapter 7: Final Discussion and Conclusions 
7.1 Significance of the study 
The first study (Chapter 2) identified honokiol and punicalagin as potent inhibitors of Aβ1-42 
aggregation, detailing their potency of inhibition and extent of neuroprotection from Aβ1-42 
induced neurotoxicity in vitro, which was comparable to noted anti-amyloid flavones myricetin 
and luteolin. The second study (Chapter 3) demonstrated a successful structure-based virtual 
screening approach validating the predictability of the molecular docking methods, which were 
subsequently used to understand prospective interactions of small molecules with amyloid-
based protein targets used throughout this thesis. The virtual screening not only identified ‘hit’ 
compounds bearing the desired five-membered heterocycle (FMH) ring fragments, but also 
identified a novel molecular scaffold. These compounds for the first time were demonstrated 
to inhibit amyloidogenic protein aggregation of Aβ and αSA53T and exert neuroprotection. In 
the third study, we demonstrated inhibition of αSA53T misfolding, amyloidogenic aggregation 
and exogenous toxicity by two selected synthetic imidazolidine compounds comparable to that 
observed with honokiol and punicalagin. Such studies highlighted the diverse molecular 
structural features that can be used as template for further generic amyloid inhibitor drug 
design. Collectively the results from Chapter 2 and 3 highlighted that the synthetic 
imidazolidine Compound 2 (1,3-dibenzyl-2-[4-(benzyloxy)-3-methoxyphenyl] imidazolidine) 
may be a suitable candidate for further development as an amyloidogenic aggregation inhibitor. 
In Chapter 4, the structure-activity relationships of flavones were further explored and 
demonstrated that only B-ring vicinal hydroxylation was required to inhibit αSA53T 
amyloidogenic aggregation and neurotoxicity, exemplified by the antiaggregatory and 
neuroprotective effects of the semi-synthetic flavone, 2-D08. Chapter 5 revealed the generic 
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amyloid inhibiting property of the neolignan magnolol, demonstrating an inhibition of 
aggregation against both Aβ and particularly αSA53T.  
The optimized conformation of these compounds and their proposed binding interactions 
according to the docking model with model Aβ1-42 and αSA53T have been foundational to later 
molecular docking guided design of novel Derivative ligands and fragments targeting Aβ1-42 
and αSA53T as described in Chapter 6. Finally, the novel Derivative ligand design using 
structural features identified by earlier studies, has provided examples of their application in 
rational drug design. Overall, the findings of this thesis provide a set of diverse structural 
features or fragments that might be helpful for early stage design of therapeutics targeting 
amyloidogenic aggregation, especially targeted to AD and PD. This research of various small 
molecular proposed interactions with Aβ and αS is fundamental in this regard, as further drug 
development is built on the initial favourable molecular structures. Table 1 summarizes the 
most effective natural and synthetic small molecules identified in the study, which inhibit 
amyloidogenic protein aggregation as well as protect neuronal cells from amyloid toxicity. 
Table 1 summarizes the molecular properties of the most effective ligands identified in this 
study. The physicochemical properties of successful CNS drugs such as polar surface area 
(PSA) or topological PSA ≤90 Ǻ2, molecular weight ≤400, LogP ≤5, H-bond donor ≤3 and H-
bond acceptor ≤7 suggests that honokiol, 2-D08 and Compound 1 are suitable for further CNS 
drug development (Pajouhesh, H. and Lenz, G. R. 2005).     
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Table 1. Summary of druglike properties of the most effective Aβ and αSA53T aggregation 
inhibitors and neuroprotective compounds  
7. 2 The neolignan biphenyl scaffold for developing disease modifying therapy in AD and
PD 
The search for new natural molecules that can be active against a common disease process of 
both AD and PD which are generally regarded as safe is valuable to facilitate the intensive 
search for disease-modifying therapeutics. Consequently, the identification of honokiol and 
magnolol as effective inhibitors of Aβ1-42 aggregation, the most toxic species of Aβ, suggests 
the effectiveness of this neolignan biphenyl scaffold in targeting Aβ. A  previous study found 
that magnolol was neuroprotective against Aβ1-40 induced toxicity in PC-12 cells (Hoi, Ho et 
al. 2010). Additionally, magnolol’s neuroprotective potential in PD was further highlighted in 
a study showing protection from 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP-) 









LogP Polar surface area 
in Ǻ2 
Honokiol 266.34 5 2 2 4.98 40.5 
Punicalagin 1084.72 0 17 30 1.7 511.0 
2-D08 270.24 1 3 5 2.5 87.0 
Compound 1 370.45 6 3 3 6.04 15.71 























honokiol acts as a potent scavenger of superoxide and peroxide radicals, owing to its 
antioxidant activity which may be a further basis for neuroprotection (Dikalov, Losik et al. 
2008). In the case of αSA53T, even though honokiol promoted small fibrillar αSA53T 
structures and magnolol produced small amorphous aggregates, they both demonstrated 
significant inhibition of aggregation (Chapter 4 and 5). This indicates that the minor structural 
differences in these two molecules might result in a different binding mode or interaction to 
the target protein, as suggested by the molecular docking simulations. The binding site for 
neolignan biphenyl scaffold in αSA53T or αS is not known. However, the docking of magnolol 
to the NAC-region of αSA53T protein was performed to understand this neolignan biphenyl 
scaffold interaction in this critical region for aggregation (Cho, Nodet et al. 2009). Thus, the 
different binding regions for honokiol and magnolol in αSA53T (Chapter 4 and 5) are selected 
to understand how the neolignan biphenyl scaffold might interact with the modelled flavonoid 
binding region or NAC region. Previous studies and the experimental studies presented here 
have not differentiated between honokiol and magnolol in terms of binding affinity towards 
amyloidogenic proteins such as Aβ and αSA53T. Nevertheless, the molecular docking studies 
in this thesis offer some theoretical insights in favour of honokiol having higher binding affinity 
towards both protein targets.  
The generic anti-amyloidogenic activity of both molecules is reflected in their inhibition of 
human calcitonin aggregation, another  amyloidogenic protein (Guo, Ma et al. 2015). The 
generic anti-aggregative activity along with neuroprotection in the present study and other 
medical effects such as antidepressant, anxiolytic and neurotrophic properties of honokiol 
rationalise its use as a template for early drug discovery efforts in dementia (Kuribara, Kishi et 
al. 2000, Fukuyama, Nakade et al. 2002, Esumi, Makado et al. 2004, Xu, Yi et al. 2008, Qiang, 
Wang et al. 2009).   
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Moreover, the neolignan biphenyl scaffold has no catechol-type functional groups, which are 
often associated with the so called ‘pan assay interference compounds’ or (PAINS) associated 
with false signalling hits in throughput assays (Baell 2016). Whereas the noted generic amyloid 
inhibitors such as EGCG, curcumin and other catechol-type flavones have been described as 
PAINS (Baell 2016, Nelson, Dahlin et al. 2017). The docking studies presented in this thesis 
suggest that the neolignan biphenyl scaffold might have a more favourable shape and proposed 
nonpolar interactions with both Aβ and αSA53T targets when compared with flavones. Shape 
complementarity plays a critical role in Aβ amyloidogenic aggregation, as demonstrated by the 
effect of stereoisomers of key amino acid residues such as Phe19 and Leu34 on Aβ1-40 
aggregation (Chandra, Korn et al. 2017). This study demonstrated that the shape alteration of 
residues Phe19 and Leu34 does not block fibril formation but does affect the pathway of 
aggregation (Chandra, Korn et al. 2017). These nonpolar residues have been shown to 
participate in honokiol and other small molecule binding to Aβ oligomeric conformations in 
the docking studies. It is possible that the shape of the neolignan biphenyl scaffold alters the 
shape of these nonpolar residues, although how the shape of a small molecule inhibitor impacts 
on the orientation of the key residues is not understood.  
In contrast, the molecular mechanisms of flavonoid interactions with Aβ and αS have been 
studied and it is known that the ortho-quinone formed by the oxidation of vicinal hydroxyl 
groups common to many flavonoids can covalently modify the lysine residue(s) of both 
proteins. Non-catechol type flavonoids with no vicinal hydroxyl groups can also interact 
through π-π interactions with residues His13,14 and Phe19,20 (Sato, Murakami et al. 2013, 
Hanaki, Murakami et al. 2016). However, the neolignan biphenyl structure is not comparable 
in this regard, as they are structurally distinct. The computationally predicted favourable shape 
of the neolignan biphenyl scaffold to bind both Aβ and αSA53T, coupled with a tractable  
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structure for derivatization warrants their further research in medicinal chemistry and drug 
discovery.     
In a recent study by Maioli et al., both magnolol and honokiol structures were used to design 
novel derivatives as an anti-proliferative against hepatocarcinoma cells (Maioli, Basoli et al. 
2018). Other studies have also synthesized several analogs of neolignan biphenyls as anti-
cancer compounds (Kong, Tzeng et al. 2005). Additionally, some neolignan derivative 
compounds have demonstrated anti-HIV properties along with anti-tumor activity (Amblard, 
Govindarajan et al. 2007). These studies validate the suitability of honokiol and magnolol 
structures as a template for pharmacophore-based drug discovery and serve to highlight a 
favourable structure for biological activity, which may be exploited towards a number of 
potential therapeutic applications. 
7.3  The novel dibenzyl imidazolidine scaffold and the ‘core’ fragment 
In the virtual screening study, the FMH ring fragment-based search identified the dibenzyl 
imidazolidine scaffold as an inhibitor of amyloidogenic aggregation and toxicity (Chapter 3 
and 4). Subsequently, the dibenzyl imidazole ‘core’ fragment was designed based on the 
molecular docking studies in Chapter 6. Imidazole fragment-bearing compounds have not been 
thoroughly explored for activity at amyloidogenic protein targets, despite their significant 
contribution in drug development (Zhang, Peng et al. 2014). Imidazolidine rings without any 
exocyclic groups or hydantoin structures, are generally lacking in examples of rational drug 
design. Several FMH rings such as the thiazole or benzothiazole ring are present in the 
established amyloid binding probe the thioflavin T (ThT) molecule and in flutemetamol, a FDA 
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approved amyloid PET tracer (Curtis, Gamez et al. 2015). Among the oxygen containing rings, 
the furan ring in the benzofuran group and oxazole ring in the benzoxazole group have also 
been used for novel design of Aβ PET tracers (Ono, Kawashima et al. 2006, Ono, Cheng et al. 
2011, Cui, Ono et al. 2012). Additionally, novel compounds bearing benzofuran groups, have 
been shown to inhibit Aβ aggregation (Rizzo, Rivière et al. 2008, Ha, Kang et al. 2018). 
Another FMH ring, the pyrrole group in the indole ring has demonstrated efficacy as an 
inhibitor of amyloidogenic aggregation (McKoy, Chen et al. 2012). In the abovementioned 
compounds, the FMH rings have been a part of a bicyclic ring or fused with a benzene ring, 
whereas the novel scaffold identified here possesses the FMH ring as an individual fragment. 
Additionally, the dibenzyl groups attached to this central imidazolidine/imidazole ring provide 
a unique shape to the fragment, which is predicted to be favourable for binding to both Aβ and 
αS in the docking simulations. While previous studies have highlighted the usefulness of FMH 
ring-bearing bicyclic compounds in designing anti-amyloid compounds, the present study 
provides new structural information about the role of imidazolidine or imidazole FMH ring 
fragment, as part of this scaffold (Chapter 3, 4 and 6).  
7.4  The novel Derivative design as Aβ and αS ligand 
The novel structures presented in this thesis are an example of designing Aβ and αSA53T 
binding ligands using the neolignan biphenyl scaffold as a template. Moreover, its 
hybridisation with the dibenzyl imidazolidine scaffold has provided a novel amyloid ligand 
design strategy. However, the effectiveness of this design strategy awaits the synthesis and 
testing of the derivatives. Another application of such a novel ligand might be for the 
development of an amyloid tracer small molecule for imaging and diagnostic purposes. As 
mentioned earlier, the presence of the thiazole group in successful amyloid PET tracer 
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molecules demonstrates the importance of this FMH ring in binding to amyloid β deposits. 
Molecular docking results predicted high binding affinity of the thiazole ‘core’ structure 
(Chapter 6) as relevant in this purpose. Notably, the majority of the amyloid tracer molecules, 
including flutemetamol, are based on the ThT molecular structure, whereas the ‘core’ structure 
presented in Chapter 6, is distinct. It is not known from the present study whether having the 
FMH ring without a bicyclic group is a rational approach for designing a selective amyloid 
binder with a high affinity towards Aβ. Notwithstanding this, a major challenge in developing 
a PET tracer for αS aggregates in Lewy bodies (LB) or Lewy neurites (LN) is an insufficient 
selectivity for αS over binding to Aβ and another amyloidogenic protein, tau (Kotzbauer, Tu 
et al. 2017). The versatile binding affinity of the ‘core’ and related derivative structures towards 
amyloidogenic proteins allude to the challenge of selective PET tracer development. The study 
is limited to further investigate the structural features that might lead to selective binding to 
either αS or Aβ. Given the similarity between these two amyloidogenic proteins, computer 
aided ligand-design methods should be combined with detailed biophysical/biochemical 
understanding of any unique binding sites within each protein.  
7.5  Amyloid hypothesis as a target: still work to do 
Among the major approaches for overcoming of Aβ and αS associated pathology, reducing the 
overall production of Aβ and αS and enhancing their clearance have been extensively studied 
for drug development, as discussed in Chapter 1. By contrast, inhibition of amyloidogenic 
aggregation by small molecules has not been well-developed but remains a valid target in the 
context of the amyloid hypothesis. Inhibition of aggregation might be a rational therapeutic 
choice in scenarios where pathogenic amyloids can act as a seed for further amyloidogenic 
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aggregation and self-propagation, which occur in a prion protein-like manner (Jucker and 
Walker 2013).    
Notably, targeting amyloidogenic aggregation with a small molecule metal chelator, PBT2 has 
not been successful in reducing Aβ burden in clinical trials (Relkin 2008). Subsequently, PBT2 
has also been investigated in clinical trials for Huntington’s disease, looking at the efficacy of 
inhibiting huntingtin amyloidogenic protein aggregation (Huntington Study Group Reach2HD 
Investigators 2015). Another small molecule NPT088, that has been shown to bind 
amyloidogenic proteins such as αS, Aβ and tau is still under development and under clinical 
trial in AD (Levenson, Schroeter et al. 2016)(ClinicalTrials.gov Identifier: NCT03008161).  
Active and passive immunization therapies aiming at clearance of amyloid aggregates have 
largely been unsuccessful in past clinical trials (Morgan 2011). Recently, a monoclonal 
antibody, aducanumab showed a lowering of amyloid levels and is still under investigation 
(Haeberlein, Gheuens et al. 2018). However, active and passive immunization therapies have 
challenges including recurrent infusion and higher cost of production (Lannfelt, Relkin et al. 
2014).  
Although the jury is still out for efficacy of many other BACE1 inhibitors, the lack of efficacy 
of verubecestat in a large clinical trial in prodromal AD patients raises doubt more generally 
about the approach of reducing amyloidogenic protein production (Mullard 2017, Egan, Kost 
et al. 2018). Previous studies targeting amyloidogenic protein aggregation by all three 
approaches, have either employed novel synthetic molecules using rigorous medicinal 
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chemistry efforts or utilized natural products in basic studies and clinical investigations. A 
hybrid derivative molecule designed from a natural product and synthetic fragment has not 
been well-documented. Consequently, the novel Derivatives presented in this thesis warrant 
further investigation to test this concept. Despite arguments about the validity of the amyloid 
hypothesis in AD, there has not been conclusive evidence to disprove amyloidogenic protein 
aggregation as a primary viable target for any disease modifying therapy.  
7.6  Limitations of this study and future directions 
Ligand-based drug design is an inexpensive and fast method in computer-aided drug discovery 
research. Despite the advantages of this in silico approach, there are some disadvantages 
compared to traditional HTS methods. Synthetic tractability of novel compounds resulting 
from ligand-based design remains a challenge, especially when the design is guided by in silico 
methods such molecular docking without simultaneous synthesis and testing of fragments. The 
scope of this study has been limited to novel ligand design, however, these novel ligands have 
not yet been synthesized to validate the design strategies in experimental models. Therefore, 
further pharmacological characterisation as well as the toxicity profile of these novel 
Derivatives await. Preliminary investigations with medicinal chemistry collaborators however 
have indicated that both the derivative structures and approaches to synthetic pathways are 
feasible and that synthesis of the core structure has commenced. 
The other limitation of this study would be the lack of understanding of a clear mechanism of 
action for the identified molecular inhibitors of amyloidogenic protein aggregation. Although, 
studying αSA53T conformational change during early aggregation by IM-MS offers new 
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insights on various molecular interactions, similar studies on the Aβ protein could not be 
undertaken due to methodological limitations for such studies. The present study has been 
unable to investigate the conformational change of Aβ proteins in the presence of each of the 
compounds tested here.  
These studies have demonstrated the anti-aggregative properties of various natural and 
synthetic compounds and tested their neuroprotection in vitro, in an attempt to correlate their 
anti-aggregative property with neuroprotection. The MTT cell viability assay used in this study 
is somewhat limited to provide an endpoint neuroprotection measure in terms of the viable 
mitochondria present in cells. This assay is unable to differentiate between different forms of 
neuroprotective actions of a molecule, such as inhibition of amyloidogenic aggregation, 
antioxidant or other cell signalling properties. As mentioned earlier, the natural polyphenol 
inhibitors identified in this study likely possess multiple bioactivities. Thus, the inhibitors 
might protect neuronal cells by different mechanisms in addition to their antiaggregative 
properties. Further research on protective mechanisms in addition to their identified 
antiaggregative properties is needed for understanding the extent of neuroprotection arising 
from a molecular inhibition of amyloidogenic aggregation. Another important future direction 
of this study would be to compare the antiaggregative and neuroprotective properties of the 
identified diverse compounds in appropriate in vivo models of AD and PD in the evolution of 
their preclinical development.   
7.7  Conclusions 
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This study set out with the aim of identifying new naturally occurring small molecule inhibitors 
of both Aβ and αSA53T amyloidogenic aggregation that are structurally distinct from known 
inhibitors such as EGCG or curcumin. A diverse set of such natural inhibitors has been 
identified and characterised for their effects on amyloidogenic aggregation and 
neuroprotection. The findings demonstrate honokiol and magnolol as inhibitors of both Aβ and 
αSA53T amyloidogenic aggregation. The other aim has been to identify FMH ring-bearing 
compounds with nitrogen as the heteroatom and without an exocycle C=O/S/N group that can 
inhibit amyloid aggregation, as well as protect neuronal cells from its toxicity. Two dibenzyl 
imidazolidine scaffold-bearing compounds, called as Compound 1 and Compound 2 in the 
thesis, have been identified as not only inhibitors of Aβ, but also αSA53T amyloidogenic 
aggregation and toxicity. Subsequently, the final major aim of this study has been to design 
novel amyloid binding ligands from the various molecular structural features revealed by this 
study. A set of novel Derivative ligands along with a ‘core’ fragment have been designed in 
silico with predicted high affinity binding to Aβ and αSA53T. 
In conclusion, the studies presented here have highlighted the neolignan biphenyl scaffold as 
efficacious naturally occurring inhibitors of both Aβ and αS amyloidogenic protein aggregation 
and further demonstrated the suitability of using the neolignan biphenyl scaffold for rational 
drug design. Furthermore, the identification of a novel dibenzyl imidazolidine scaffold with 
predicted high binding affinity to Aβ has expanded exploration of new chemical spaces in the 
search for anti-amyloid compounds. A novel Aβ and αSA53T binding ligand designed from 
combining a naturally occurring scaffold with screening ‘hit’ fragment was also revealed.  This 
study testifies as an example of an inexpensive and ligand-based drug design approach. Such 
approaches may fuel new drug design research and serve the unmet medical need of 
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discovering new disease-modifying therapeutics for common and currently incurable 
neurodegenerative diseases.   
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